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Abstract 
  Cancer is still one of the leading causes of deaths in the world and chemotherapy 
remains the major treatment modality for most advanced cancers. However, 
traditional anticancer agents have numerous problems due to their non-specific 
distribution and low therapeutic index in vivo, leading to serious side effects in 
patients. Thus, there is a big challenge to develop new chemotherapeutics that can 
target cancer cells effectively. In recent years, nanotechnology has been widely 
developed and utilised in the treatment of cancers and the study of liposomes is a 
critical direction in this area. Liposomes have become well-recognised vehicles for 
drug encapsulation and have been shown to enhance the therapeutic efficacy of 
several traditional antitumour drugs. 
  Ideally, liposomes for drug delivery have the ability to accumulate in tumour tissues 
via the enhanced permeability and retention effects (the EPR effect) in tumours. 
Moreover, modification with ligands on the surface of liposomes could further 
enhance the targeting property of liposomes. Sulfatide, a glycosphingolipid which 
can bind to several extracellular matrix proteins, has the potential to become a 
targeting agent in tumours overexpressing tenascin-C. As a result, sulfatide was used 
in the development of sulfatide-containing nanoliposomes (SCL) for doxorubicin 
(DOX) encapsulation to overcome its dose-limiting toxicity.  
  This project was aimed to analyse in vitro characteristics of sulfatide-containing 
liposomal DOX (SCL-DOX) and to assess its cytotoxicity in vitro, as well as 
pharmacokinetics (PK) and biodistribution (BD) in healthy rats. Then, the human 
glioblastoma cell line U-118MG and the human colorectal adenocarcinoma cell line 
HT-29, which both have high expression of tenascin-C, were utilised as models for 
 11 
 
the studies of therapeutic efficacy and systemic toxicity both in vitro and in vivo. As 
there is potential for SCL-DOX to cross the blood-brain barrier (BBB), an 
intracranial brain C6 tumour xenograft model in rats was established for the 
evaluation of tumour uptake of SCL-DOX. To further improve the active targeting 
property of SCL-DOX, an aptamer targeting the epithelial cell adhesion molecule 
(EpCAM), a cell surface marker for the cancer stem cells (CSCs), was used to 
modify the SCL and the cellular uptake and retention of drugs was compared 
between an EpCAM-positive cell line and an EpCAM-negative cell line. 
  The results indicated that the SCL-DOX had a satisfactory drug loading efficiency, 
a high drug-to-lipid ratio, an ideal average size as well as a remarkable in vitro 
stability. It was also shown that the SCL-DOX could prolong the retention property 
in both U-118MG cells and HT-29 cells in vitro when compared to the free DOX. 
Besides the improved pharmacokinetic profile in healthy SD rats, in vivo data also 
suggested improved tissue distributions in both healthy rats and tumour-bearing mice. 
Meanwhile, the enhanced treatment efficacy and reduced systemic toxicity of SCL-
DOX were observed in U-118MG and HT-29 tumour-bearing mice compared to the 
free drug. Furthermore, the findings indicated that the SCL-DOX was able to 
penetrate the BBB and accumulate in the glioma. As well, modification with the 
EpCAM targeting aptamer on the SCL-DOX demonstrated specific targeting to the 
EpCAM-positive cell line.  
  In conclusion, the current project shows that the SCL could be an effective and safe 
nanocarrier for the anticancer agent DOX. The SCL-DOX has the potential to target 
tumours with high expression of tenascin-C. Moreover, SCL encapsulation could be 
a new strategy for the treatment of diseases in the central nervous system (CNS). The 
 12 
 
aptamer functionalised DOX-encapsulated PEG-SCL might be a novel nanodrug to 
improve the treatment efficacy in the CSCs.  
 13 
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1.1 Cancer and anticancer chemotherapy 
1.1.1 Cancer and anticancer chemotherapy 
Cancer is still one of the most devastating diseases in the world despite vast 
government funding and a heroic effort by cancer researchers to reduce mortality and 
improve survival (Klein, Christoph A. 2009). Cancer treatment modalities include 
surgery, radiation and chemotherapeutics (Chabner & Roberts 2005; Peer, Dan et al. 
2007; Sapra, P., Tyagi & Allen 2005). However, radiation therapy, as well as surgery, 
cannot eradicate metastatic tumours (Chabner & Roberts 2005). The majority of 
tumour-induced fatalities are attributable to metastatic diseases, and early cancer 
detection and prevention of metastases has become the centre of clinical attention 
(Klein, Christoph A. 2009). Due to its spectacular success in curing certain types of 
leukaemia, chemotherapy is becoming the major weapon in the management of 
metastatic solid tumours (Balis 1988). 
During the quest to provide a cure for cancer, cancer drug development has been 
transformed from a low-budget, government-supported research effort to a high-
stakes, multi-billion dollar industry (Chabner & Roberts 2005). However, most 
traditional chemotherapeutic agents lack specificity to cancer cells. Thus, they often 
kill healthy cells as well as tumour cells (Alexis, Frank , Rhee, June-Wha , et al. 
2008; Bawarski et al. 2008). Moreover, chemotherapy also causes severe toxicity to 
patients, leading to serious side effects, low efficacy and poor quality of life (Peer, 
Dan et al. 2007; Sapra, P., Tyagi & Allen 2005). In addition, most anticancer agents 
have an extensive distribution in the human body after intravenous (i. v.) 
administration, resulting in a low therapeutic index and a high level of toxicity to 
healthy tissues. This non-specific biodistribution (BD) and the resulting side effects 
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limit the clinical application of anticancer drugs (Ganta, Srinivas et al. 2008). 
Furthermore, there are many barriers to the effective delivery of anticancer drugs to 
the tumour due to its pathophysiological properties. This is further exacerbated by 
the fact that tumours can be located in parts of body where anticancer agents cannot 
easily penetrate, such as the brain, or protected by the local environment due to 
increased tissue hydrostatic pressure or altered tumour vasculature (Drummond, D. C. 
et al. 1999b; Klein, Christoph A. 2009; Szakács et al. 2006). Thus, there is an urgent 
need to develop new chemotherapeutics that can target tumour cells effectively.  
1.1.2 Tumour microenvironment 
1.1.2.1 Tumour vasculature 
The structure of newly generated blood vessels in tumours are abnormal (Alexis, 
Frank , Rhee, June-Wha , et al. 2008; Tang et al. 2007), with studies indicating that 
the abnormal vasculature in the tumour plays an important role in tumour 
permeability. Tumour blood vessels are characterised by leakage, tortuousness, 
dilation and disordered interconnection (Tang et al. 2007). In some tumours, vessels 
share features of arterioles, capillaries and venules. Furthermore, the walls of tumour 
vessels lack normal basement membranes and perivascular smooth muscle when 
compared with that of healthy tissues (Trédan et al. 2007). Moreover, the integration 
of tumour cells into the vessel wall exacerbates the leakiness of the tumour 
vasculature. Due to these structural abnormalities, the capillary network of tumours 
is highly permeable to macromolecules when compared to their normal counterpart 
(Campbell 2006; Greish 2007; Kong, Braun & Dewhirst 2000). The newly formed 
tumour vessels have fenestrations ranging from 100 to 780 nm, while the pore size of 
the vascular endothelium in most healthy tissues is smaller than 6 nm (Drummond, D. 
 19 
 
C. et al. 1999b). Consequently, macroparticles, such as albumin, and even larger 
nano-sized particles (Kratz et al. 2008), remain in the bloodstream when passing 
through the normal tissues where the openings are not large enough for them to pass 
in, but would extravasate through the leaky vasculature of tumours (Gullotti & Yeo 
2009). In most cases, particles smaller than 200 nm would be able to cross into the 
tumour microvasculature (Alexis, Frank, Rhee, June-Wha, et al. 2008). 
1.1.2.2 The enhanced permeability and retention effect in tumours 
The clearance route of macromolecules in the interstitial space is the lymphatic 
system in both normal tissues and tumours (Maeda, H., Bharate & Daruwalla 2009). 
However, tumours are characterised by an irregular lymphatic system. Due to the 
absence of functional lymphatics, the clearance of macromolecules is retarded from 
the tumour interstitium (Brigger, Dubernet & Couvreur 2002). Moreover, in many 
solid tumours, such as rectal and breast tumours, there is an elevated interstitial fluid 
pressure when compared with normal tissues (Jain 1990). Consequently, as 
interstitial fluid pressure can drive the pressure gradient or fluid flux in the tumour 
interstitium back to the vascular compartment, it reduces the pressure gradients from 
the vascular compartment into the interstitial space (Ferretti et al. 2009; Lunt, 
Chaudary & Hill 2009). As a result, limited delivery and transport of 
macromolecules ensue due to the increased interstitial fluid pressure gradient from 
the tumour centre to the periphery (Heldin et al. 2004). Thus, unlike normal tissues 
where clearance of macromolecules proceeds rapidly and steadily via the lymphatic 
system, clearance of macromolecules from the tumour lymphatic system is impaired 
and they can remain in the tumour interstitium for a long period of time (Maeda, 
Hiroshi 2001). 
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The characteristics of tumour vasculature enhance the permeability of 
macromolecular compounds such as nanoparticles in tumour tissues, while the 
impaired lymphatic system contributes to the retention of macromolecules in the 
interstitial space of tumours for long periods (Maeda, Hiroshi 2001). Thus, the highly 
permeable vessel structures and the lack of an intact lymphatic system in tumours 
result in the phenomenon termed the enhanced permeability and retention (EPR) 
effect (Figure 1-1) (Bisht & Maitra 2009). The EPR effect, discovered by Maeda and 
Matsumura in 1986, is characterised by enhanced extravasation of macromolecules 
from tumour blood vessels and their retention in tumour tissues (Maeda, H., Bharate 
& Daruwalla 2009). The EPR effect, modulated by abnormal secretion of vascular 
endothelial factors, such as bradykinin, nitric oxide, prostaglandins and matrix 
metalloproteins (Alexis, Frank, Rhee, June-Wha, et al. 2008), forms the foundation 
of cancer-targeting drug design as it is observed in almost all solid tumours in 
humans (Maeda, H., Bharate & Daruwalla 2009; Miles & Williams 2008).  
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Figure 1-1.  The Enhanced permeability and retention (EPR) effect in tumours (adapted 
from Cassidy and Schätzlein 2004). Normal tissue vasculatures are characterised by tight 
endothelial cells which thereby prevent macromolecules from passing in, whereas tumour 
vasculatures are leaky and hyperpermeable for the nanoparticles. Small blue dots: small 
molecules; Large green dots: macromolecules. (Cassidy & Schätzlein 2004) 
 
1.1.2.3 Multidrug resistance 
Multidrug resistance (MDR), the resistance of cancer cells to one or more drugs in 
chemotherapy, is a significant obstacle to effective treatment of tumours by 
chemotherapeutics (Peer, Dan et al. 2007). It is postulated that MDR results in lower 
therapeutic effects as well as resistance to various drugs in cancer cells (Domb et al. 
2007; Gottesman 2002; Gottesman, Michael M. , Fojo, Tito & Bates, Susan E. 2002; 
Peer, Dan et al. 2007). The mechanisms of MDR in cancer include a decreased 
uptake of water-soluble drugs, cellular changes affecting the cytotoxicity of drugs 
and an increased efflux of hydrophobic cytotoxic drugs (Figure 1-2) (Jabr-Milane et 
al. 2008; Szakács et al. 2006). 
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Figure 1-2. Mechanisms of multidrug resistance (MDR) development in tumour cells 
(adapted from Gottesman, Fojo et al. 2001). Tumour cells can develop resistance to 
anticancer agents by different mechanisms, such as elevated drug efflux by incresing activity 
of pumps or reduced drug influx. Alternatively, resistance can be induced by the activation 
of detoxifying proteins, disruption of apoptotic signalling patheways, or increased of DNA 
repair.  (Gottesman, M. M., Fojo, T. & Bates, S. E. 2002) 
 
The most widely studied mode of MDR action is drug efflux. Many clinical 
anticancer drugs are derivatives of natural products, such as anthracyclines and vinca 
alkaloids. These agents share properties in terms of high affinity with energy-
dependent membrane transporter proteins, leading to the efflux of drugs out of cells 
(Patel & Tannock 2009). According to current wisdom, MDR occurs as a result of 
overexpression of an ATP-dependent transporter protein family on the cancer cell 
surface. These proteins are known as the ATP-binding cassette (ABC) transporters, 
utilising ATP for exporting drugs against the concentration gradient (Dean, Rzhetsky 
& Allikmets 2001; Peer, Dan et al. 2007; Spiegl-Kreinecker et al. 2002; Szakács et al. 
2006). The ABC transporters are found in all cells of all species from the most 
primitive microorganism to humans, and play central roles in various physiologic 
systems as well as drug resistance in tumour cells (Surowiak et al. 2006).  
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P-glycoprotein (P-gp), a transmembrane glycoprotein with a molecular weight of 
170 kDa, is a key protein in the ABC transporter family. It is encoded by the MDR 
gene, MDR1. P-gp plays a critical role not only in regulating drug access through the 
blood-brain-barrier (BBB), as it is involved in the exclusion of both neutral and 
cationic organic compounds (Roya et al. 2009), but also in chemoresistance in 
tumours. The role of P-gp in MDR in tumours has been confirmed by many studies 
(Bradley & Ling 1994; Taheri, Mahjoubi & Omranipour 2010; Thomas & Coley 
2003). It functions as a pump transporting anticancer drugs out of tumour cells in an 
ATP-dependent manner, and confers cancer cells with the strongest resistance to the 
widest variety of agents among the ABC transporters (Bradley & Ling 1994; Li, Y et 
al. 2010; Szakács et al. 2006; Taheri, Mahjoubi & Omranipour 2010).  
However, there are some resistant tumour cells overexpressing other proteins from 
the MDR related protein (MRP) family instead of P-gp. Two main MRP transporters, 
MRP 1 and MRP 2, contribute to drug resistance in some multidrug resistant tumour 
cells. The overexpression of human MRP 1 in cancer patients has been reported by 
many independent laboratories (Burger et al. 2003; Komdeur et al. 2001; Mahjoubi 
et al. 2008). MRP 1 has the potential to confer drug resistance to a variety of drugs, 
such as anthracyclines, vinca alkaloids, and VP-16 (Mahjoubi et al. 2008; Minko et 
al. 2006), which is related to a reduced intracellular drug accumulation in tumours 
(Mahjoubi et al. 2008). Another drug transporter protein in the MRP family is the 
MRP 2. It has been shown that the MRP 2, a 190 kDa phosphoglycoprotein, is 
expressed on the apical membrane of hepatocytes, enterocytes, and renal proximal 
tubules (Surowiak et al. 2006; Zhang, Yuanyuan , Li & Vore 2007). The MRP 2 is 
also involved in the transport of chemotherapeutic agents out of the tumours (Choi et 
al. 2007). In vitro experiments also showed that overexpression of the human MRP 2 
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could confer resistance to platinum-containing anticancer drugs (Surowiak et al. 
2006). 
These transporters are associated with the efficient pumping of a drug out of the 
tumour cells, and therefore, their expression level is inversely correlated with the 
chemotherapeutic phenotype in various cancers (Choi et al. 2007). Conceivably, the 
suppression of the P-gp expression, the human MRP 1 and/or the human MRP 2 
transporters could decrease chemoresistance by increasing drug concentration inside 
the cancer cells and therefore enhance the efficacy of chemotherapeutic treatments. 
1.1.2.4 Cancer stem cells 
There are at least two different models which can explain tumour initiation in vivo 
(Figure 1-3), the stochastic model or the cancer stem cells model. In the stochastic 
model, it is assuming that every cancer cells has the potential to proliferate and 
regenerate a tumour (Ward & Dirks 2007). However, in the 1960s, studies had 
already indicated that even if millions of cancer cells were inoculated in vivo, not all 
the inplantations could develop into a palpable nodule (Brunschw, Southam & Levin 
1965; Foo, Leder & Michor 2011). Thus, it is very difficult for the stochastic model 
to account for this phenomenon as all cancer cells have an equal probability to 
regenerate a tumour in this assumption. 
Over the past several years, it has become widely accepted that the limited 
efficacy of current anticancer treatments can be attributed to a small subset of cells 
within tumours with the ability to proliferate and form new tumours (Al-Hajj et al. 
2003; Koch, Krause & Baumann 2010). As these highly tumourigenic cancer cells 
display some functional properties of normal stem cells, such as self-renewal and 
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mulipotent differentiation (Deonarain, Kousparou & Epenetos 2009; Ebben et al. 
2010; Shackleton 2010), they are often referred to as cancer stem cells (CSCs). CSCs 
were initially identified in leukaemias and then implicated in various solid tumours 
(Alvero et al. 2009; Hanahan & Weinberg 2011; Wakimoto et al. 2009). Increasing 
evidence indicates that many, perhaps all, cancers are organised hierarchically with 
CSCs and non-CSCs (Heuser & Humphries 2010). CSCs have the ability to generate 
a xenograft histologically similar to the parent tumour. Daughter cells generated 
from CSCs are able to proliferate but unable to initiate or mantain tumours due to 
their lack of intrinsic regenerative potential (O'Brien, CA, Kreso, A & Jamieson, 
CHM 2010). Although CSCs only represent a very limited proportion of all tumour 
cells, they are resistant to traditional chemotherapy and radiotherapy which can kill 
other cells in tumours (Bao et al. 2006). Thus, CSCs have the potential to propagate 
and sustain tumourigenesis (Moitra, Lou & Dean 2011; Trumpp & Wiestler 2008; 
Visvader & Lindeman 2008). Therefore, CSCs are defined as a small subpopulation 
of self-renewing tumour cells which have the capacity to generate heterogeneous 
lineages of all cancer cells comprising a tumour (Clarke et al. 2006). 
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Figure 1-3. Stochastic versus cancer stem cell hypothesis of tumours (adapted from Ward 
and Dirks 2007). In the stochastic model (right), all cells within a heterogeneous human 
tumour have the ability to regenerate tumours. In contract, the cancer stem cell model (left) 
suggests that only a small subpopulation of cells within the tumour is tumourigenic.(Ward & 
Dirks 2007) 
The CSC hypothesis is an attractive model to explain how established tumours are 
able to propagate (Shackleton 2010). Based on this hypothesis, the bulk of cells in 
the tumour are composed of non-CSCs which are non-tumourigenic and have limited 
potential of proliferation (Koch, Krause & Baumann 2010). Compared to these 
differentiated cancer cells, CSCs have slower cell cycling, lower proliferation, anti-
apoptosis genes and protective mechanisms for DNA repair (Deonarain, Kousparou 
& Epenetos 2009; Phillips, TM, McBride & Pajonk 2006). Thus, CSCs are more 
resistant to common chemotherapy and radiotherapy. There is increasing evidence 
that CSCs share similar critical features with normal stem cells. For example, self-
renewal, the mechanism required for maintaining and expanding populations in 
normal stem cells, can be found in CSCs (Hope, Jin & Dick 2004). Moreover, 
differentiation, another functional capability of normal stem cells, can also be 
observed in CSCs. Thus, due to these properties, the initiation of tumours and tumour 
recurrences after anticancer therapies are thought to be associated with CSCs 
 27 
 
(Sánchez-García, Vicente-Dueñas & Cobaleda 2007). Furthermore, Chaffer et al. 
indicated that non-CSCs have the potential to convert to CSCs both in vitro and in
vivo (Chaffer et al. 2011). Therefore, studies about CSCs will lead to a better 
understanding of the mechanisms driving tumour growth as well as improved 
diagnosis and therapy for tumours. The development of efficient treatment strategies 
requires reliable and sufficient isolation of CSCs. Measurements of specific cell 
surface markers by flow cytometry have been used for characterisation of CSCs 
(Table 1-1).   
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Table 1-1. Summary of markers used for cancer stem cells 
Tumours Markers References 
Acute myeloid leukemia CD34+/CD38- (Kassem 2008) 
Breast cancer 
CD44+/CD24-/low
ALDH1+ 
CD133+ 
CD44+/CD24-/epithelial cell 
adhesion molecule + 
(EpCAM +) 
(Lorico & Rappa 2011; 
Stratforda et al. 2010; Velasco-
Velázqueza et al. 2012; Zheng, 
Wb et al. 2012)  
Brain cancer 
CD133+ 
Nestin+ 
A2B5+ 
CD15+ 
(de Antonellis et al. ; Ishiwata, 
Toshiyuki, Matsuda, Yoko. & 
Naito, Zenya. 2011; 
Tchoghandjian et al. 2010; Yu, 
S-p et al. 2011) 
Colon cancer 
CD133+
EpCAM+ 
EpCAMhigh/CD44+/CD166+ 
CD44+/CD24+ 
CD24+/CD133+ 
CD24+/CD29+ 
(Kemper, Grandela & Medema 
2010; LaBarge & Bissell 2008; 
Levin et al. 2010; Yeung, Trevor 
M. et al. 2010; Yu, X et al. 
2011) 
Pancreatic cancer 
CD44+/CD24+/ EpCAM+
CD133+ 
CXCR4+ 
DCAMKL-1+ 
(May et al. 2010; Singh, S et al. 
2010; Wei, H-J et al. 2011) 
Prostate cancer 
CD133+
CD44+/integrin Į2ȕ1+/CD133+
CD44+ 
FAM65Bhigh/MFI2low/LEF1low 
ALDH1A1+ 
CD133+/ Trop-2+ 
(Hellsten et al. 2011; Lee, HJ et 
al. 2011; Trerotola et al. 2010; 
Zhang, K & Waxman 2010; 
Zhang, Ye. et al. 2012) 
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1.1.2.4.1 Breast cancer 
Breast cancer is a complex and heterogeneous disease (Lorico & Rappa 2011). 
Amongst solid tumours, it was the first one in which CSCs were identified and 
isolated (Al-Hajj et al. 2003). A subpopulation of cells with high expression of CD44 
but low levels of CD24 were able to form tumours in vivo with as few as 100 cells. 
On the contrary, a large number of cells without this surface marker were found to 
lack of tumour-initiating capacity. Moreover, a study into the role of CD44+ breast 
CSCs in mice indicated its role in metastasis (Liu, H et al. 2010). Analysis in the 
clinic also found there was a relationship between CD44+/CD24-/low breast cancer 
cells and metastasis. Abraham et al. indicated that breast cancer patients who had a 
high percentage of CD44+/CD24-/low cells had distant metastasis (Abraham et al. 
2005). However, CD44 and its isoforms can be expressed in many cancer cell types. 
It can also be used as a marker for other epithelial tumours, such as colon tumours 
(Cho et al. 2012). Moreover, it has been shown that the silencing of CD24 did not 
contribute to tumourigenicity (Lorico & Rappa 2011). Thus, more attention has been 
given to other surface markers, such as aldehyde dehydrogenase (ALDH) and CD133, 
with high activity of ALDH isoform 1 (ALDH1) observed in the tumourigenic cells 
(Ginestier et al. 2007). Activation of the enzymatic activity of ALDH1 in breast 
epithelium has been shown to be a marker of breast CSCs. Meanwhile, breast cancer 
cells with ALDH1 displayed functional properties of stem cells such as renewal and 
differentiation (Kunju et al. 2011). CD133, which is also known as Prominin-1, is a 
transmenmbrane glycoprotein and is one of the most commonly studied markers for 
isolating CSCs. Interestingly, CD133 has a much restricted expression compared to 
CD44. Breast cancer cells with CD133 expression have been reported to possess a 
higher ability to initiate tumours in nonobese diabetic/severe combined 
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immunodeficiency (NOD/SCID) mice (Liu, Q et al. 2009). In other studies, EpCAM, 
was used as another cell surface marker for CSCs. Fillmore et al. demonstrated that 
breast cancer cells with CD44+/CD24-/EpCAM+ phenotype enriched for CSCs in 
human breast cancer cell lines (Fillmore & Kuperwasser 2008). 
1.1.2.4.2 Brain cancer 
The cell surface marker CD133 is also used for the identification of CSCs in brain 
tumours. Increasing data indicates the correlation between the CD133+ cells in 
primary tumours and clinical outcome. Singh et al. demonstrated that a 
subpopulation of CD133+ cells possesses stem cell properties in vitro. Meanwhile, 
only the CD133+ brain tumour fraction was reported to initiate tumours in 
NOD/SCID mice (Singh, SK et al. 2004). In clinical studies, an increased CD133 
expression was reported to be related to a higher risk of tumour relapse in patients 
with the World Health Organisation (WHO) grade 2 and grade 3 gliomas 
(Zeppernick et al. 2008). Moreover, as few as 100 CD133+ cells could lead to the 
initiation of tumours in NOD/SCID mice while 100-times more CD133- cells were 
unable to propagate a tumour in vivo (Das, Srikanth & Kessler 2008). Nestin, an 
intermediate filament (IF) protein, has been reported as another marker for brain 
CSCs. The CD133+/Nestin+ cells showed self-renewal and tumour initiation 
capacities (Ishiwata, Toshiyuki., Matsuda, Yoko. & Naito, Zenya. 2011). A2B5, 
which is a cell surface ganglioside that marks neural precursor cells in the adult 
human brain, was also demonstrated as another marker of brain CSCs (Gilbert & 
Ross 2009). Tchoghandjian et al. reported that expression of A2B5 played a role in 
the initiation and maintenance of brain tumours (Tchoghandjian et al. 2010). 
Additionally, reports have shown that both A2B5+/CD133- and A2B5+/CD133+ cells 
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had a higher ability to form tumours than A2B5-/CD133- cells (Ogden et al. 2008). 
CD15, also known as stage-specific embryonic antigen 1 (SSEA-1), has been 
demonstrated as an additional CSC marker for brain tumours. Cells isolated from 
glioblastomas with CD15+ phenotype displayed stem cell properties (Kim, K-J et al. 
2011).  
1.1.2.4.3 Colon cancer 
Colon CSCs were initially identified by CD133 expression. However, the use of 
CD133 as a marker for identification and isolation for colon CSCs has been debated 
as it can be expressed in many other tumours, such as brain tumours, kidney tumours 
and prostate tumours, and epithelial cells of normal tissues (LaBarge & Bissell 2008; 
Todarolow et al. 2010). Thus, cell surface markers other than CD133 have been 
studied. For instance, cells positive for EpCAM have been reported to have an 
engraftment property in NOD/SCID mice (Dalerba et al. 2007). Moreover, ALDH1 
has been identified as a marker to detect CSCs in colon cancer (Deng et al. 2010). 
Meanwhile, CD24, CD29, CD44 and CD166 were reported to enrich for colon 
cancer CSCs (Abdul Khalek, Gallicano & Mishra 2010), and 
EpCAMhigh/CD44+/CD166+ was identified as a phenotype of tumourigenic cells in 
colorectal cancer (Dalerba et al. 2007). Cells sorted by fluorescence-activated cell 
sorting (FACS) indicated that CD44 and CD24 can also be used as cell surface 
markers of CSCs in the colorectal carcinoma cell line SW1222. SW1222 cells with a 
CD44+/CD24+ phenotype have the ability to initate tumours in vivo (Yeung, Trevor. 
M. et al. 2010). As well, Vermeulen et al. found that cells coexpressing CD24 and 
CD133 had higher clonogenic potential. Meanwhile, cells with CD24 and CD29 
 32 
 
expression have been defined as the colorectal CSC population (Vermeulen et al. 
2008).  
In summary, as CSCs seems to be associated with mechanisms protecting tumour 
cells from standard therapy, this minority subpopulation of cells could be used to 
assist in the design of new and more effective anticancer therapies. For example, 
disulfiram, an inhibitor of the cellular surface marker of CSCs ALDH, has been 
reported to inhibit the mammosphere formation of breast cancer cells effectively in a 
copper (Cu)-dependent manner (Yip et al. 2011). 
1.1.2.5 Targeted anticancer therapy 
Traditional anticancer therapy is based on the inhibition of cell division. Thus, 
rapidly dividing cells, such as cells of the hair, gastrointestinal epithelium and bone 
marrow, could be affected by drugs during treatment (Gerber 2008). In contrast, 
targeted therapy is an approach which aims to block the proliferation of tumour cells 
only. For example, targeted therapy can focus on the molecules which are mutant or 
overexpressed in tumours. Antibodies against the cell surface markers cluster of 
differentiation 20 (CD20) were utilised as one of the earlist targeted therapies in the 
treatment of autoimmune disease, such as non-Hodgkin’s lymphoma (Feugier et al. 
2005).  
Targeted therapy includes various direct and indirect approaches. In direct 
approaches, monoclonal antibodies (mAbs) or other small molecules which could 
interfere with targeted proteins are used to target tumour antigens that have the 
potential to alter signalling pathways; while in indirect approaches, ligands 
containing a variety of effector molecules are utilised to target the antigens expressed 
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on the cell surface (Wu, H-C, Chang & Huang 2006). Thus, anticancer 
chemotheraputics can target tumour cells via tumour-specific receptor-ligand binding 
of mAbs or other small molecules.  
1.1.2.5.1 Antibody-targeted therapy 
Antibodies, also known as “targeting missiles”, play a critical role in targeted 
therapy. The US Food and Drug Administration (FDA) approved muromonab-CD3 
(Orthoclone OKT3) as the first monoclonal antibody to prevent acute organ rejection 
after transplantation by blocking T-cell function in 1986. Since then, another 20 
mAbs have been approved, and approximately half of them are utilised for anticancer 
treatment (Gerber 2008). The mechanisms underlying anticancer effects of mAbs 
vary, such as recruiting host immune functions to attack target cells, or carrying a 
lethal payload which is toxic to the targeted cells (Adams, GP & Weiner 2005). As 
their protein structures are denatured in the gastrointestinal tract, mAbs are usually 
administrated via i.v. injection. To minimise the undesirable effects of the 
hypersensitivity reaction to the mouse proteins in humans, more and more mAbs 
used now are humanised, having an greater proportion of human components (Carter 
2001).  
1.1.2.5.2 Small molecule inhibitors 
Extensive investigations  have indicated that mutation or overexpression of protein 
phosphorylation-related pathways is often found in tumour cells (Freedman et al. 
2002; Lammering et al. 2001). Thus, targeted anticancer therapy could be designed 
to be mono-specific to avoid side effects to normal cells. Therefore, as well as mAbs, 
small molecule inhibitors which could interrupt aberrant cellular signaling by 
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interfering with key protein kinases involved, are also utilised for the targeted 
anticancer therapy.  
Unlike mAbs, small molecule inhibitors are chemically manufactured which is less 
expensive than antibodies (Tanner 2005). However, due to the multitargeting nature 
of the inhibitors, they are often less specific compared to mAbs (Imai & Takaoka 
2006). Moreover, the half lives of most small molecule inhibitors are only a few 
hours whereas mAbs have much longer half lives from days to weeks (Kantarjian, H 
et al. 2002).  
Most small molecule inhibitors are used to target plasma membrane-associated 
protein tyrosine kinases (Cohen 1999). The first inhibitor was developed in the early 
1980s and more than 30 agents are now in clinical trials (Dancey & Sausville 2003). 
Imatinib, one of the first small molecule inhibitors, was approved in 2001 for the 
treatment of chronic myeloid leukemia (Kantarjian, HM et al. 2003). Meanwhile, 
small molecule inhibitors that target the epidermal growth factor receptor (EGFR) 
pathway are utilised for solid cancer treatment, including non-small cell lung cancer 
(Gerber 2008). 
1.1.2.5.3. Aptamer-targeted therapy 
Although antibodies have been widely used for active targeting in anticancer 
treatments, the long clearance half-time and the incomplete penetration into target 
tissues limit their use for imaging and therapy in the clinic (Hicke, Brian J. et al. 
2005). Thus, new targeting agents are needed.  
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Aptamers, single-stranded or double-stranded oligonucleotides selected via an in
vitro process of systematic evolution of ligands by exponential enrichment (SELEX, 
Figure 1-4), can be considered as nucleic acid analogues of antibodies (Lee, JH et al. 
2010). Compared to traditional antibodies, aptamers have strong affinities and high 
specificities to their targets. Moreover, aptamers can bind to various non-nucleic acid 
targets (Edwards & Baeumner 2007), such as ions (Ciesiolka, Gorski & Yarus 1995), 
small molecules, proteins (Latham, Johnson & Toole 1994) or bacteria.  In addition, 
aptamers are simple to synthesis (Ellington & Szostak 1990; Tuerk & Gold 1990) 
with reduced batch-to-batch variability (Floege et al. 1999; Thiel & Giangrande 2010) 
and a lack of immunogenicity compared to antibodies (Wang, P, Yang, et al. 2011a). 
Furthermore, the affinity and specificity of aptamers can be further optimised via 
post-selection engineering (Floege et al. 1999; Keefe & Cload 2008). Notably, 
aptamers have been well-documented to be quite stable even under extreme 
conditions, such as extremely high or low pHs, which means they can be denatured 
and renatured multiple times without significant loss of activity (Liss et al. 2002). 
Furthermore, aptamers are capable of greater specificity and affinity compared to 
antibodies (Willner & Zayats 2007). Thus, aptamers have the potential to greatly 
facilitate the development of novel anticancer applications. As CSCs have become 
the focus of anticancer treatments nowadays, new aptamers have been developed for 
targeting CSCs. For example, Shigdar et al. has developed the RNA aptamer against 
a CSCs marker EpCAM and it was demonstrated to be internalised through receptor-
mediated endocytosis efficiently upon binding cancer cells (Shigdar et al. 2011). 
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Figure 1-4. SELEX technology (adapted from Esposito, Catuogno et al. 2011). The initial 
step of SELEX procedure is the synthesis of a single-stranded nucleic acid (RNA/DNA) 
library of large sequence complexity. Then, the folded oligonucleotides are selected by the 
capability of binding with high affinity and specificity to target molecules. Unbound 
oligonucleotides are removed by several stringent washing steps of the binding complexes. 
The target-bound oligonucleotides are eluted and subsequently amplified by the polymerase 
chain reaction (PCR) or reverse transcription-polymerase chain reaction (RT-PCR). The 
newly generated nucleic acid pool serves as a starting library for a new SELEX cycle. The 
number of SELEX repetitions depends on the library type used and on specific enrichment 
achieved per selection cycle and 6 to 20 SELEX rounds are usually needed for the selection 
of high affinity, target-specific aptamers. After the last round of aptamer selection, the PCR 
products are cloned and sequenced. (Esposito et al. 2011)  
 
1.2. Cancer nanotechnology 
Traditional anticancer chemotherapy is characterised by poor functional specificity 
for tumour cells. As a result, anticancer drugs generally have relatively low 
therapeutic effects as well as serious side effects, such as bone marrow suppression, 
gastric erosion, hair loss, renal toxicity and cardiomyopathy, etc. (Myc et al. 2010; 
Surendiran et al. 2009). Hence, one of the main goals of modern cancer 
chemotherapy is to develop a safe and effective drug carrier that could act 
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preferentially at the selected targets while leaving normal tissues intact (Gullotti & 
Yeo 2009). To improve the efficacy of drug delivery, nanotechnology-based drug 
delivery systems are gaining considerable attention as they have the potential to 
reduce side effects, minimise toxicity and improve anticancer efficacy (Suri, Fenniri 
& Singh 2007). 
Nanotechnology is the engineering and manufacturing of nano-sized molecules 
using atomic or molecular components, which can be expected to benefit all fields of 
medicine (Alexis, Frank, Rhee, June-Wha, et al. 2008). It is considered to be an 
emerging technology that will have a significant impact on the advancement of 
tumour therapies (Kim, KY 2007). Novel advances in drug delivery and formulations 
to tumours are utilising nanotechnology that has been applied to overcome some of 
the problems associated with traditional chemotherapeutic treatment of tumours 
(Bawarski et al. 2008; Minko et al. 2006). Various nanotechnology platforms such as 
dendrimers, liposomes, polymeric micelles and solid nanoparticles are being 
developed (Bawarski et al. 2008; Surendiran et al. 2009). The utilisation of 
nanoparticles as carriers of conventional chemotherapeutic agents has been shown 
experimentally to improve cancer treatment efficacy (Ma et al. 2009).  
Tumour tissues differ from healthy tissues in several aspects, with researchers 
exploiting these differences when developing improved anticancer agents. The 
defective vasculature and impaired lymphatic system leads to the EPR effect, 
resulting in selective extravasation and accumulation of macromolecules in tumours 
(Gullotti & Yeo 2009). The nanoparticle delivery system, such as nanoshells, 
polymer micelles and liposomes, is based on the EPR effect, enhancing drug efficacy 
and reducing non-specific toxicity as a reduction in systemic exposure (Ma et al. 
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2009; Maeda, Hiroshi 2001). Indeed, according to extensive studies, the 
concentration of polymer drugs in the tumour could be 10 to 100 fold higher than 
that of the free drug (Ganta, Srinivas et al. 2008). To take advantage of the EPR 
effect, nanoparticles with passive targeting properties are utilised. Most fenestrate 
openings in tumours are below 150 nm, so the nanocarriers can be made with a size 
smaller than 150 nm for efficient extravasation. However, the filtration ability of the 
kidney can filter particles smaller than 10 nm (about 70,000 Da), while particles 
larger than 100 nm could be captured by the liver. Therefore, the ideal size of 
nanocarriers for drug delivery is 10 to 100 nm as particles with such sizes minimise 
extravasation in normal tissues but allow efficient accumulation at the tumour site 
(Gullotti & Yeo 2009). 
When nanoparticles are i.v. administered, they often bind with serum proteins and 
are recognised by the scavenger receptor on the surface of macrophages, which leads 
to a significant loss of nanoparticles in the circulation (Li, S-D & Huang 2008). The 
proteins binding to the nanoparticles are termed “opsonins”, and the system 
contributing most to the loss of injected nanoparticles is known as the 
reticuloendothelial system (RES) or mononuclear phagocyte system (Drummond, D. 
C. et al. 1999b). Thus, it is also critical to prevent nanoparticle uptake by the RES 
(Drummond, D. C. et al. 1999b), which can destroy foreign materials by opsonisation 
followed by phagocytosis (Gullotti & Yeo 2009). A widely used strategy for 
shielding nanocarriers is to coat the surface of nanocarriers with a hydrophilic 
polymer or glycolipid, such as polyethylene glycol (PEG) (Drummond, D. C. et al. 
1999b; Gullotti & Yeo 2009; Yan et al. 2009). These flexible chained polymers or 
glycolipids can occupy the sites on the surface of nanocarriers that would otherwise 
bind with plasma opsonins from the RES macrophages (Drummond, D. C. et al. 
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1999b; Newton 2006; Remauta et al. 2007). Thus, the prolonged circulation time of 
nanoparticles in the bloodstream increases the ability of drugs to reach their sites of 
action, thereby improving the efficacy and safety as compared with conventional 
preparations (Ma et al. 2009; Surendiran et al. 2009).   
1.2.1 Nanoparticle therapeutics for cancer 
Anticancer nanoparticle therapeutics typically utilise particles composed of 
therapeutic agents that are assembled with nanomaterials, such as lipids, dendrimers, 
and inorganic semiconductor nanocrystals (Davis, Chen & Shin 2008; Ganta, 
Srinivas et al. 2008). The resulting nanoparticles may have functional properties that 
are conferred through the assembly of individual components but not by the 
individual components alone (Alexis, Frank , Rhee, June-Wha , et al. 2008). Studies 
indicate that nanoparticles used in cancer chemotherapeutics possess more specific 
targeting ability to tumour cells. The enhanced drug absorption and bioavailability of 
anticancer agents results in an improved anticancer efficacy and decreased side 
effects (Davis, Chen & Shin 2008; Li, S-D & Huang 2008). Some nanoformulations 
of traditional anticancer agents have already been approved for use in the clinic. For 
example, Doxil® and Abraxane® are two nanoformulations approved by the US FDA 
for cancer treatment. Doxil® is a long circulating formulation of doxorubicin (DOX), 
which has been well known for significant improvements over free DOX. Abraxane® 
is an albumin-bound nanoparticle formulation of paclitaxel for the treatment of 
metastatic breast cancer, reducing the hypersensitivity reaction associated with the 
traditionally used solvent for paclitaxel (Bharali et al. 2009). Other nanocarriers, 
such as co-polymer poly (lactic-co-glycolic acid), have also been approved by the US 
FDA for the use of drug delivery, diagnostics and other applications of clinical and 
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basic science research, including cancer (Lü et al. 2009). The enhanced anticancer 
effects and improved safety compared with their free-drug counterparts are due to the 
size and surface properties of the nanoparticles. 
1.2.1.1 Size 
To protect the human body from invasion by foreign particles, the immune system 
and other mucosal barriers function as biological barriers (Alexis, Frank , Pridgen, 
Eric , et al. 2008). Anticancer nanoparticles should have the potential to bypass these 
barriers to reach their target. The unique size of nanoparticles contributes to 
overcoming these barriers as well as the accumulation in tumours. It is widely 
accepted that the diameter of nanoparticles for cancer treatment should be in the 
range of 10 to 100 nm (Davis, Chen & Shin 2008; Gullotti & Yeo 2009). The lower 
limit is based on renal filtration, where particles smaller than 10 nm are rapidly 
cleared by the kidneys. The upper limit is based upon pore sizes in the liver and the 
spleen. The diameter of fenestrae sizes in the liver is 50-100 nm, while the size can 
be up to 150 nm in the spleen (Alexis, Frank , Pridgen, Eric , et al. 2008; Campbell 
2006; Drummond, D. C. et al. 1999b). Therefore, nanoparticles of 10 - 100 nm in 
size which can penetrate the tumour vasculature will still be accumulated in the liver 
and spleen which are two other accumulation sites of nanoparticles in addition to 
tumours (Davis, Chen & Shin 2008; Drummond, D. C. et al. 1999b) and are removed 
mainly by macrophages residing in these two organs. Thus, if the nanocarriers can 
avoid being removed by macrophages, they are free to pass in and out of the liver 
and spleen and have more opportunities to get into the tumours (Drummond, D. C. et 
al. 1999b). One of the classical approaches to avoid particle clearance of 
macrophages is to administer large doses of placebo carriers to impair the phagocytic 
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capacity of macrophages, thereby allowing subsequently administered drug-
encapsulated nanoparticles to remain in systemic circulation for prolonged periods or 
to reach designated targets (Moghimi & Davis 1994). Other approaches, including 
modification of the surface of nanocarriers, have been introduced to prolong the 
circulation life (Fang, Hu & Zhang 2012). 
1.2.1.2 Surface properties of nanoparticles 
Nanoparticles have higher surface-to-volume ratio than larger particles. As a result, 
control of nanoparticle surface properties is essential to control their behaviour 
(Davis, Chen & Shin 2008). Key nanoformulation properties that are important for 
drug delivery are biocompatibility and biodegradability, ensuring that unloaded 
carriers are human degradable or metabolised into non-toxic components and cleared 
by the body (Malam, Loizidou & Seifalian 2009). The rapid loss of nanoparticles 
from the circulation before reaching their targets can affect the efficacy of the 
nanoparticle therapeutics. To minimise the loss, strategies have been devised not 
only with regard to optimising their size, but also surface modification of 
nanoparticles. To improve tumour targeting, the surface of nanoparticles can be 
modified in different ways, with both passive and active targeting strategies are 
utilised to modify the surface of nanoparticles.  
1.2.2.2.1 Passive targeting properties 
Passive targeting strategies rely on the passive accumulation of nanoparticles due 
to the properties of the delivery system and/or the pathophysiology of target tissues. 
For example, retention due to the increased size of nanoparticles is one approach of 
passive targeting, taking advantage of the EPR effect (Hoffman 2008). Furthermore, 
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nanoparticles that are sterically stabilised by other polymers, such as PEG, on their 
surface can also increase the circulation time of nanoparticles in the bloodstream and 
protect the nanoparticles from the RES, a property that is critical for nanoparticles to 
escape from rapid clearance in the circulation (Drummond, D. C. et al. 1999b). In 
addition, it has been well-documented that the physicochemical characteristics of 
nanoparticles such as surface charge or functional groups can affect its uptake by 
cells of the phagocytic system, resulting in a prolonged half-life in the bloodstream 
(Gabizon, A, Shmeeda & Barenholz 2003; Ogawara, K-i et al. 2009; Yan et al. 2009). 
A slightly charged surface, either positive or negative, on the nanoparticle can 
protect the nanoparticles from undesired aggregation due to a reduction in self-to-self 
or self-to-non-self interactions (Davis, Chen & Shin 2008; El-Aneed 2003). However, 
renal filtration has the ability to filter positively charged particles (Gullotti & Yeo 
2009). On the other hand, blood vessels repel negatively charged nanoparticles 
(Davis, Chen & Shin 2008). Therefore, nanoparticles carrying a positively charged 
surface are expected to have a high non-speci¿c internalisation rate and short blood 
circulation half-life whereas negatively charged particles would perform better when 
delivering drugs into tissues as they diffused at a faster rate (Kim, B et al. 
2010). Taken together, control of surface charge will help to prevent the loss of 
nanocarriers. The pH-sensitive nanoparticle is another example of passive targeting 
nanocarriers. Tumour cells often proliferate rapidly. As a result, it is difficult for the 
expanding tumour cell population to obtain sufficient oxygen and nutrients from the 
tumour vasculature. Regions distant from vessels have slow cellular growth, 
substantial cell death, and necrosis due to insufficient oxygen and nutrient supply 
from vessels (Figure 1-5) (Campbell 2006). Moreover, lack of oxygen leads to 
production of CO2, carbonic acid and lactic acid, resulting in low interstitial pH, 
another characteristic of the tumour microenvironment (Schornack & Gillies 2003). 
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As a result, the pH around tumour tissues could be 5.5 to 6.5 (Ganta, Srinivas et al. 
2008). Therefore, pH-responsive nanocarriers have significant enhanced stability in 
circulation but release their payload (chemotherapy drugs) in the tumour. For 
example, a 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier showed a 
significant faster release rate at pH 6.5 than at pH 7.4, resulting in a longer half-life 
after i.v. administration and high tumour targeting in mice (Jin et al. 2011). 
 
Figure 1-5. The tumour microenvironment (adapted from Minchinton and Tannock 2006). 
Tumour cells generally have accelerated proliferation which is dependent on the supply of 
oxygen and nutrients. Therefore, cells surrounding blood vessels proliferate actively while 
those away from blood vessels inevitably die.   (Minchinton & Tannock 2006)  
 
1.2.2.2.2 Active targeting 
Passive targeting approaches, however, have several limitations and nanoparticle 
targeting is ubiquitous and non-specific, leading to inefficient diffusion and 
difficulties in the control of the drug delivery process. Moreover, certain tumours 
lack the EPR effect which is a prerequisite for passive targeting (Peer, Dan et al. 
2007). Functionalising the surface of nanoparticles with ligands such as antibodies, 
aptamers, peptides, or small molecules that are tumour-speci¿c or tumour-associated 
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can promote the active binding of nanoparticles to tumours (Alexis, Frank, Rhee, 
June-Wha, et al. 2008).  
Recently, due to a better understanding of cancer and the revolution in medicine, 
targeted therapies in cancer has been developed (Malinowsky et al. 2010). MAbs and 
small molecule inhibitors are two major types of targeted therapy that can lead to the 
selective inhibition of proliferation of cancer cells rather than normal rapidly 
dividing cells such as hair, gastrointestinal epithelium and bone marrow (Gerber 
2008). The FDA has already approved several mAbs for cancer treatment. For 
example, Alemtuzumab, targeting CD52, was approved for chronic lymphocytic 
leukemia successfully (Gerber 2008). Signaling pathways in tumours now become 
the focus of development of targeted anticancer therapies and kinases within such 
pathways are of specific intesest. For example, cetuximab, which targets the 
epidermal growth factor receptor (EGFR), has been used for the treatment of 
metastatic colorectal cancer in clinic (Dietel & Sers 2006). In a word, mAbs have 
been extensively used for molecular targeting as its high affinity, specificity as well 
as a variety of targets (Hicke, Brian J.  et al. 2005; Syed & Pervaiz 2010).  
Thus, combining nanoparticles with small molecules which could target cancer 
cells or CSCs could improve the targeting property of nanoparticles as they can 
recognise and bind to target cells via ligand-receptor interactions. Importantly, to 
maximise specificity in binding, the antigen or receptor on the target cells should be 
overexpressed in cancer. For example, nanoparticles with folic acid can target 
tumour cells overexpressing folic receptor (Goren, D. et al. 2000). The poly[N-(2-
hydroxypropyl) methacrylamide] copolymer containing DOX, known as PK2, was 
used to target the asialoglycoprotein receptor which is highly expressed on primary 
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liver cancer cells (Julyan et al. 1999). Anti-Her2-targeted immunoliposomal DOX 
was designed based on the overexpression of HER2 receptors and study has 
indicated that the therapeutic efficacy of the targeted liposomal formulation was 
superior to its non-targeted counterpart for breast cancer (Park, JW et al. 2002). 
Furthermore, binding of certain ligands to their receptors can result in receptor-
mediated internalisation, while binding of some other ligands can lead to non-
internalisation. The former approach can contribute to the release of agents inside the 
cells. For example, immunoliposomes with an internalizing anti-CD19 ligand had a 
significantly improved therapeutic efficacy than their counterpart with a non-
internalizing anti-CD20 ligand (Sapra, P. & Allen 2002). On the contrary, the latter 
approach has the advantage of killing tumours by releasing drugs outside the tumour 
cell, followed by passive diffusion into the target cells (Figure 1-6) (Allen, T. M. 
1994a, 2002).  
 Figure 1-6. Active cellular targeting of nanoparticles (adapted from Peer, Karp et al. 
2007). Binding of certain ligands on nanocarriers to their receptors can result in (i) Releasing 
their contents in close proximities to the target cells; (ii) Attaching to the membrane of the 
cell and acting as an extracellular sustained-release drug depot, or (iii) Internalising into the 
cell. (Peer, Dan   et al. 2007) 
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Overall, surface functionality is a critical parameter in the development of 
nanoparticles. The minimisation of the loss of nanoparticles via sterical stabilisation, 
control of surface charge and modification with ligands would enhance their 
diagnostic and therapeutic potential (Yang, C et al. 2008). 
1.3. Liposomes 
Lipids are functional components of the biomembrane. Liposomes are created by 
self-assembly of lipids, which enclose an aqueous space (Figure 1-7) (Bawarski et al. 
2008; Hafez & Cullis 2001; Kshirsagar et al. 2005). Liposome research into drug 
encapsulation and delivery has been carried out since the 1970s. Liposomes have 
been used for anticancer nanoparticles since the mid-1990s (Davis, Chen & Shin 
2008; Kim, KY 2007) and liposome-derived technology is established as one of the 
cornerstones of nanotechnology in various fields, including medicine (Jesorka & 
Orwar 2008). Several liposomal formulations, such as liposomal formulation of 
DOX (Doxil®) and daunorubicin (DaunoXome®), have received clinical approval 
due to their improved pharmacokinetics (PK) and pharmacodynamics of anticancer 
agents. Other liposomal anticancer drugs are currently being studied in clinical trials 
(Allen, T. M. & Cullis 2004). 
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Figure 1-7. Liposomes (adapted from Davis, Chen et al. 2008). Liposomes are self-
assembling colloid structures composed of lipid bilayers surrounding an aqueous 
compartment, and can encapsulate a wide variety of therapeutic agents both in the internal 
aqueous space and/or in the lipid bilayer. (Davis, Chen & Shin 2008) 
 
1.3.1 History and development of liposomes for anticancer drug delivery 
Liposomes were discovered in 1965 (Bangham, Standish & Watkins 1965). As 
liposomes are bilayers of lipids, they were widely used as a model of cellular 
membranes initially (Metteucci & Thrall 2000). However, soon after their initial 
discovery, they were recognised as novel drug carriers for diagnostic and therapeutic 
agents (Phillips, WT, Goins & Bao 2009; Wiechers 2005). 
Stability is a critical factor that should be taken into consideration for the design 
and development of liposome-based drug delivery systems. The chemical stability of 
lipids and drugs, the physical or colloidal stability of liposomes and the drug release 
properties contribute to the overall stability of liposome-based formulations of drugs 
(Domb et al. 2007). The classic liposomes, also known as conventional liposomes, 
might be cleared by the RES quickly from circulation within minutes to hours after i. 
v. administration (Domb et al. 2007; Metteucci & Thrall 2000; Oku & Namba 1994). 
Therefore, due to the poor performance of conventional liposomes in vivo, they have 
limited clinical applications. As a result, reduced opsonisation of liposomes is 
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expected to prolong their circulatory half-life in the bloodstream and increase the 
possibility of accumulation in tumour tissue due to the EPR effect (Fenske & Cullis 
2005). As opsonins and RES play important roles in the stability of nanoparticles, 
minimising the binding of opsonins to nanocarriers is critical to developing long 
circulating nanocarriers (Lasic, Danilo D. & Needham 1995; Ogawara, K-i et al. 
2009). To avoid RES trapping of liposomes, the approach to surface modification of 
liposomes to escape fast removal from the circulation has been considered (Hao et al. 
2005; Oku & Namba 2005). Improvement, including the reduction in diameter and 
modification of the surface of conventional liposomes had been introduced to 
prolong the liposomes circulation life. One of the most important breakthroughs in 
liposome-based formulations was the discovery of a PEG coating (Metteucci & 
Thrall 2000). PEG is a semi-crystalline, hydrophilic polyether with a high solubility 
in water and other aqueous media (Allen, T. M. et al. 1991; Senior et al. 1991). PEG 
can slow down liposome recognition by opsonins via the formation of a protective 
layer over the liposome surface, leading to decreased clearance of liposomes 
(Gabizon, AA 2001b). As a result, PEG-coated liposomes generally have a longer 
circulation half-life in the bloodstream than conventional liposomes. Numerous 
studies have demonstrated that PEG-coated liposomes could accumulate in the 
cancer via the EPR effect avoiding the fast clearance in the RES (Cattel, Ceruti & 
Dosio 2003; Dos Santos et al. 2005; Ogawara, K et al. 2008). Thus, they are known 
as sterically stabilised liposomes (Domb et al. 2007; Metteucci & Thrall 2000; 
Moreira et al. 2002). The sterically stabilised liposomes also have the potential to 
improve the efficacy of chemotherapy for cancer and reduce side effects (Song, CK 
et al. 2009). This is best illustrated by Doxil®, a liposomal formulation of DOX. 
DOX is an anthracycline anticancer drug. Although it is widely used in the clinic, the 
cardiotoxicity of this drug limits its clinic utility. When a cumulative DOX dose 
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reaches 450 to 500 mg/m2, congestive heart failure and death often occur. The 
advantages of Doxil® are greater efficacy and lower cardiotoxicity when compared 
with free drug (Goyal et al. 2005; Hofheinz et al. 2005; Malam, Loizidou & Seifalian 
2009). It is widely used to treat cancer in AIDS-related Kaposi sarcoma and multiple 
myeloma in clinic (Ning et al. 2007). 
Additional surface functionalities of liposomes have also been utilised. 
Conjugating targeting molecules, such as antibodies, ligands, peptides, or aptamers, 
to the surface of liposomes leads to active targeting liposome formulations (Gullotti 
& Yeo 2009; Nallamothu et al. 2006; Newton 2006). The surface of circulating cells 
such as lymphocytes, various antigens like p185HER-2, and low molecular weight 
mAbs have also been the subject of research for targeting liposome formulations 
(Domb et al. 2007). Tumour targeting agents can be attached to the liposome 
phospholipid headgroups or to the end of a PEG derivative, and the latter approach 
has proven to be more effective due to better accessibility of the antibody to its target 
(Domb et al. 2007; Newton 2006). Several mAbs have been shown to deliver 
liposomes to their targets (An et al. 2008; Lapalombella et al. 2008). For example, 
when liposomal formulations of topotecan, vinorelbine, and DOX were attached with 
the anti-CD166 single chain variable fragment, they showed efficient and targeted 
uptake by prostate cancer cell lines, Du-145, PC3, and LNCaP (Roth et al. 2007). 
Recent research on ligands for liposomes has focused on specific receptors 
overexpressed on target cells or certain specific components of pathological cells. 
For example, folic receptor is frequently overexpressed in a range of tumour cells. 
The folate-targeted liposomes have already demonstrated their therapeutic potential 
for murine lung carcinoma and human epidermoid KB carcinomas (Gabizon, A et al. 
2003; Lu & Low 2002). Epidermal growth factor receptor-targeted liposomes were 
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shown to have improved efficacy of encapsulated DOX, epirubicin and vinorelbine 
in vivo (Mamot, C.  et al. 2005; Molema 2005).  
1.3.2 Characterisation of liposomes 
Liposomes are composed of natural components such as pure lipids or lipid 
mixtures. The most commonly utilised lipids are phospholipids, in particular the 
neutrally charged phosphatidylcholine and the negatively charged phosphatidic acid, 
such as phosphatidylglycerol, phosphatidylserine and phosphatidylethanolamine 
(Jesorka & Orwar 2008; Lammers, Hennink & G 2008). The amphiphilic 
phospholipid molecule has a structure containing both a polar region and nonpolar 
aliphatic chains. When placed in an appropriate environment and at specific 
concentrations, these lipids self-associate into a spherical structure with an aqueous 
interior core. The hydrophilic polar groups face the core, while the hydrophobic 
nonpolar portions are tucked into the interior of the membrane bilayer (Bawarski et 
al. 2008; Phillips, WT, Goins & Bao 2009).  
Liposomes can vary in the number of lipid layers they possess and therefore be 
classified into several categories according to their size and lamellarity: 
multilamellar vesicles, oligolamellar vesicles, unilamellar vesicles, giant unilamellar 
vesicles, large unilamellar vesicles, medium-sized unilamellar vesicles, small 
unilamellar vesicles and multivesicular vesicles (Figure 1-8) (Malam, Loizidou & 
Seifalian 2009), and can range from 50 nm to several micrometres (Phillips, WT, 
Goins & Bao 2009). Multilamellar vesicles bigger than 0.5 ȝm are frequently used in 
pharmaceutical and cosmetic applications, whereas small unilamellar vesicles (from 
20 nm to 200 nm), large unilamellar vesicles (up to 1 ȝm) and giant unilamellar 
vesicles (larger than 1 ȝm) are the three most important groups for analytical 
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applications (Domb et al. 2007; Jesorka & Orwar 2008). Furthermore, small 
unilamellar vesicles are widely used for novel drug delivery carriers. However, 
considering the loading efficiency, stability in the bloodstream and the ability of 
extravasation, liposomes ranging from 50 to 150 nm are most promising for drug 
delivery (Metteucci & Thrall 2000; Phillips, WT, Goins & Bao 2009). 
 
Figure 1-8. Liposome classification (adapted from Jesorka and Orwar 2008). Liposomes 
can be classified into different categories, such as multilamellar vesicles, giant unilamellar 
vesicles, large unilamellar vesicles, small unilamellar vesicles and multivesicular vesicles.  
(Jesorka & Orwar 2008) 
As liposomes are composed of naturally biodegradable substances, they are 
metabolised and cleared while in circulation or upon reaching the target sites, making 
them safe novel drug delivery carriers (Domb et al. 2007). Both water-soluble and 
lipid soluble drugs can be carried by liposomes due to its amphiphilic property. The 
closed bilayer vesicles have two potential compartments to encapsulate substances. 
The hydrophilic substance can be entrapped by the hydrophilic aqueous core while 
lipid soluble substances can be trapped by the hydrophobic interior of the membrane 
(Samad, Abdus, Sultana, Y. & Aqil, M. 2007). Moreover, various methods can be 
used to encapsulate substances. Depending on molecular weight, solubility and 
polarity, substances can be trapped either during liposome assembly or loaded into 
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preformed liposomes by different methods. For example, drug loading into 
liposomes can be achieved via liposome formation in an aqueous solution saturated 
with soluble drug, via solvent exchange using organic solvents, via the use of 
lipophilic drugs, and via gradient loading methods (Qiu, Jing & Jin 2008). 
Amphipathic drugs such as DOX can be encapsulated into preformed liposomes with 
an ammonium sulphate gradient method or a pH gradient while hydrophlic drugs can 
be trapped into liposomes upon lipid hydration by passive loading (Domb et al. 2007; 
Metteucci & Thrall 2000). Furthermore, the surface of liposomes can be modified by 
different approaches. For example, PEGylation, the coating liposomes with PEG, or 
ligand attachment are widely utilised to improve the stability and targeting of 
liposomes. 
1.3.3 Advantages of liposomes for anticancer drug delivery 
Many current anticancer drugs have non-ideal properties, which can lead to 
serious consequences, including side effects, lack of efficacy or poor quality of life 
with high drug toxicity being a major barrier to the efficacy of anticancer drugs 
(Allen, Theresa M.  et al. 2006). Since the 1960s, liposomes as carriers for cancer 
chemotherapeutic agents have been investigated in order to improve the efficacy of 
anticancer drugs (Song, CK et al. 2009). 
Liposomes are very versatile drug carriers. Pharmaceutical properties such as 
encapsulation efficiencies of drugs and drug release rates can be manipulated. The 
various sizes of liposomes contribute to a wide variety of options for utilisation 
(Chrai, Murari & Ahmad 2002; Tran, Watts & Robertson 2009; Wiechers 2005; 
Yang, C et al. 2008). Moreover, liposomes can carry abundant agents due to their 
large payload. In addition, the outer lipid bilayer allows the incorporation of other 
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molecules, and therefore liposomes can target specific tissues by either active or 
passive targeting modification (ElBayoumi, aA & Torchilin, VP 2009; Malam, 
Loizidou & Seifalian 2009; Song, CK et al. 2009). Thus, different formulations of 
liposomes can match different requirements in the chemotherapeutic treatment of 
tumours.  
As the size and surface properties of liposomes can be easily manipulated, one can 
manufacture liposomes that have desired circulation times in the bloodstream. In 
addition, the release kinetics of drugs in liposomes can also be modulated to match 
different requirements (Davis, Chen & Shin 2008; Park, K 2007; Torchilin 2006). 
Thus, the pharmacokinetic features as well as the targeting specificities of liposomes 
can be controlled and modified to reduce the side effects of anticancer drugs and 
enhance the efficacy.  
1.3.3.1 Enhanced stability of liposomal drug formulation  
Liposomes have a high therapeutic drug-to-carrier ratio relative to their diameter 
(Allen, Theresa M.  et al. 2006). The drug carried by the liposome (the payload), 
particularly those encapsulated in the liposomes, can be substantially protected from 
enzymatic degradation or inactivation in the plasma as well as unfavourable pH 
which can lead to rapid breakdown of free drugs. As a result, when drugs are inside 
liposomes, their half-life can be prolonged several hours or more due to enhanced 
stability. Paclitaxel (Taxol), a strong antitumour agent, is a prime example. The low 
aqueous solubility of paclitaxel and hypersensitivity reactions in patients to 
Cremophor EL-containing paclitaxel range from mild pruritus to systemic 
anaphylaxis and limit its clinical applications (Paál, Müller & Hegedûs 2001). 
Studies showed that liposome formulations of Taxol enhanced the aqueous solubility 
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as well as the physicochemical stability (Yang, T, Cui, Choi, Lin, et al. 2007). 
Another example is topotecan that is hydrolysed rapidly at physiological pH, limiting 
its clinic applications. To improve the stability and antitumour activity of topotecan, 
Drummond and colleagues encapsulated the drug in liposomal formulations with an 
acidic internal pH (Drummond, D. C. et al. 2010; Hao et al. 2005). 
1.3.3.2 A controlled release system of anticancer drugs  
The rate of release of the payload in liposome formulations depends on drug 
properties, liposome composition, the presence or absence of pH or osmotic 
gradients, the liposome environment and the in vivo stability of the liposomes (Allen, 
Theresa M.  et al. 2006; Lamprecht , Bouligand & Benoit 2002). Arsenic trioxide can 
be used for the treatment of acute promyelocytic leukemia and relapsed multiple 
myeloma. However, its clinical utility has been limited by its toxicity at high doses. 
Liposome encapsulated arsenic trioxide appeared to be stable in physiological 
situations but released the drug in a lower pH environment, such as in tumour tissues 
or in endosomes. As a result, the liposome formulation of arsenic trioxide has the 
potential to decrease the toxicity of this powerful anticancer drug in healthy tissues 
(Chen, H et al. 2006).  
Moreover, the phospholipids at the surface of liposomes can be modulated to 
provide desired drug release rates. For example, alteration of surface charge can not 
only enhance drug incorporation but also influence the rate of drug release (Ranade 
1989). As a result, liposomes can function as sustained release systems due to their 
ability to control drug release rates and to protect assembled labile drugs. Sterically 
stabilised liposomes, for example, usually have a sustained release of loaded 
substances as well as prolonged circulation time, leading to the improvement of 
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bioavailability of the agents. A number of studies showed Doxil® targeted tumours 
passively, and released DOX slowly in tumours once the liposomes localise in the 
tumour interstitial space (Allen, Theresa M.  et al. 2006; Cabanes et al. 1999; 
Unezaki et al. 1994). 
Furthermore, the release kinetics of agents from the liposomes can be modified by 
other factors. One of the examples is pH-responsive liposomes that belong to a 
specific-sensitive system (Kale & Torchilin 2010). The pH surrounding the tumour 
ranging from 5.5 to 6.5, tends to be more acidic than physiological pH which is 7.4 
(Trédan et al. 2007). As a result, utilising pH-responsive nanocarriers has significant 
enhanced stability in circulation and accumulation in the tumour when compared 
with non-pH-responsive carriers (Yu et al. 2004). Long circulation pH-responsive 
liposomes can be designed by modifying sterically stabilised liposomes via insertion 
of a hydrophobically modified N-isopropylacrylamide/methacrylic acid copolymer in 
the lipid bilayer of sterically stabilised liposomes (Bertrand, Simard & Leroux 2010). 
The pH-responsive liposomes with target-specificity are used to deliver molecules or 
macromolecules into the cytoplasm (Mujumdar & Siegel 2008). By selecting the pH 
and interliposomal buffer, pH-stimulated release of drugs entrapped in liposomes has 
the potential to increase membrane permeability upon acidification (Ganta, Srinivas 
et al. 2008). Studies regarding pH-sensitive immunoliposomes encapsulated with 
cytosine arabinoside indicated that the pH-sensitive liposomal formulation could be 
beneficial in the treatment of acute myeloid leukaemia (Roux et al. 2002; Simard & 
Leroux 2009). Another example of the specific-sensitive systems is thermo-sensitive 
liposomes that are composed of appropriate phospholipids with a phase transition 
temperature around 40°C. The liposome formulation can release their contents by 
selective application of hyperthermia (40-42°C). As a result, the release of drugs 
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from temperature-sensitive liposomes can be controlled via the use of the 
hyperthermia. Studies on the therapeutic efficacy of DOX encapsulated temperature-
sensitive liposomes found that these liposomes could be highly efficacious carriers 
for the in vivo delivery of anticancer drugs, and have potential anticancer 
applications in combination with hyperthermia (Han et al. 2006; Hauck et al. 2006).  
1.3.3.3 Reversal of MDR 
Evidence is accumulating to indicate that liposomes have the potential to bypass 
MDR, mediated by the MRP or P-gp, which is a key obstacle to cancer treatment 
(Malam, Loizidou & Seifalian 2009). Targeted liposomes may overcome MDR as 
they can bind to cell-surface receptors and are then endocytosed, leading to the 
potential to bypass MDR conferred through cell-surface protein pump mechanisms 
(Alexis, Frank, Rhee, June-Wha, et al. 2008; Malam, Loizidou & Seifalian 2009). 
Previous studies have already indicated that liposomal DOX has anti-tumour effects 
on both DOX-resistant and non-DOX-resistant mouse tumour C26 cancer models 
(Malam, Loizidou & Seifalian 2009). Moreover, liposomes with specific antibodies 
which blocked P-gp mediated efflux have been shown to increase intracellular drug 
accumulation and enhanced cytotoxic effects of DOX on multidrug-resistant P388 
cells (Gatouillat et al. 2007). Other liposomal anticancer drugs, such as verapamil, 
had also illustrated the ability to overcome P-gp-mediated MDR phenotype in K562 
leukaemia cells when conjugated to transferrin modified liposomes (Wu, J et al. 
2007). Furthermore, pH-sensitive liposomes demonstrate greater antitumour activity 
when compared with free drugs in a drug-resistant mouse model (Davis, Chen & 
Shin 2008). Recently, liposomes conjugated to oligonucleotides and small interfering 
RNA were effectively tested to overcome MDR in cancers expressing P-gp (Minko 
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et al. 2006). Finally, liposomes composed of certain phospholipids, such as 
cardiolipin, have been shown to elevate the cytotoxicity of loaded anticancer agents 
against resistant cells by either direct blocking of P-gp or increasing intracellular 
drug concentration (Gokhale et al. 1996; Thierry et al. 1993). 
1.3.3.4 Improved PK and BD 
The most compelling property of liposomes is their ability to significantly alter the 
PK and BD of many of their associated drugs. Encapsulation within liposomes 
allows the drug to be bioavailable following their release from carriers at the tumour 
site under optimal conditions. The liposomes protect drugs from metabolism and 
inactivation in the circulation as well as from clearance due to the size of the free 
drug (Li, S-D & Huang 2008). Furthermore, due to the size limitation of healthy 
vasculature endothelium, the drug distribution in healthy tissues can be reduced, thus 
drug accumulation in tumours can be increased. Investigations have demonstrated 
that the accumulation of conventional liposome encapsulated DOX was higher in 
tumours than that of free DOX in a mouse model (Drummond, D. C. et al. 1999b; 
Ogawara, K-i et al. 2009). Moreover, drugs encapsulated in liposomes are not 
bioavailable until they are released from the carriers to become free drugs (Allen, 
Theresa M. et al. 2006). As long as they are released from the liposomes, the released 
drugs function as free drugs. In turn, as the drugs carried by nanoparticles are located 
within the particles, the amounts and types of the payload will not affect the PK and 
BD of nanocarriers (Davis, Chen & Shin 2008). In addition, liposomes are high 
molecular water-soluble nanoparticles. Drugs with low molecular weight 
encapsulated by high molecular weight liposomes are inefficiently removed by 
lymphatic drainage and therefore have more chance to accumulate in tumours 
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(Minko et al. 2006). Taken together, the liposome encapsulation approach has the 
potential to improve treatment efficacy of various traditional anticancer agents. 
One barrier for the early liposomal formulations is the rapid clearance in the 
bloodstream. To avoid the trapping of liposomes by the RES, approaches to limiting 
the size, or coating liposomes with a hydrophilic barrier to protect them from 
recognition by the RES, have been considered. Sterically stabilised liposomes, 
liposomes coated with PEG, have been shown to display an enhanced stability in the 
circulation, a prolonged half-life and an improved pharmacokinetic profile over both 
free drugs and conventional liposomes (Minko et al. 2006; Moreira et al. 2002). For 
example, studies comparing different formulations of DOX illustrated that Doxil® 
has an 87-fold higher area under time versus concentration, one important 
pharmacokinetic parameter related to the efficacy of drugs, than free DOX seven 
days post-injection. On the contrary, area under time versus concentration of 
conventional liposomes with a more rapid DOX release rate was only 14-fold higher 
than that of free DOX (Lasic, Danilo D. & Needham 1995; Minko et al. 2006). 
PEGylated liposomal formulations of paclitaxel have also been reported to increase 
the biological half-life of paclitaxel from 5.05±1.52 hours to 17.8±2.35 hours 
compared to conventional liposomes in rats (Yang, T, Cui, Choi, Cho, et al. 2007). 
Sterically stabilised liposomal formulation of CKD-602, a camptothecin analogue, 
was shown to have more favourable pharmacokinetic parameters, such as a lower 
clearance rate, both in plasma and tumour when compared with non-liposomal CKD-
602 (Zamboni et al. 2007).  
The BD of anticancer agents can be improved by liposomal encapsulation. The 
EPR effect is an important factor in the improvement of the BD of liposomal drug 
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formulations (Allen, Theresa M. et al. 2006). Due to their size, liposomes are thought 
to extravasate more easily into the tumour vasculature due to increased gaps between 
tumour endothelial cells. For example, free DOX has a wide distribution in vivo, 
accumulating in most tissues to a significant extent, while studies regarding DOX-
loaded liposomes in vivo indicated a decreased drug concentration in the heart and 
kidneys, but an increased concentration in tumours when compared with that of the 
free DOX (Song, CK et al. 2009). This altered distribution reduced the concentration 
of DOX at potential sites of toxicity, such as the heart. 
1.3.3.5 Aptamer and CSCs targeting 
Previous studies have conjugated aptamers with liposomes to achieve better 
tumour targeting. For example, Mann et al. conjugated amino-PEG liposomes with a 
thioated oligonucleotide aptamer (thioaptamer) against E-selectin (ESTA) (Mann, 
Bhavane, Somasunderam, Liz Montalvo-Ortiz, et al. 2011; Mann et al. 2010). The 
ESTA-liposomes showed an elevated tumour vasculature accumulation in nude mice 
bearing MDA-MB-231 breast xenograft tumours. In the study using TMR-sgc8 
aptamer-modified liposomes (Kang et al. 2010a), liposomes could bind specifically 
to the target tumour cells in 30 min. Moreover, an RNA aptamer binding to the 
prostate-specific membrane antigen (PSMA) using PLA-PEG-COOH nanoparticle 
bioconjugates could target cell lines expressing PSMA protein with a 77-fold higher 
cellular uptake than the control (Farokhzad et al. 2004b).  
New aptamers can be developed that specifically targeting the CSCs. For example, 
Shigdar et al. developed an RNA aptamer against the cancer stem cell marker 
EpCAM (Shigdar et al. 2011). As the CSCs are responsible for chemoresistance and 
recurrence after various treatments, the novel chemotherapeutic agents delivery 
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systems designed to target CSCs could prevent recurrence of tumours (Ambasta, 
Sharma & Kumar 2011). An approach to target CSC markers is to combine 
liposomes with aptamers to develop liposomes which have the potential to provide 
an enhanced targeting efficiency as a selective delivery system. Thus, the 
conjugation of aptamers and liposomes has the potential to improve the 
chemotherapeutics efficacy loaded by liposomes.  
1.4. Project significance and aims 
As a novel drug delivery system for anticancer chemotherapeutics, liposomes have 
been extensively studied in recent years. The liposomal formulation of anticancer 
agents affords enhanced stability, improved targeting to tumours, controllable release 
rate and more favourite PK and BD. However, challenges for a better drug delivery 
system remain, particularly regarding targeted therapy. This project focuses on the 
development and characterisation of DOX encapsulated sulfatide-containing 
liposomes (SCL) that possess enhanced tumour targeting properties. 
DOX is an anthracycline antibiotic widely used in oncology clinics as an 
anticancer chemotherapeutic agent. It was firstly introduced in the 1970s, and has 
now become one of the most commonly used anticancer drugs in the treatment for 
haematological malignancies and solid tumours (Arola et al. 2000). However, when a 
cumulative dose reaches 450 to 500 mg/m2, it may lead to cardiomyopathy, resulting 
in congestive heart failure (Imondi et al. 1996; Olson et al. 1988). Moreover, due to 
the excretion of DOX occurring predominantly by the hepatobiliary route and 
partially by the kidneys (Cosan et al. 2008), recent data indicates that DOX could 
induce renal damage (Bárdi et al. 2007) and decreased hepatic activity (Yokogawa et 
al. 2006). As a result of ongoing efforts to develop a nanoparticle drug delivery 
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system, the liposomal formulations of DOX entering the clinic have improved 
efficacy and reduced side effects (Elbayoumi, T. A. & Torchilin, V. P. 2008). 
Nevertheless, the use of long-circulating formulations of liposomal DOX is limited 
by its toxicity to the skin. Palmar-plantar erythrodysesthesia (PPE), also known as 
hand-foot syndrome, is a relatively common dermatologic toxic reaction associated 
with pegylated liposomal DOX (PLD), such as Doxil® (Farr, K. P. & Safwat, A. 
2011). 
The composition and structure of the extracellular matrix in tumours is different 
from that in normal tissues (Liu, F et al. 2008). Certain extracellular matrix 
glycoproteins are highly up-regulated in many different cancers, including breast 
cancer, ovarian cancer, prostate cancer and gliomas (Fernando et al. 2008; Quemener 
et al. 2007). Tenascin-C is a protein expressed at low levels in normal adult tissues 
but high levels in many tumours (Mackie & Tucker 1999). The function of tenascin-
C is complex. It can influence the cell behaviour directly or indirectly. It has been 
implicated in the regulation of cell migration, focal adhesion and cell proliferation 
(Sage & Bornstein 1991; Trojanowska 2000). Moreover, expression of genes 
modifying the extracellular matrix can be induced by tenascin-C. These genes have 
the potential to promote tumour growth and invasion. Taken together, tenascin-C has 
been implicated as an important target for the treatment of cancer (Adams, M et al. 
2002). 
A possible strategy to improve anticancer agent binding and penetration into 
tumours is to modify the drug carriers with a composition that can bind to the tumour 
cell surface or the extracellular matrix of tumours. Sulfatide, a lipid that is found in 
humans, is involved in a variety of biological processes such as cell adhesion, 
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platelet aggregation, cell growth, protein trafficking, signal transduction, neuronal 
plasticity and cell morphogenesis. Sulfatide is known to bind several extracellular 
matrix glycoproteins including tenascin-C (Townson et al. 2007). Therefore, 
sulfatide was chosen to be one of the components of nanoliposomes to target tumours 
expressing high levels of tenascin-C in this project.  
DOPE, 1,2-dioleoyl-snglycero-3-phosphoethanolamine, is a neutral lipid that is 
also found in humans. It is an attractive lipid component of liposomes for 
intracellular delivery of anticancer drugs. This is because DOPE is thought to be the 
most superior of all the fusogenic (ability to promote membrane fusion) lipids (Hafez 
& Cullis 2001). When mixed with another ionisable anionic lipid, DOPE adopts a 
bilayer organisation (forming liposomes) at physiological pH due to the stabilising 
effect of the helper lipids. At a lowered pH (where the pH values drops below the pK 
of the helper lipid), the helper lipid is unable to stabilise the bilayer. As a 
consequence, DOPE adopts a non-bilayer inverted hexagonal (HII) phase, leading to 
membrane inversion, membrane fusion and the release of entrapped chemotherapy 
drugs to the cytoplasm. Thus, under physiological pH, DOPE confers stability to 
SCL via its inhibitory effects on liposome fusion, as the incorporation of sulfatide 
into DOPE vesicles greatly enhances the stability of the liposomes formed, even in 
the presence of plasma, presumably due to the hydration of the negatively charged 
sulfate head-group of the glycosphingolipid (Shao, Ke et al. 2006). One of the key 
aspirations in liposome research is to develop a liposome that is very stable in 
physiological pH to confer a long half-life in the blood stream but quickly releases its 
payload at lowered pH in the endosome once internalised. Previous research has 
demonstrated that DOPE-sulfatide liposomes do enter the cells and release the 
payload inside the tumour cells in vitro (Shao, Ke et al. 2006). It has been shown that 
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sulfatide was specifically required for robust uptake of liposomes by human 
glioblastoma cells U-87MG. The SCL has been found to remain intact for hours after 
uptake by the glioblastoma cells. As well, intracellular distribution studies have 
indicated a high accumulation of DOX in the nuclei where it exerts its cytotoxic 
effect after 12 h incubation with SCL at 37 °C. Meanwhile, therapeutic efficacy 
studies of SCL in immunocompromised mice bearing human glioblastoma cell line 
U-87MG displayed much improved therapeutic effects over the free drug (Shao, Ke 
et al. 2006; Wu, X & Li 1999).  
However, the in vitro and in vivo stability of the liposomes, the pharmacokinetic 
behaviour and the BD pattern are yet to be established. The critical parameters of 
tumour uptake, pharmacodynamic data of the sulfatide-containing liposomal DOX 
(SCL-DOX) in tumour xenograft models and the safety profile remain to be 
established. Moreover, due to various barriers that impede the efficient delivery of 
drugs to the brain interstitium, the potential of SCL-DOX for circumventing the 
blood-brain barrier (BBB) remains to be explored. Therefore, this project aims to 
address these important outstanding issues in preclinical settings, especially in 
human glioma and colorectal cancer models. The study also explores the active 
targeting property of SCL surface functionalised by CSC targeting aptamers. 
Therefore, the long term goal of this project is to develop a better drug delivery 
system, and in particular, a targeted therapeutic. To achieve this goal, the current 
project focused on the development and characterisation of DOX encapsulated SCL 
that possesses enhanced tumour targeting properties. The specific aims of this project 
are: 
1) To further characterise SCL-DOX and to develop PEG-SCL-DOX. 
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2) To analyse cellular uptake and cytotoxicity of SCL-DOX in vitro. 
3) To study the PK and BD of SCL-DOX in healthy Sprague Dawley (SD) rats. 
4) To study tumour uptake of SCL-DOX in tumour-bearing 
immunocompromised mice. 
5) To study therapeutic efficacy and safety of SCL-DOX in xenograft tumour 
models. 
6) To study the potential of SCL-DOX in penetrating the BBB in healthy SD 
rats. 
7) To study tumour uptake of SCL-DOX in glioma-bearing Wistar rats. 
8) To study cellular uptake and retention properties of CSCs targeting aptamer 
functionalised PEG-SCL-DOX. 
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Chapter 2 - Methodology 
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2.1 Ethics Statement 
The Deakin University Animal Welfare Committee has approved all animal 
protocols used in this research. 
2.2 Materials 
2.2.1 Chemicals, reagents and equipment 
  The following companies supplied reagents and equipment used in this work: 
x Avanti Polar Lipids, In, Alabaster, Alabama 
x Abacus ALS, Brisbane, Australia 
x Auspep Pty Ltd, Tullamarine, Australia 
x Barwon Health Pharmacy, Geelong, Australia 
x BD, New Jersey, USA, 
x BD Medical, Scoresby, Australia 
x Bovogen Biologicals Pty Ltd, East Keilor, Australia 
x David Kopf Instruments, KOPF®, California, America 
x Grale Scientific Pty Ltd, Ringwood, Australia 
x Hitachi, Japan 
x HyClone, South Logan, Canada 
x IBA GmbH, Goettingen, Germany  
x Interpath Services, Melbourne, Australia 
x Instech Laboratories, Inc., America 
x Invitrogen Australia Pty Ltd, Mulgrave, Australia 
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x Malvern Instruments Ltd, Worcestershire, UK 
x MatTek Corporation, Ashland, America 
x Medicago, Uppsala, Sweden 
x Merck, Kilsyth, Australia 
x Millipore, Billerica, MA, USA 
x NANOCS, Melbourne, Australia 
x Olympus, Tokyo, Japan 
x Pall Australia, Cheltenham, Australia 
x PerkinElmer, Melbourne, Australia 
x Promega Corporation, Madison,USA 
x Sigma-Aldrich Pty. Ltd, Sydney, Australia 
x Tecniplast S.p.A, Buguggiate, Italy 
x Thermo Fisher Scientific, Scoresby, Australia 
x ATA Scientific Pty Ltd, Taren Point, Australia 
x Waters, Milford Massachusetts, USA 
x Westlab, Madison , USA 
All the organic reagents, including methanol and chloroform, used in this study 
were analytical or high-performance liquid chromatography (HPLC) grade. All other 
chemicals were of the highest grade available. 
2.2.2 Cells used in this study  
The U-118MG (human glioblastoma) cell line, HT-29 (human colorectal 
adenocarcinoma) cell line, MCF-7 (human breast adenocarcinoma) cell line and C6 
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(rat glioma) cell line were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). HEK-293T (the human embryonic kidney 293) cell line 
was a generous gift from Dr Hongjian Zhu (Melbourne University, Australia). U-
118MG, HEK-293T and C6 cells were cultured in DMEM medium (InvitrogenTM, 
Australia) supplemented with 10% foetal bovine serum (FBS, Hyclone, Canada), 
penicillin (50 U/mL, InvitrogenTM, Australia), and streptomycin (50 μg/mL, 
InvitrogenTM, Australia) in a humidified atmosphere containing 5% CO2 at 37 °C. 
HT-29 cells were cultured in McCoy's 5A medium (InvitrogenTM, Australia) 
supplemented with 10% FBS, penicillin (50 U/mL), and streptomycin (50 μg/mL) in 
a humidified atmosphere containing 5% CO2 at 37 °C.  
For subculturing cells from monolayer, cell culture medium was removed and 
cells were rinsed gently with sterilised phosphate saline buffer (PBS) twice, followed 
by detachment with 0.05% trypsin-EDTA (InvitrogenTM, Australia) at 37 °C until 
cells were rounded up and detached from the surface of flasks. Then, complete 
medium was used to inactivate the trypsin. Cells were collected and centrifuged at 
room temperature (RT), followed by resuspension with appropriate buffer or medium. 
2.2.3 Animals used in this study 
Animals were purchased from Deakin Upper Animal House, Monash University 
and The Animal Resources Centre (Perth, Australia).  
Male Sprague-Dawley (SD) rats (200 to 250 g) were housed in a temperature 
controlled room (25 ± 1°C) with a 12-h light-dark cycle. Rats were fed ad libitum 
with a standard diet and were fasted overnight before treatments administration. 
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Male Wistar rats (200 to 250 g) were housed in a temperature controlled room (25 
± 1 °C) with a 12-h light-dark cycle. Rats were fed ad libitum with a standard diet 
and were fasted overnight before treatment administration. 
Six-week-old female BALB/c-Foxn1nu mice were used for U-118MG and HT-29 
xenografts established. The mice were housed in the TECNIPLAST SealsafeTM 
Individually Ventilated Cages which were placed in a temperature controlled room 
(25 ± 1 °C) with a 12-h light-dark cycle. Mice were fed ad libitum with a standard 
diet. Beddings, cages and water were autoclaved at 121 °C for 30 min while the 
fodder was sterilised by ultraviolet irradiation before use. 
2.2.4 Aptamers used in this study 
Aptamers were synthesised by IBA GmbH.  
EpCAM targeting aptamer: 5’-Amino-12 Carbon linker-G (2’-F-C) G A (2’-F-C) 
(2’-F-U) G G (2’-F-U) (2’-F-U) A (2’-F-C) (2’-F-C) (2’-F-C) G G (2’-F-U) (2’-F-
C)-G-9-atom spacer- fluorescence-3’ (F: 2’-fluoro, fluorescence: FITC). 
Negative control aptamer: 5’-Amino-12 Carbon linker--mG C mG A C U mG mG 
U U mA C C C mG mG U C mG-9-atom spacer-fluorescence-3’ (m: 2’-O-methyl, 
fluorescence: FITC). 
Due to their susceptibility to degradation by serum nucleases, aptamers are 
unsuitable for most therapeutic applications (Burmeister et al. 2006). Resistance to 
nuclease-mediated degradation can be greatly improved by incorporating modifying 
groups at the nucleotide 2’-position, and both 2’-fluoro and 2’-O-methyl 
modifications have been shown to significantly increase resistance to serum 
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nucleases (Burmeister et al. 2005; Ruckman et al. 1998). Thus, the 2’-fluoro and 2’-
O-methyl modifications have been utilised for our aptamers to increase aptamer 
stability both in vitro and in vivo. 
However, the aptamer modified with 2’-O-methyl is an aptamer of the same 
sequence as EpCAM targeting aptamer but with a different side-chain modification 
which could affect the 3-dimensional structure of aptamer (Chushak & Stone 2009). 
As a result, it is used as a negative control aptamer which is not able to bind to 
EpCAM and does not specifically target the cancer cells with high expression of 
EpCAM. 
2.3 Methods 
2.3.1 Development of sulfatide-containing nanoliposomal doxorubicin (SCL-
DOX) and PEG-sulfatide-containing nanoliposomal doxorubicin (PEG-SCL-
DOX) 
2.3.1.1 Development of SCL-DOX. 
Liposomes were prepared according to a previously published method with some 
modifications (Shao, Ke et al. 2006). Briefly, DOPE unilamellar vesicles containing 
30% (molar ratio) sulfatide were prepared by a hydration method followed by 
polycarbonate membrane extrusion. DOPE (13.35 mM, Avanti Polar Lipids, Inc., 
Cat No: 850725P-500mg) and sulfatide (6 mM, Avanti Polar Lipids, Inc., Cat No: 
131305P-100mg) were dissolved in a mixture of chloroform (Deakin University, 
LES store, CH1751) and methanol (Sigma, Cat No: 366927) (2:1, v/v,), and the lipid 
mixture, composed of DOPE/sulfatide (3:7, mol/mol), was transferred to glass tubes.  
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Samples were then reduced to a minimum volume under a nitrogen stream, and 
stored under vacuum for 24 h at 4 °C to completely evaporate the organic solvent. 
The thin lipid films were hydrated by the addition of 1 mL of 250 mM ammonium 
sulfate (pH 8.5, Sigma, Cat No: A4418-500g). The samples were then placed in an 
ice-water bath and sonicated under nitrogen for 2.5 min with 50% amplitude using a 
sonicator (Sonics & Materials, Inc). Following sonication, the liposomes were 
formed via extrusion through polycarbonate membranes (Avanti Polar Lipids, Inc.) 
with consecutive pore sizes of 400 nm for 14 times, 200 nm for 14 times and 100 nm 
for 19 times at room temperature. To establish a trans-bilayer ammonium sulfate 
gradient, the extruded liposomes were dialyzed against a 250-fold volume of 10% 
sucrose in 25 mM Trizma (Sigma, Cat No: T6066) at pH 8.5 at 4 °C for 24 h. The 
external buffer was changed three times during dialysis. After dialysis of the 
liposomes, DOX (Sigma, Cat No: 44583-1 mg), in 10% sucrose at a final 
concentration of 5 mg/mL, was added to the liposomes at a drug-to-lipid ratio of 
0.3:1 (w/w), followed by incubation in a water bath at 60 °C for 1 h. Non-
encapsulated DOX was removed by size exclusion chromatography using a 
Sephadex G-50 (Sigma, Cat No: G5080-10g) column. 
2.3.1.2 Development of PEG-SCL-DOX. 
For development of PEG-SCL-DOX, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (PEG2000-DSPE, 
NANOCS, Cat No: PG2-LPCA-2K) was dissolved in chloroform (Deakin University, 
LES store, CH1751) and methanol  (Sigma, Cat No: 366927) (2:1, v/v). Then, 
PEG2000-DSPE was added to DOPE/sulfatide (3:7, mol/mol) as a molar ratio at 3% or 
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5% of the whole lipids amount. All the following procedures were the same as those 
in the Section 2.3.1.1. 
2.3.1.3 Development of DOX-encapsulated, aptamer functionalised PEG-SCL  
DOX-encapsulated nanoliposome (with 5% DSPE-PEG-COOH) was prepared as 
previously described (Section 2.3.1.1). The coupling of  aptamer  to  liposomes was 
performed through an amide bond between the carboxylic groups of the linker lipid, 
DSPE-PEG-COOH, and amino groups of the aptamer in the presence of a water-
soluble carbodiimide, 1- [3-dimethylaminopropyl]-3-ethylcarbodiimide 
hydrochloride (EDC) (Otsubo et al. 1998). The reaction of carboxyl group in the 
presence of EDC forms an amine-intermediate, which after reacting with sulfo-N-
hydroxysuccinimide (Sulfo-NHS) will form a semi-stable amine reactive NHS ester 
that afterwards will react with amino groups of aptamer leading to a stable amide 
bond. For conjugation, EDC (Thermo, Cat No: 22980) and NHS (Thermo, Cat No: 
24520) were added into the DOX-encapsulated nanoliposome in PBS (pH= 6.0, 
Medicago, Cat No: 09-9400-100) to a final concentration of 2 mM and 5 mM, 
respectively. The mixture was then incubated for 0.5 h at room temperature with 
gentle stirring (Dhar et al. 2008). The pH value of the mixture was raised to 7.2-7.5 
with phosphate buffer (Medicago, Cat No: 09-9400-100) (or other non-amine buffer) 
immediately before the reaction to the amine-containing molecule. When conjugated 
with PEG-SCL, aptamer from a stock solution in RNA-free H2O was added into the 
NHS-activated nanoliposomes at 1:10 molar ratio (aptamer-to-DSPE-PEG-COOH in 
nanoliposome ratio) and gently stirred for 2 h at room temperature. Unreacted EDC, 
Sulfo-NHS and free aptamer were removed by gel filtration using a Sephdex-G50 
column (Estevez et al. 2010b; Karathanasis, Bhavane & Annapragada 2007). After 
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purification, samples were collected for spectrophotometry, fluorescence and particle 
size analysis. All the analytical procedures were the same as described in Section 
2.3.1. 
2.3.1.4 Chromatographic instrumentation and system 
Chromatographic instrumentation was used based on a previously published 
method with some modifications (Alvarez-Cedron, Sayalero & Lanao 1999). Briefly, 
the High Performance Liquid Chromatography (HPLC) system (Milford, MA, USA) 
used in this study consists of a Waters e2695 Separation Module and a Waters 2475 
Multi Ȝ Fluorescence Detector. The excitation and emission wavelengths were set at 
the 470 nm and 585 nm, respectively. Chromatographic separation was performed 
using a Nova-Pak® C18 column (3.9 × 150 mm i.d., 4 ȝm, Waters, USA) with a 
Nova-Pak® C18 guard column (3.9 × 20 mm i.d., 4 ȝm, Waters, USA). A mixture 
(55:45, v/v) of methanol and 10 mM phosphate buffer (pH = 3.0, Fluka, Cat No: 
71500) was used as the mobile phase. The flow-rate used in the assay was 1 mL/min 
and the column was maintained at 40 ± 5 °C throughout the chromatographic process. 
All solvents for HPLC procedures were prepared freshly and filtered with 0.22 ȝm 
membrane before using. 
2.3.1.5 Establishing standard curves for determination of DOX loading 
efficiency 
DOX in 10% sucrose was loaded into the liposomes as described above without 
passing through the Sephadex G-50 (Sigma, Cat No: G5080-10g) column. The 
solution was then diluted with a methanol and phosphate buffer mixture (55:45, v/v) 
to a final DOX concentration of 20 ȝg/mL. The mixture was diluted with the same 
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solution (methanol and phosphate buffer, 55:45, v/v) to different concentrations, 
including 50 ng/mL, 200 ng/mL, 400 ng/mL, 800 ng/mL, 1,000 ng/mL, 4,000 ng/mL, 
8,000 ng/mL, 10,000 ng/mL and 20,000 ng/mL. The samples were centrifuged at 
21,000 × g for 5 min. The supernatant layers were collected into HPLC vials, which 
were measured via HPLC as described in the Section 2.3.1.4. Calibration curves 
were constructed by plotting peak area of fluorescence derived from DOX vs. DOX 
concentrations. A linear regression was used for quantitation. The standard formulas 
were determined by linear regression as y = mx + b, where y is the peak area of DOX 
and x is the DOX concentration.  
2.3.1.6 Determination of drug loading efficiency of SCL-DOX or PEG-SCL-
DOX 
The amount of DOX encapsulated in SCL-DOX or PEG-SCL-DOX was 
determined by disrupting the liposomes with methanol, followed by quantification of 
DOX using a fluorescence detector in the HPLC system. Sample concentrations were 
determined by linear regression using the standard formula y = mx + b obtained from 
Section 2.3.1.5, where y is the peak area and x is the concentration of the standard in 
ng/mL. Briefly, 10 ȝL aliquot of the SCL-DOX eluted from a Sephadex G-50 column 
was diluted in 100-fold phosphate buffer/methanol (45:55, v/v), and the mixture was 
centrifuged at 21,000 × g for 5 min. Then, the supernatant was measured via using 
HPLC. Encapsulation efficiency was calculated by the following equation:  
Encapsulation efficiency (%) = DOX encapsulated in liposomes ×100%       DOX added to liposomes 
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2.3.1.7 Establishing standard curves for phospholipids assay 
The concentration of phospholipids (DOPE, Avanti Polar Lipids, Inc., Cat No: 
850725P-500mg) in the liposomes was determined as previously described (Stewart 
1980). For the standard curve of phospholipids assay, 10 mg DOPE was dissolved in 
10 mL of chloroform as a stock. Then, different concentrations (0, 100, 300, 500, 700, 
900 and 1,000 ȝg/mL) of DOPE were prepared with dilution in chloroform. 
Following this, 1 mL chloroform (Deakin University, LES store, CH1751) and 0.5 
mL ferri-thiocyanate reagent (containing 1M ferric chloride hexahydrate, MPBio, 
Cat No:153500-100g, and 0.4 M ammonium thiocyanate, Westlab, Cat No: AA010-
500G) were added to the sample, followed by vortexing for 1 min, and centrifugation 
at 12,000 × g for 5 min. Following the removal of supernatant, the absorbance of 
samples was measured at 488 nm against the chloroform blank using 
spectrophotometer (U-1800, HITACHI, Japan). Absorbance were plotted against the 
concentration to obtain the analytical curve followed by linear regression analysis. 
The method was considered linear when R2>0.99. The calibration curve was obtained 
by plotting the absorbance (y) vs. the concentrations (x). 
2.3.1.8 Determination of phospholipids in SCL-DOX or PEG-SCL-DOX 
The concentration of phospholipids (DOPE) in liposomes was determined as 
previously described (Stewart 1980). Briefly, 1 mL chloroform and 0.5 mL ferri-
thiocyanate reagent (containing 1M ferric chloride hexahydrate and 0.4 M 
ammonium thiocyanate) were added to a 100 ȝL aliquot of SCL-DOX. The 
following steps were the same as described in Section 2.3.1.6. The DOPE 
concentration in the samples was calculated according to a standard curve of its 
absorbance intensity vs. DOPE concentration. 
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2.3.1.9 Determination of particle size and zeta potential of SCL-DOX or PEG-
SCL-DOX 
Following the size exclusion chromatography assay, a 10 ȝL aliquot of SCL-DOX 
was diluted in 990 ȝL PBS and mixed gently. The vesicle size and zeta potential of 
SCL were measured using Zetasizer Nano ZS Particle Characterisation System from 
Malvern Instruments (Malvern, UK). 
2.3.1.10 In vitro release kinetics of SCL-DOX/PEG-SCL-DOX in PBS 
The in vitro leakage of DOX from SCL-DOX/PEG-SCL-DOX was measured by a 
dialysis method (Rai et al. 2008; Song, H et al. 2006a). Briefly, 2.5 mL SCL-
DOX/PEG-SCL-DOX was added into a Slide-A-Lyzer Dialysis Cassette (Pierce, 
molecular weight cut-off of 2 kDa). The dialysis cassette was placed into a beaker 
containing a 250-fold excess of PBS. The SCL-DOX/PEG-SCL-DOX was dialysed 
with stirring for 72 h at 37°C. At various time points (0 h, 0.5 h, 1 h, 4 h, 8 h, 24 h, 
48 h and 72 h), a 500 ȝL aliquot was withdrawn from the external buffer for release 
kinetics analysis, and replaced with the same volume of fresh external buffer. For 
HPLC measurement, the aliquots were mixed with 500 ȝL methanol, followed by 
centrifuged at 21,000 × g for 5 min. Supernatants were then collected for 
measurement by HPLC. The drug concentration in the external buffer was calculated 
according to a standard curve of DOX concentration vs. its fluorescence intensity. 
2.3.1.11 In vitro release kinetics of SCL-DOX/PEG-SCL-DOX in PBS/10% FBS 
The dialysis procedure was the same as that in the Section 2.3.1.9 except the 
dialysis buffer consisted of PBS containing 10% FBS, penicillin (50 U/mL), and 
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streptomycin (50 μg/mL). In addition, 1 mL methanol was added to a 500 ȝL aliquot 
of external buffer for protein precipitation. After centrifuged at 21,000 × g for 5 min, 
supernatants were collected for measurement of the DOX concentration by HPLC. 
The drug concentration in the external buffer was calculated according to a standard 
curve of DOX concentration vs. its fluorescence intensity as described in Section 
2.3.1.11. 
2.3.1.12 Establishing standard curves for in vitro release kinetics in PBS  
DOX stock was dissolved in methanol and diluted with PBS/methanol (1:1, v/v) at 
the final concentration of 20 ȝg/mL. The stock was then diluted by PBS and 
methanol mixture (1:1, v/v) to cover three concentration ranges (0.1-100 ng/mL, 50-
1000 ng/mL and 800-20000 ng/mL), each of which contained five or eight standard 
solution (0.1-100 ng/mL: 0.1, 0.5, 1, 5, 10, 25, 50 and 100 ng/mL; 50-1,000 ng/mL: 
50, 200, 400, 800 and 1,000 ng/mL; 800-20000 ng/mL: 800, 4,000, 8,000, 10,000, 
20,000 ng/mL). The samples were centrifuged at 21,000 × g for 5 min. The 
supernatant layers were collected into the vials, followed by measurement under the 
conditions as described in Section 2.3.1.4. Calibration curves were constructed as 
described in Section 2.3.1.5. 
2.3.1.13 Establishing standard curves for in vitro release kinetics in PBS/10% 
FBS 
DOX stock was dissolved in methanol and diluted by methanol/PBS (2:1, v/v) at a 
final concentration of 20 ȝg/mL. The stock was then diluted with PBS and methanol 
mixture (2:1, v/v) to the three concentration ranges (0.1-100 ng/mL, 50-1,000 ng/mL 
and 800-20000 ng/mL), each of which contained five or eight standard solution (0.1-
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100 ng/mL: 0.1, 0.5, 1, 5, 10, 25, 50 and 100 ng/mL; 50-1000ng/mL: 50, 200, 400, 
800 and 1,000 ng/mL; 800-20,000 ng/mL: 800, 4,000, 8,000, 10,000, 20,000 ng/mL). 
The samples were centrifuged at 21,000 × g for 5 min. The supernatant layers were 
collected into the vials, followed by measuring under the conditions as described in 
Section 2.3.1.4. Calibration curves were constructed as described in Section 2.3.1.5. 
2.3.2 In vitro uptake, retention and cytotoxicity assay 
2.3.2.1 MTT assay 
The viabilities of treated and untreated cells was determined by the (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) MTT assay which 
measures the mitochondrial conversion of MTT to formazan as detected by the 
change of optical density at 570 nm (Jung et al. 2009b; Zhang, FY et al. 2009). 
Briefly, the MTT (Sigma, Cat No: M5655) stock was dissolved with Milli Q water to 
a final concentration of 5 mg/mL. This solution was filtered through a 0.22 Pm filter 
and stored at -20°C in the dark before use. One T-75 flask of U-118MG cells or HT-
29 cells was trypsinised and 5 mL of complete media was added to the trypsinised 
cells. The cell suspension was centrifuged in a sterile 15 mL Falcon tube at 500 × g
in the swinging bucket rotor for 5 min. Then, U-118MG cells were plated at a density 
of 4.0 × 103 cells per well in 100 ȝl DMEM medium and HT-29 were plated at a 
density of 3.0 × 103 cells per well in 100 ȝL McCoy's 5A medium in 96-well plates 
and allowed to grow for 24 h. The cells were then exposed to a series of 
concentrations (0.1 ȝg/mL, 0.5 ȝg/mL, 1 ȝg/mL, 5 ȝg/mL, 10 ȝg/mL, 50 ȝg/mL and 
100 ȝg/mL) of free DOX, SCL-DOX or blank SCL for 48 h at 37° C under 5% CO2. 
Ten microlitres of MTT reagent was added into each well and incubated for 4 h. The 
reaction was terminated by removing MTT prior to the addition of 150 ȝL/well 
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solubilisation reagent (Dimethyl Sulfoxide, DMSO, Merck, Cat No: 1.02952.1000). 
The absorbance of the wells, including the blanks, was measured at 570 nm using a 
VICTOR TM X5 Multilabel HTS Reader (PerkinElmer Life and Analytical 
Sciences). DOX concentration leading to 50% cell-killing (IC50) was calculated using 
the statistical software package SPSS 13.0 (Cheng et al. 2009). All experiments were 
performed in triplicate and repeated thrice. 
2.3.2.2 Confocal microscopy analysis for cellular uptake and retention of SCL-
DOX 
U118MG cells (1.5 × 105 cells/well) or HT-29 cells (1 × 105 cells/well) were 
seeded in 35-mm glass bottom dishes and incubated at 37°C in 5% CO2 for 24 h. The 
medium was then replaced with full culture medium containing 2 Pg/mL free DOX 
or SCL-DOX. Twenty-four hours later, cells were washed twice with phosphate 
buffered saline (PBS) and imaged for cellular uptake studies. For retentions studies, 
cells were first exposed to 2 Pg/mL free DOX or SCL-DOX in full cell culture 
medium for 24 h and then washed twice with PBS. Cells were then incubated with 
fresh cell culture medium and serially imaged at 1 h, 2 h, 4 h, and 24 h using a 
Fluoview FV10i fluorescence laser scanning confocal microscopy (Olympus, Japan). 
2.3.2.3 Cellular uptake and retention of aptamer-functionalised DOX-
encapsulated PEG-SCL 
HEK-293T cells (1.0 × 105 cells/well) or HT-29 cells (1.0 × 105 cells/well) were 
seeded in 35-mm glass bottom dishes and incubated at 37°C in 5% CO2 for 24 h. The 
medium was then replaced with full culture medium containing 2 Pg/mL free DOX, 
SCL-DOX, aptamer-functionalised DOX-encapsulated SCL (ap-PEG-SCL-DOX) 
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and SCL-DOX conjugated with negative control aptamer (negative ap-PEG-SCL-
DOX). Cellular uptake and retention was evaluated as described in Section 2.3.2.2. 
2.3.2.4 Flow cytometry analysis for intracellular uptake of SCL-DOX 
To measure the intracellular uptake of free DOX and SCL-DOX, U-118MG 
glioblastoma cells or MFC-7 breast cancer cells were cultured in a 12-well plate to 
achieve approximately 80% confluence. DOX was dissolved in PBS at a 
concentration of 1 mg/mL, and diluted in DMEM to a final concentration of 4 Pg/mL. 
SCL-DOX was prepared fresh before each experiment. One millilitre of 4 Pg/mL 
DOX or SCL-DOX in full culture medium was added into each well. Following 
incubation at 37 °C for different periods (0 h, 1 h, 2 h, 4 h, 6 h and 24 h), the culture 
medium was discarded. Cells were then washed three times with ice-cold PBS, 
detached by trypsinisation, centrifuged at 500 × g for 5 min, resuspended in 0.1 mL 
ice-cold PBS, and then analysed using a BD FACSCantoTM II flow cytometer 
(Becton-Dickinson) using excitation wavelength of 488 nm and emission between 
543 and 627 nm. Fluorescent histograms were recorded by BD FACSCantoTM II flow 
cytometer and analysed using BD FACSDiva software (v6.0). A minimum of 10,000 
events were analysed for each sample from three independent experiments (Gariboldi 
et al. 2007; Meschini et al. 2002; Tang et al. 2007; Zheng, C et al. 2009). 2.3.3 In
vivo methods  
2.3.3.1 Development of [3H]-tracking of liposome. 
[3H] Cholesteryl hexadecyl ether (CHE, Perkin Elmer, Cat No: NET859001MC) 
was added at a molar ratio of 1:24000 (CHE/DOPE) as a nonmetabolised, 
nonexchangeable lipid tracer into the lipid mixture (Hussain et al. 2007). The 
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preparation of SCL-DOX or PEG-SCL-DOX was carried out as described above 
(Section 2.3.1.1 and 2.3.1.2). 
2.3.3.2 Pharmacokinetics (PK) study in SD rats 
To investigate the PK properties of SCL-DOX and PEG-SCL-DOX in vivo, 
healthy male SD rats were randomly divided into 3 experimental groups (five to six 
rats per group) and were injected i.v. with free DOX, SCL-DOX or PEG-SCL-DOX 
via the tail vein with a single dose of 5 mg DOX/kg (administration rate 0.4 mL/min). 
After injection, blood was serially sampled from the tail of the same animal at 2 min, 
30 min, 2 h, 6 h, 24 h and 48 h. Blood samples (500 ȝL) were collected in 
heparinised tubes, and then centrifuged at 3,000 × g at 4 °C for 10 min to separate 
the plasma and stored at -20 °C until assayed for DOX and [3H] (Ahmed et al. 2009; 
Rahman et al. 1986b). 
2.3.3.3 Biodistribution (BD) study in rats 
For BD study, healthy male SD rats were randomly divided into 3 experimental 
groups (five to six rats per group). Free DOX (5 mg/kg) or SCL-DOX (5 mg/kg in 
DOX) was administrated via the tail vein. Rats were then sacrificed by Lethabarb R 
(100 mg/kg) at 0.5 h, 2 h, 4 h and 24 h after the injection and tissues (heart, liver, 
spleen, lung, kidney and brain) were collected. Tissues were then lightly washed in 
cold physiological saline to remove any excess blood, blot-dried using filter paper 
and weighed (Xiong, Huang, Lu, Zhang, Zhang, Nagai, et al. 2005). Tissues were 
then stored at -20 °C until assayed for DOX and [3H]. 
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2.3.3.4 Establishing standard curves of DOX in plasma 
Free DOX was dissolved in methanol to a stock concentration of 1 mg/mL. For 
each concentration (2, 5, 10, 50, 100, 200, 500, 1000, 2000, 5000 and 10000 ng/mL), 
stock was then diluted with 100 ȝL blank plasma and methanol/phosphate buffer 
mixture (55:45, v/v) to the final volume of 1 mL. Samples were vortexed for 1 min, 
and centrifuged at 21,000 × g for 10 min at 4 qC. The supernatant was transferred to 
another tube followed by the addition of 2 ȝL of freshly prepared perchloric acid 
(35%, v/v,). Then, samples were vortexed for another 1 min and centrifuged at 
21,000 ×g for 10 min at 4 °C. The supernatant was collected into vials, followed by 
measuring of DOX via HPLC under the conditions as described in Section 2.3.1.4. 
Calibration curves were constructed as described in Section 2.3.1.5. 
2.3.3.5 Determination of the stability of SCL-DOX in plasma 
To determine DOX levels in plasma, 495 ȝL of methanol and 405 ȝL of phosphate 
buffer was added to 100 μL plasma. Then, samples were vortexed and treated as the 
procedure above (Section 2.3.3.4). The supernatant (100 PL) was injected into the 
HPLC system (Alvarez-Cedrón, Sayalero & Lanao 1999). The chromatographic 
instrumentation and system were used as described in Section 2.3.1.4. The drug 
concentration was calculated according to a standard curve of DOX concentration vs. 
its fluorescence intensity. 
2.3.3.6 Establishing standard curves of DOX in tissues 
To establish a standard curve of DOX in tissues, 100 ȝg of tissue was placed in a 
tightly sealed 2-mL screw-capped tube. Then, 1 mL methanol/phosphate buffer 
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mixture (55:45, v/v) with different free DOX concentrations (50, 100, 500, 1000 and 
5000 ng/mL) was added into the tubes. Samples were homogenised via the 
FastPrep®-24 tissue and cell homogeniser (MP Biomedicals, US). The tissue 
homogenate was centrifuged at 21,000 × g for 10 min at 4 °C. The supernatant was 
transferred to another tube and extracted with the addition of 2 ȝL freshly prepared 
perchloric acid (35%, v/v), vortexed for 1 min, and centrifuged at 21,000 × g for 10 
min at 4 °C. The supernatant was collected into vials, followed by measurement 
under the conditions as described in Section 2.3.1.4. Calibration curves were 
constructed as described in Section 2.3.1.5. 
2.3.3.7 Determination of the release of DOX from SCL-DOX in tissues 
To determine DOX levels in tissues, 100 ȝg of tissue was added to 495 ȝL of 
methanol and 405 ȝL of phosphate buffer in a tightly sealed 2-mL screw-capped tube 
followed by homogenisation using the FastPrep®-24 tissue and cell homogeniser 
(MP Biomedicals, US). The preparation procedure was the same as that in Section 
2.3.3.6. The chromatographic instrumentation and system were used as described in 
Section 2.3.1.3. The drug concentrations in the tissues were calculated according to a 
standard curve of DOX prepared in the respective tissue homogenate. 
2.3.3.8 Liquid scintillation counting assay for [3H] in plasma 
To determine lipid levels in plasma, 1 mL of Solvable (PerkinElmer, Cat No: 
6NE9100) was added to 100 μL plasma in a screw-cap air-tight glass tube and 
digested for 1 h at 50 °C. After cooling to room temperature, 200 μL of 100 mmol/L 
ethylenediamine tetraacetic acid (EDTA, Scharlau chemie SA, Cat No: AC0965) was 
added, followed by the addition of 200 μL of 30% (v/v) H2O2. Samples were allowed 
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to stand for 15 min at room temperature followed by incubation at 55 °C for 1 h and 
cooling to room temperature. After the addition of 10 mL of scintillation cocktail 
(ULTMA GOLDTM, PerkinElmer, Cat No: 6013329),  the samples were analysed in 
a Tri-Carb 2910TR liquid scintillation analyser (PerkinElmer, USA) after the 
adaption for light and temperature for 1 h in the counter prior to counting.  
2.3.3.9 Liquid scintillation counting assay for [3H] in tissues 
For determination of [3H] in tissues, 2 mL of Solvable was added to 100 mg 
tissues. Tissues were then digested for 3 h at 50 °C. The following steps and 
analytical procedures were the same as described in Section 2.3.3.8. 
2.3.3.10 Tumour xenograft model 
Six-week-old female BALB/c-Foxn1nu mice were allowed a 7 day acclimatisation 
period after arrival. The animal weight was recorded upon arrival. For uptake and 
therapeutic studies, single cell suspensions were harvested by trypsinisation.  The 
cells were washed in PBS, and resuspended in PBS at a seeding concentration of 
5×107 cells/mL for U-118MG or 3×107/mL for HT-29. Cell suspensions (5 × 106 
cells in 0.1 mL PBS for U-118MG, 3 × 106 in 0.1 mL PBS for HT-29) were 
inoculated subcutaneously (s. c.) into the right flank of the mice with a 1 mL syringe 
and 26 gauge needle. Tumour size was assessed using a digital calliper every other 
day after implantation and approximate tumour burden (mm3) was calculated as 
length × width2/2 (V=lw2/2), where length and width are the longest and shortest axis 
in millimetres (Elbayoumi, T. A. & Torchilin, V. P. 2008).  
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2.3.3.11 Establishing standard curves of DOX in tissues and tumours in tumour-
bearing mice 
  The establishment of standard curves of DOX in tissues and tumours in tumour-
bearing mice were the same as described in Section 2.3.3.6. 
2.3.3.12 Tumour uptake and tissue distribution of SCL-DOX in tumour-bearing 
mice 
  Once the tumour reached a volume of 150 mm3, the nude mice were randomly 
divided into 2 experimental groups (5 to 6 mice per group) for injection. 
Formulations of either free or SCL-DOX at doses of 5 mg/kg DOX or equivalent 
were administered via the tail vein at a rate of 0.4 mL/min. After injection, mice 
were sacrificed by injection of Lethabarb R (100 mg/kg) at 24 h post-injection. 
Tumours and tissues were collected and then processed as described in Section 
2.3.3.7 (Cheng et al. 2009; ElBayoumi, aA & Torchilin, VP 2009; Li, X et al. 2009). 
2.3.3.13 Treatment efficacy of SCL-DOX in tumour-bearing mice 
For therapeutic experiments, the nude mice were randomly divided into 4 
experimental groups (8 to 10 mice per group) for injection when the xenograft 
tumours reached 150 mm3 (for U-118MG) or 35 mm3 (for HT-29). Mice received 
injection of saline, free DOX (5 mg/kg), SCL-DOX (5 mg/kg in DOX) or blank SCL 
via tail vein once a week for 6 weeks (for U-118MG) or twice a week for 3 weeks 
(for HT-29). Tumour growth was monitored by measuring tumour diameter every 
other day with a calliper and animal weights were monitored at the same time (Lopes 
de Menezes et al. 2000; Tang et al. 2007). 
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2.3.3.14 Analysis of systemic toxicity of SCL-DOX 
To evaluate the general toxicity of free DOX, SCL-DOX and blank SCL, blood 
was collected when the mice for therapeutic experiments were sacrificed. Plasma 
biochemistry, blood cells counts and troponin were analysed by a veterinary 
pathology laboratory (Gribbles Veterinary Pathology, Clayton, Victoria, Australia). 
Blood smears were obtained for each animal to obtain a relative white cell count 
adapted from the Fonio method for platelet counting (Adams, E 1948; Oliveira et al. 
2003), with minor modifications. Slides were stained with Giesma and an area of the 
blood smear was chosen where the red cells abutted each other but did not overlap, 
with consecutive fields chosen to eliminate bias. The total number of white cells per 
1500 red cells were counted (n=3 for each slide) and compared for each group.  
2.3.3.15 Perfusion in healthy SD rats 
  The perfusion in healthy SD rats was performed based on a previously published 
method (Balasubramanian et al. 2010). Briefly, the heavily anesthetised rat was 
placed on its back in a dissection tray. A cut along the sternum (~8 cm long) was 
made to expose the sternum's end. Sharp scissors were used to cut diaphragm 
laterally on both sides and cut toward the head across ribs and parallel to lungs. The 
heart was exposed and held steady with forceps, and then a large bore blunt needle 
(18 gauge) was inserted into left ventricle to extend straight up about 5 mm. Rats 
were perfused through the left cardiac ventricle with saline (>150 mL) until the 
venous return was clear. The cortex was collected and then processed as described in 
Section 2.3.3.7 
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2.3.3.16 Establishment of a intracranial brain tumour xenograft model 
The establishment of an intracranial brain tumour xenograft model was based on 
previously published methods with some modifications (Madhankumar et al. 2009; 
Yamashita et al. 2007). Briefly, seven-week-old male Wistar rats were allowed a 7 
days acclimatisation period after arrival. The animal weight was recorded upon 
arrival. Immediately before surgery, single cell suspensions of C6 were harvested by 
trypsinisation. The cells were washed in PBS, and resuspended with serum free 
DMEM at a seeding concentration of 1×107 cells/mL. Rats were deeply anesthetised 
by i.p. injection of Ketamine-Xylazine (75 mg/kg - 10 mg/kg body weight) and then 
placed in a stereotactic device (Model 900 Small Animal Stereotaxic Instrument, 
KOPF®, USA). The head was mounted in a head holder. Hair was shaved and the 
head was cleaned with Betadine Surgical Scrab solution, followed by 80% ethanol 
twice. The skin was incised in the midline and a small hole was made with a drill at a 
point approximately 3 mm from mid-line, 2 mm posterior to the coronal suture in the 
anterior part of the right skull. One million C6 cells, suspended in a total volume of 
10 ȝL DMEM, was injected using the Harvard Apparatus Pump 11 Elite Syringe 
Pumps (USA) with the 26 gauge needle (Harvard apparatus, USA) at the rate of 1 
ȝL/min over a period of 10 min into the right brain hemisphere, 6 mm beneath the 
bone surface. After injection, the needle was left in the brain for 10 min to minimise 
movement of the cells away from the site and to improve reproducibility. Then, the 
needle was withdrawn slowly, with 5 min suspension for each millimetre. The needle 
hole on the scalp was sealed with bone wax, and the incision was closed using 
sutures. Rats were monitored every day. Eighteen days after the surgery, free DOX 
or SCL-DOX (at the dosage of 5 mg/kg of DOX) was given via i. v. administration 
through the tail vein. Rats were sacrificed 24 h after injection by injection of 
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Lethabarb R (100 mg/kg). Tumours and tissues were collected for DOX 
concentration analysis. All the measurement procedures were the same as described 
in Section 2.3.3.7. 
2.3.3.17 Establishing standard curves of DOX in tissues and tumours in 
intracranial brain tumour xenograft models 
  The establishment of standard curves of DOX in tissues and C6 gliomas were the 
same as described in Section 2.3.3.6. 
2.3.3.18 Tumour uptake and tissue distribution in intracranial brain tumour 
xenograft models 
  The glioma-bearing rats were randomly divided into 2 experimental groups (3 mice 
per group) for injection at day 18 after tumour inoculation. Formulations of either 
free or SCL-DOX at doses of 5 mg/kg DOX or equivalent were administered via the 
tail vein at a rate of 0.4 mL/min. After injection, rats were sacrificed by injection of 
Lethabarb R (100 mg/kg) at 24 h time point. Tumours and tissues were collected and 
then processed as described in Section 2.3.3.7. 
2.3.4 Data analysis 
The pharmacokinetic parameters were calculated from the average plasma 
concentrations using the pharmacokinetic software DAS 2.0 software (Mathematical 
Pharmacology Professional Committee of China, Shanghai, China). Data and results 
were reported as means and standard error (means ± S.E.) unless otherwise stated. 
The differences in the mean values among different groups were analysed using a 
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one-way analysis of variance (ANOVA) using SPSS 13.0. Significance was 
considered at values of p<0.05. 
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Chapter 3 - Development of sulfatide-
containing nanoliposomal doxorubicin and 
PEG-sulfatide-containing nanoliposomal 
doxorubicin  
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3.1 Introduction 
Indiscriminate exposure of all cells in the body to a systemically administered 
chemotherapy agent kills healthy cells as well as tumour cells (Alexis, F. et al. 2008; 
Bawarski et al. 2008), causing severe toxicity to the patients and leading to serious 
side effects, low efficacy and poor quality of life (Peer, Dan. et al. 2007; Sapra, P., 
Tyagi & Allen 2005). This non-specific tissue distribution and the resulting side-
effects limit the clinical application of anticancer drugs (Ganta, S. et al. 2008). Thus, 
there is an urgent need to develop new chemotherapeutics that can target tumour 
cells effectively. Over the past few decades, nanoscale therapeutic systems have 
emerged as novel therapeutic modalities for combating cancer (Segal & Saltz 2009). 
The nanoparticle formulations of traditional free antitumour drugs may have 
improved pharmacokinetics (PK) and biodistribution (BD) profiles, enhanced 
antitumour efficacy, as well as reduced toxicity to healthy tissues. 
Liposomal drugs were the first approved and widely used such nanomedicine for 
the treatment of cancers (Barenholz 2012; Krown et al. 2004; Sawant & Torchilin 
2012; Wang, AZ, Langer & Farokhzad 2012). Liposomes are microscopic 
phospholipid vesicles with a bilayered membrane structure. Preclinical and clinical 
studies have shown that the pharmacokinetic profiles, as well as the targeting 
specificities, of liposomes can be controlled and modified to reduce the side effects 
of encapsulated drugs and enhance their efficacy (Davis, Chen & Shin 2008; Park, K 
2007; Torchilin 2006). 
The targeted delivery of anticancer agents to the tumour microenvironment is a 
promising avenue for the therapy of metastatic tumours. Tenascin-C, a large 
extracellular matrix (ECM) hexabrachion glycoprotein, is highly expressed in the 
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microenvironment of most solid tumours, but is absent or greatly reduced in most 
adult tissues (Brellier & Chiquet-Ehrismann 2012). As sulfatide, a lipid that is found 
in humans, is known to bind several ECM glycoproteins including tenascin-C 
(Kappler et al. 2002), it has the potential to be one of the components of 
nanoliposomes to target tumours expressing high levels of tenascin-C. We had 
recently developed a novel liposomal carrier system that was composed of two lipids 
found in humans, sulfatide and DOPE (He et al. 2010; Townson et al. 2007). Under 
physiological pH, DOPE confers stability to sulfatide-containing liposomes (SCL) 
via its inhibitory effects on liposome fusion, as the incorporation of sulfatide into 
DOPE vesicles greatly enhances the stability of the liposomes formed, even in the 
presence of plasma, presumably due to the hydration of the negatively charged 
sulfate head-group of the glycosphingolipid (Shao, Ke et al. 2006). Previous study 
indicated that the SCL could significantly improve the cellular uptake in cells with 
high level of tenascin-C expression compared to the nanoliposomes without sulfatide 
(Shao, Ke et al. 2006). We had also demonstrated that the interaction between 
sulfatide and tenascin-C mediates the binding of SCL to the ECM and endocytic 
uptake of the liposomes by tumour cells at least in vitro (Shao, Ke et al. 2006; Shao, 
K. et al. 2007). As a result, the sulfatide-containing liposomal carrier system 
represents a new class of natural lipid-guided intracellular delivery system targeting 
the tumour microenvironment.  
In exploring such a new direction for the development of more effective anticancer 
chemotherapeutics, it is important to understand the in vivo behaviour of the 
nanocarrier, as the unique distribution governed by the properties of the nanocarrier 
can change the therapeutic efficacy as well as alter the toxicity profile of the 
encapsulated drug. However, the in vitro and in vivo stability of the drug 
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encapsulated SCL, as well as its pharmacokinetic behaviour and the BD pattern are 
yet to be established. Thus, this chapter explores the physiochemical properties of the 
sulfatide-containing liposomal doxorubicin (SCL-DOX) in vitro, as well as the 
pharmacokinetics (PK) and BD in vivo.  
The work presented here was performed in collaboration with Yan Yu. 
Parts of this Chapter have been published (Lin J, Yu Y, Shigdar S, Fang DZ, Du 
JR, Wei MQ, Danks A, Liu K and Duan W. “Enhanced antitumor efficacy and 
reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a 
xenograft model of colorectal cancer”. PLoS ONE, 2012, 7(11): e49277.) 
3.2 Results 
3.2.1. Characterisation of nanoliposomes 
3.2.1.1 Establishing standard curves for determination of DOX loading 
efficiency 
To evaluate DOX loading efficiency in SCL via HPLC, standard curves were 
constructed by plotting peak area of fluorescence derived from DOX vs. DOX 
concentrations. To mimic samples to be determined, SCL-DOX or PEG-SCL-DOX 
without purification using size-exclusion chromatography were used as standards and 
diluted to series of DOX concentrations from 50 ng/mL to 20,000 ng/mL, followed 
by the HPLC measurement. A linear regression analysis was used for quantitation. 
As shown in Figure 3-1, a good linearity between peak areas and concentrations was 
obtained within the tested concentrations with a correlation coefficient of R2=0.9980 
(for SCL-DOX and 3% PEG-SCL-DOX) or R2=0.9991 (for 5 % PEG-SCL-DOX).  
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Figure 3-1. Standard curves for determination of DOX loading efficiency. The standard 
formulas were determined by linear regression as y = mx + b, where y is the peak area of 
DOX and x is the DOX concentration. (a) Standard curve for determination of DOX loading 
efficiency in SCL. (b) Standard curve for determination of DOX loading efficiency in SCL 
with 3% PEG2000-DSPE. (c) Standard curve for determination of DOX loading efficiency in 
SCL with 5% PEG2000-DSPE. Liposomal formulations were diluted with a methanol and 
phosphate buffer mixture (55:45, v/v) to different concentrations and measured using HPLC.  
3.2.1.2. Establishing standard curves for phospholipids assay 
To determine the DOPE concentration in the SCL-DOX, DOPE standards with 
different concentrations were prepared and measured using a spectrophotometer for 
construction of the calibration curve by plotting absorbance (y) vs. concentrations (x). 
As shown in Figure 3-2, the correlation coefficients (R2) of the standard curve was 
0.9996, suggesting a good linear regression of the absorbance vs. the concentration 
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within the concentration range of 0 – 1,000 ȝg/mL in UV-spectrophotometry for 
DOPE. 
 
 
Figure 3-2. Standard curves for phospholipids assay. One mg/mL DOPE stock in 
chloroform were diluted with chloroform to different concentrations and measured by UV-
spectrometry. The standard formulas were determined by linear regression as y = mx + b, 
where y indicated the absorbance while x was the concentration of DOPE. Data are shown as 
means r S.E. (n=3). 
3.2.1.3 Characterisation of nanoliposomes 
As the composition and preparation method of liposomes could directly affect 
their physicochemical characteristics (Fatouros & Antimisiaris 2001), the loading 
efficiency, size, drug-to-lipid ratio and surface charge were analysed for drug-
incorporating SCL and PEG-SCL for comparison. The physicochemical 
characteristics of SCL and PEG-SCL are presented in Table 3-1. The mean vesicle 
size of SCL incorporating DOX was 92.32 ± 1.31 nm with a polydispersity index 
(PDI) of 0.15 ± 0.01. At an initial weight ratio of DOX-to-DOPE of 0.3:1, the 
efficiency of DOX loading to SCL using an ammonium sulfate gradient was 94.11% 
± 2.27%, consistent with the previous report (Fritze et al. 2006). The zeta potential 
value of SCL was -26.38 ± 2.20 mV. The DOX to DOPE weight ratio after DOX 
encapsulation into SCL was 0.50:1. When compared within different formulations, 
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SCL showed the highest loading efficiency, as well as the best DOX to DOPE ratio, 
while the SCL with 3% PEG2000-DSPE indicated the smallest particle size (75.23 ± 
6.73 nm), the lowest DOX encapsulation efficiency (81.47% ± 1.89%) and the 
lowest drug-to-lipid ratio (0.23:1). The loading efficiency of SCL with 5% PEG2000-
DSPE was 89.54% ± 1.36%. The size and PDI were found to be 75.86 ± 5.62 nm and 
0.11 ± 0.1, respectively. The average value of zeta potential was -11.37 ± 0.26 mV. 
Table 3-1. Physical properties of the liposomal formulations. 
Composition DOX loading efficiency (%) Particle size (nm) DOX-to-DOPE ratio (w/w) Polydispersity index (PDI) Zeta potential (mV) 
SCL-DOX 94.11 ± 2.27 92.32 ± 1.31 0.50:1 0.15 ± 0.01 -26.38 ± 2.20 
PEG-SCL (3 % PEG) 81.47% ± 1.89 75.23 ± 6.73 0.23:1 0.14 ± 0.01 -19.44 ± 1.82
PEG-SCL (5 % PEG) 89.54 ± 1.36 75.86 ± 5.62 0.24:1 0.11 ± 0.01 -11.37 ± 0.26 
Data are shown as means ± S.E. of at least three independent experiments.  
3.2.2 In vitro drug retention properties. 
3.2.2.1 Establishing standard curves for in vitro release kinetics in PBS and 
PBS/10% FBS 
To analyse the stability of SCL-DOX in vitro, standard curves for the 
measurement of DOX in PBS or in PBS/10%FBS were established using 16 standard 
DOX solution concentrations covering a range from 0.1 ng/mL to 20,000 ng/mL and 
measured using HPLC. As shown in Figure 3-3, peak area of fluorescence derived 
from DOX vs. analytic concentration showed a good linear relationship with a 
correlation coefficient of R2 > 0.999.  
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Figure 3-3. Standard curves for in vitro release kinetics in PBS and PBS/10% FBS. The 
standard formulas were determined by linear regression as y = mx + b, where y is the peak 
area of fluorescence derived from DOX and x is the DOX concentration. (a) Standard curves 
of SCL-DOX for in vitro release kinetics in PBS. (b) Standard curves of SCL-DOX for in 
vitro release kinetics in PBS/10% FBS. (c) Standard curves of SCL-DOX with 3% PEG2000-
DSPE for in vitro release kinetics in PBS. (d) Standard curves of SCL-DOX with 3% 
PEG2000-DSPE for in vitro release kinetics in PBS/10% FBS. (e) Standard curves of SCL-
DOX with 5% PEG2000-DSPE for in vitro release kinetics in PBS. (f) Standard curves of 
SCL-DOX with 5% PEG2000-DSPE for in vitro release kinetics in PBS/10% FBS. DOX stock 
in methanol was diluted with methanol/PBS (v/v=1:1, for standard curve in PBS, or v/v=2:1, 
for standard curve in PBS/10% FBS) to different concentrations and quantified using HPLC.  
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3.2.2.2 In vitro drug retention properties 
Having established that SCL showed high loading efficiency, ideal size for in vivo 
delivery and negative surface charge, study was proceeded to evaluate the stability of 
drug encapsulation as it is essential for efficient drug delivery to the target site. In
vitro DOX release from SCL or PEG-SCL was determined by dialysing SCL-DOX 
or PEG-SCL-DOX against PBS or PBS with 10% FBS at 37 °C and measuring the 
DOX concentration over time from the fluid within the dialysis container. As shown 
in Figure 3-4, there was minimal DOX leakage from the SCL during the first 48 h 
dialysis period, with more than 99% of DOX retained in the SCL after 48 h under 
both PBS and PBS/serum dialysis conditions. The release of DOX was found to 
increase following 48 h incubation. The percentage of DOX retained in the SCL after 
72 h was 84.06% ± 8.63% in PBS and 91.91% ± 1.36% in PBS with 10% serum, 
respectively. The percentage of DOX retained in the PEG-SCL with 3% PEG after 
72 h was 99.96% ± 1.21% in PBS and 99.98% ± 0.95% in PBS with 10% FBS 
respectively. Similarly, there were more the 99% of DOX retained in the SCL with 5% 
PEG2000-DSPE in both PBS and PBS/10% FBS dialysis condition (99.97 ± 0.74% 
and 99.98% ± 0.82%, respectively). Thus, all liposome formulations in the study 
were very stable for 48 h 37 °C and retained substantial physical stability after 72 h 
in vitro. 
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Figure 3-4. In vitro stability of SCL-DOX and PEG-SCL-DOX. (a) In vitro stability of 
SCL-DOX. (b) In vitro stability of SCL-DOX with 3% PEG2000-DSPE. (c) In vitro stability 
of SCL-DOX with 5% PEG2000-DSPE. The stability of SCL-DOX or PEG-SCL-DOX was 
studied by analysing the release of DOX via dialysis assay in PBS or PBS with 10% FBS at 
37 °C. Aliquots of dialysis buffer were collected at designated time points (0, 0.5, 1, 4, 8, 24, 
48 and 72 h). DOX released into the dialysis buffer was quantified using HPLC. Data are 
shown as means r S.E. of at least three independent experiments.  
3.2.3 Flow cytometry analysis for intracellular uptake of SCL-DOX 
To evaluate the accumulation of SCL-DOX in vitro, the intracellular uptake of 
DOX and SCL-DOX was studied using flow cytometry utilising the natural 
fluorescent property of DOX. Human glioblastoma cells U-118MG and human 
adenocarcinoma cells MCF-7 were incubated with 4 ȝg/mL DOX or equivalent 
amounts of SCL-DOX for 1 h, 2 h, 4 h, 6 h or 24 h followed by washing with PBS 
three times. Cells were then trypsinised and the fluorescence of cells was measured. 
As shown in Figure 3-5, the intracellular fluorescence intensity of SCL-DOX was 
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lower than that of free DOX in both MCF-7 and U-118MG cells at all time points 
during the time period assayed, suggesting that free DOX was taken up more rapidly 
by the breast cancers and glioma cells than SCL-DOX in vitro. 
 
 
Figure 3-5. DOX uptake in MCF-7 and U-118MG cells. Cells were treated with 4 ȝg/mL 
of either free DOX or SC-DOX for the time indicated. The intracellular mean intensity of 
DOX fluorescence was analysed using flow cytometry (excitation wavelength: 552 nm, 
emission wavelength: 578 nm). Data are expressed as means ± S.E. of triplicates. 
3.2.4. In vivo characteristics of SCL-DOX and PEG-SCL-DOX. 
3.2.4.1 Establishing standard curves for DOX concentration in plasma 
Before the quantitative determination of DOX in plasma, plasma spiked with a 
serial dilution of DOX concentrations were prepared to obtain the calibration line for 
the following PK study. A linear regression was used for quantitation. The 
correlation coefficient (R2) for the calibration curve was 0.9998 (Figure 3-6), 
indicating a good linearity between peak areas and DOX concentrations was obtained 
within the tested concentrations ranging of 2 ng/mL to 10,000 ng/mL. 
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Figure 3-6. Standard curve for DOX concentration in plasma. The standard curve was 
constructed by measurements of plasma spiked with a serial dilution of DOX solutions. The 
calibration curve was generated by plotting peak area of fluorescence derived from DOX 
against the DOX concentrations in solution. Sample concentrations were determined by 
linear regression using the formula y = mx + b, where y is the peak area of DOX (ȝV × sec) 
and X is the DOX concentration (ng/mL). 
3.2.4.2 Improved pharmacokinetic properties of SCL in healthy SD rats 
Pharmacokinetic parameters were evaluated after the single i.v. administration of 5 
mg/kg free DOX, SCL-DOX or PEG-SCL-DOX. Due to better encapsulation 
efficiency, higher drug-to-lipid ratio and similar stability in vitro compared to SCL 
with 3% PEG2000-DSPE (Table 3-1 and Figure 3-4), SCL with 5% PEG2000-DSPE 
were chosen as the formulation for PK studies. The pharmacokinetic properties in 
healthy male SD rats were determined from plasma concentration-time profiles of 
free DOX, SCL-DOX and PEG-SCL-DOX. The main pharmacokinetic parameters 
are shown in Table 3-2. In the study, the terminal half-life with free DOX in plasma 
was 20.65 ± 1.34 h.. However, the terminal half-life was 41.89 ± 3.58 h with SCL-
DOX, showing a 2.03-fold increase in the terminal half-life. Indeed, the steady state 
Vd of free DOX (18.36 L/kg) was 25.15-fold higher than SCL-DOX (0.73 L/kg). The 
clearance rate of DOX encapsulated by SCL-DOX (1.39 L/h/kg) was significantly 
lower than that of DOX solution (2.68 L/h/kg, p < 0.01). The area under the plasma 
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concentration-time curves (AUC0-) of DOX delivered through SCL was 2.06-fold 
higher than free DOX (3597.03 ± 99.36 ȝg/Lh and 1746.87 ± 69.94 ȝg/Lh, 
respectively). PK parameters given in Table 3-2 also indicated that PEG-SCL 
formulation had the highest AUC0- (73730.54 ± 6161.04 ȝg/Lh), the slowest rate of 
clearance (0.62 ± 0.02 L/h/kg) and smallest Vd (0.05 ± 0.01 L/kg) among the tested 
formulations. However, DOX in the serum of rats injected with PEG-SCL-DOX 
decreased significantly after 2 h (Figure 3-7), which resulted in a decreased 
elimination half-life (T1/2) when compared with that of free DOX and SCL-DOX.  
Table 3-2. Pharmacokinetic parameters for free DOX, SCL-DOX and PEG-SCL-DOX. 
Formulations AUC0-(ȝg/Lh) t1/2 (h) CL (L/h/kg) Vd (L/kg) 
Free DOX 1746.87 ± 69.94 20.65 ± 1.34 2.68 ± 0.22 18.36 ± 0.80 
SCL-DOX 3597.03 ± 99.36** 41.89 ± 3.58** 1.39 ± 0.04** 0.73 ± 0.01**
PEG-SCL-DOX 73730.54 ± 6161.04*** ### 0.06 ± 0.01*** ### 0.62 ± 0.02*** # 0.05 ± 0.01***## 
Data are shown as means ± S.E. of at least three independent experiments.  
AUC: Area under the plasma concentration-time curves.  
t1/2, Elimination half-life.  
Vd: Volume of distribution.  
 **, p<0.01 compared to free DOX. ***, p<0.001 compared to free DOX. 
#, p<0.05 compared to SCL-DOX. ##, p<0.01 compared to SCL-DOX. ###, p<0.001 compared 
to SCL-DOX. 
 
 
Figure 3-7. Plasma clearance of different DOX formulation in healthy SD rats. Free 
DOX or DOX containing nanoliposomes were injected i. v. via tail vein with a single dose of 
5 mg DOX/kg. At selected time points after injection (0.033, 0.5, 2, 6,  24 and 48 h), rats 
were euthanised and the DOX was extracted and quantified. Data are shown as means r S.E. 
for Pg DOX per g of tissue (n=4-5). 
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3.2.4.3 Establishing standard curves for tissue distribution 
Before the quantitative determination of DOX in tissues, tissues (including heart, 
liver, spleen, lung and kidney) spiked with a serial dilution of DOX solutions were 
prepared to obtain calibration line which was used for assessing the concentration 
corresponding to the different peaks in the chromatograms. The relationship between 
peak areas and DOX concentrations was assessed over a range of 50-5,000 ng/mL. 
The correlation coefficients (R2) for calibration curves was better than 0.996 (Figure 
3-8), suggesting a good linear regression within the tested ranges. 
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Figure 3-8. Standard curves for tissue distribution. The standard curve was constructed 
by measurements of tissues spiked with a serial dilution of DOX solutions. The calibration 
curve was generated by plotting the peak area of fluorescence derived from DOX against the 
DOX concentration in solution. Standard formulas were determined by linear regression as y 
= mx + b where y is the peak area of DOX (ȝV × sec) and x is the DOX concentration 
(ng/mL). 
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3.3.4.4 Tissue distribution advantages of SCL-DOX in SD rats 
Next, the BD characteristics were evaluated of SCL-DOX after i. v. injection of a 
single dose of 5 mg/kg free DOX or SCL-DOX in healthy SD rats. As shown in 
Figure 3-9, treating the rats with SCL-DOX led to a significantly decreased DOX 
accumulation in the heart, lung and kidneys. In the heart and lung, the DOX 
concentration was significantly lower in the animals receiving SCL-DOX than those 
receiving free DOX at all time points, with as much as a 9-fold and 7-fold lower 
concentration in the SCL-DOX group at 2 h for the heart and lung, respectively 
(Figures 3-8(a) and (d)). Moreover, distribution of DOX at 0.5 h, 2 h and 4 h time 
points in the kidney was significantly reduced by i. v. administered SCL-DOX when 
compared to free DOX (Figure 3-9(e)). Consistent with the reported enhanced 
sequestration of nanoparticles, including liposomes, by organs of the 
reticuloendothelial (RES) system (Rahman et al. 1986a; Sugiyama & Sadzuka 2011), 
the DOX concentration was significantly higher in the liver of animals receiving 
SCL-DOX than those received free DOX (Figure 3-9(b)). In the spleen, the DOX 
concentration in the SCL group was significantly higher than the free DOX group 
only during the first 2 h following administration. There was no statistically 
significant difference in the DOX concentration at 4 h and 24 h points in the spleen 
between different treatment groups (Figure 3-9(c)). 
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Figure 3-9. Biodistribution of DOX encapsulated in SCL in SD rats. Biodistribution of 
DOX encapsulated in SCL in SD rats. Healthy rats were injected with a single dose of 5 
mg/kg free DOX or SCL-DOX i. v. Rats were euthanised at 0.5 h, 2 h, 4 h and 24 h after the 
administration. Organs were harvested, washed, weighed, and the DOX was extracted and 
quantified. Data are shown as means r S.E. for Pg DOX per g of tissue (n=5-6). ***p<0.001 
compared to free DOX. 
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3.2.4.5 Drug-to-lipid ratios in vivo 
In order to evaluate the in vivo stability of SCL-DOX in various tissues, DOX-to-
lipid ratios in tissues were measured after i. v. injection of a single dose of 5 mg/kg 
free DOX or SCL-DOX in healthy SD rats. [3H] cholesteryl hexadecyl ether (CHE) 
was added to DOPE as a nonmetabolised, nonexchangeable lipid tracer (Hussain et al. 
2007). The [3H] labelled lipids in tissues were analysed using a liquid scintillation 
analyser and DOX concentrations were measured using HPLC. The DOPE levels in 
tissues were determined by scintillation counting of [3H] followed by converting [3H] 
to DOPE using the calculating DOPE-to-[3H] CHE ratio of 1:24000. As shown in 
Table 3-1, the DOX-to-DOPE ratio before administration (set as the baseline for 
intact SCL-DOX) was 0.5:1.  The DOX-to-lipid ratios in different tissues and in 
plasma of healthy rats were determined and shown in Figure 3-10. As 3H-CHE is a 
nonmetabolised, nonexchangeable lipid tracer, DOX-to-lipid ratios increased when 
DOX accumulated or liposome contents were lost. As shown in Figure 3-10, there 
were significant increased DOX-to-DOPE ratios in tissues except in the liver and the 
spleen which are two major organs for the clearance of liposome formulations 
(Drummond, D. C. et al. 1999a) after the i.v. administration, suggesting the breaking 
down of DOX encapsulated liposomes by the macrophages of the reticuloendothelial 
system (RES) (De Jong & Borm 2008). Meanwhile, the elevated DOX-to-DOPE in 
the kidney might be related to the renal clearance of small molecules (Haas et al. 
2002). On the other hand, the peak ratio occurred at 2 h point in the spleen and lung 
(Figure 3-10 (a)), while in the heart, the highest ratio was at 4 h point following 
injection. Conversely, the peak ratio was reached at 0.5 h after SCL-DOX injection 
in the liver and kidney (Figure 3-10 (b) and 10 (c)). The early time to peak ratio in 
the liver may reflect the sequestration of liposomes by the RES. Moreover, the ratio 
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decreased significantly in all tissues after the peak point. Notably, unlike other 
organs which displayed an elevated ratio at 24 h compared to 4 h, there was a 
persistent decrease of drug-to-lipid ratio in the heart. The early accumulation but 
rapid clearance of the drug in the heart (Figure 3-9 (a) and Figure 3-10 (a)) indicated 
the potential of reduced cardiotoxicity of DOX encapsulated by SCL. Furthermore, 
the significantly increased ratio data in the liver at 24 h suggests that drug-depleted 
SCL continued to accumulate in this organ. Meanwhile, there was a significant 
increase of drug-to-lipid ratio in the bloodstream at 0.5 h. Then, the ratio decreased 
significantly after the peak (Figure 3-10 (d)), indicating that there might be a DOX 
accumulation in the plasma in a short period after i.v. administration. 
 Figure 3-10. DOX-to-lipid ratios in tissues and plasma of rats. Healthy rats were injected 
with a single dose of with 5 mg/kg [3H]-tracking SCL-DOX i. v. For tissue distribution study, 
rats were euthanised at 0.5 h, 2 h, 4 h and 24 h after the administration. For plasma study, 
rats were euthanised at 0.033 h, 0.5 h, 2 h, 6 h, 24 h and 48 h after the administration. Organs 
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were harvested, washed, weighed, and [3H] were quantified using liquid scintillation 
counting. Data are shown as means r S.E. (n=5-6). 
3.3 Discussion 
In the present study, the physicochemical characteristics and in vitro stability of 
different liposomal formulations were investigated. In addition, in vitro cellular 
uptake of DOX and SCL-DOX in U118MG and MCF-7 were compared. Meanwhile, 
following the instrumental conditions reported in the Methodology Chapter, the 
correlation coefficient (R2) for all calibration curves were equal to 0.990 or higher, 
presenting a good linear relationship between instrument response and analytical 
concentration within the analytical concentration ranges. Furthermore, this is the first 
study investigating the PK properties and BD profiles of SCL-DOX in healthy SD 
rats. 
DOX was successfully encapsulated in the SCL or PEG-SCL efficiently. The PDI 
of different formulations were less than 0.2 for all formulations, which indicated that 
liposomes had a homogeneous size distribution. Zeta potential is another important 
index for the stability of liposomal formulations. High absolute values of zeta 
potential indicates high electric charge on the surface of the drug loaded liposomes, 
which can prevent the aggregation of liposomes in buffer due to strong repellent 
forces (Kim, JY et al. 2009). It was shown that formulations in the study have 
negative surface charge. Meanwhile, the zeta potential of SCL and PEG-SCL in this 
study was within -30 mV (Table 3-1). The decreased absolute value of zeta potential 
in PEG-SCL with 5% PEG2000-DSPE and with 3% PEG2000-DSPE compared to SCL 
might be attributed to the inclusion of PEG (Sezgin, Yuksel & Baykara 2006). One 
of the possible mechanisms for the PEG effect on surface charge is that the presence 
of PEG on the liposome may lead to the slipping plane away from liposome surface 
 110 
 
and hence reduce the zeta potential. Another possible mechanism is the reduced 
mobility of liposomes caused by the presence of the PEG chains on the liposome 
surface, which could also lead to the decreased zeta potential (Kim, JY et al. 2009).  
In the literature, most of the reported DOX-to-lipid ratio after loading was between 
0.2:1 and 0.3:1 (w/w) (Hernández, Martí & Estelrich 1991; Hussain et al. 2007; 
Mayer et al. 1989) while in this study, a DOX-to-DOPE ratio was 0.50:1 (w/w) for 
SCL after encapsulation (Table 3-1). Therefore, the SCL might have the potential to 
encapsulate more drugs than many other published formulations of nanoliposomes. 
However, the loading efficiency and drug-to-lipid ratio was lower in the PEG-coated 
SCL. In a previous study, Wang et al. had indicated that encapsulation efficiency of 
liposomes would be decreased significantly when PEG was added (Wang, CH & 
Huang 2003). Reduced entrapping efficiency of PEGylated liposome might be a 
result of the 3-dimensional steric hindrance around the liposomes inducing by 
inserting PEG into lipids bilayers, which would keep drugs from entering the inside 
of the vesicles (Wang, CH & Huang 2003). 
The stability of the encapsulated drug in nanocarriers, which is essential for 
efficient drug delivery to the target site, is another important concept to consider 
when interpreting these data. The in vitro stability study suggested that SCL were 
very stable for 48 h 37 °C and retain substantial physical stability at 72 h in vitro 
(Figure 3-4). Interestingly, the percentage of liposomal DOX leakage after 24 h 
incubation in other studies was generally more than 5% (Huang et al. 2010; Lim et al. 
1997; Sadzuka et al. 2003; Song, H et al. 2006b), in contrast to minimal payload 
leakage of SCL-DOX at 48 h in this study. Moreover, PEG-SCL formulations 
displayed better DOX retention properties during dialysis as expected due to the 
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sterically stabilised function of PEG (Meyer et al. 1998). Therefore, both SCL and 
PEG-SCL displayed superior DOX retention properties in vitro under the 
experimental conditions used. 
In the cellular uptake study evaluated by flow cytometry, the mean intensity of 
fluorescence of DOX in cells treated with free drugs was higher than those treated 
with SCL-DOX (Figure 3-5), suggesting a lower cellular uptake of SCL-DOX in 
culture dishes. Similar results can be found in previous studies. For example, PEG-
complexed cationic liposome had been shown to have a lower uptake than free DOX 
in murine melanoma cells (Jung et al. 2009a). Meanwhile, in human cancer cell lines, 
including A375P (human melanoma), MCF-7 (human breast adenocarcinoma) and 
HepG2 (human hepatoma), free DOX displayed a higher level of uptake when 
compared with their liposomal formulation as well (Song, CK et al. 2009). As the 
lower intracellular uptake might be associated with the lower cytotoxicity, the 
liposomal formulation might be less toxicity to tumour cells in vitro. However, cells 
cultured in monolayer are exposed to a constant drug concentration throughout the 
entire assay period, and often take up free DOX more rapidly than liposomal 
formulations (Accardo et al. 2012). Therefore, uptake in vitro may not provide a 
reliable prediction of therapeutic efficacy in vivo (Xu & Anchordoquy 2011). 
The comparison of pharmacokinetic properties between free DOX and SCL-DOX 
in healthy SD rats displayed a significantly decreased clearance rate of SCL-DOX 
compared to free DOX (p<0.01). The pharmacokinetic studies of SCL-DOX in 
healthy SD rats also revealed the elimination half-life of SCL-DOX to be 
significantly longer than that of free DOX (p<0.01). The same improvements were 
found in the area under the plasma concentration-time curve from time 0 to infinity 
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and apparent Vd (Table 3-2), indicating significantly prolonged circulation time and 
enhanced bioavailability of SCL-DOX compared to free DOX. In the study, the short 
terminal half-life with free DOX in plasma was consistent with data from previous 
studies (Rahman et al. 1986a; Wei, G et al. 2008). The terminal half-life showed a 
2.03-fold increase in the terminal half-life, suggesting a significantly increased 
circulation time of SCL-DOX (p<0.01) as well as a decrease of volume of 
distribution (Vd) compared to free drug. Moreover, the significant decreased 
clearance rate of DOX encapsulated by SCL-DOX suggested a different rate of 
clearance of SCL-DOX compared to free drug. The increased AUC0- of DOX 
delivered through SCL (2.06-fold higher than free DOX), suggesting a decreased in 
non-specific binding as well as a selective sequestration of the drug to tissues when 
administered entrapped in SCL, leading to enhanced bioavailability. The decreased 
half-life of PEG-SCL-DOX compared with that of free DOX and SCL-DOX might 
be related to the significant clearance from the bloodstream 2 h after 
injection.( Figure 3-7), which resulted in a decreased elimination half-life (T1/2). 
Unexpectedly, liposomes modified with PEG showed a very short circulation half-
life in vivo. Therefore, although PEG coating has been widely used to prolong the 
half-life of liposomal formulations and most studies have indicated that PEG-coated 
liposomes generally have a longer circulation life in the bloodstream than 
conventional liposomes (Allen, T. M. et al. 1991; Immordino, Dosio & Cattel 2006), 
the PEG-SCL-DOX in this study showed no advantage to the circulation life. 
Another study has also indicated a shorter half-life of PEG-coated liposomal 
doxorubicin compared to free DOX (Wei, G et al. 2008). The possible reasons for the 
reduced half-life of our PEG-SCL might be the rapidly exchange out of the lipid 
bilayer in vivo (Gregoriadis, G (ed.) 2006). Due to the decreased particle size of 
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PEG-SCL-DOX compared with SCL-DOX, the smaller particles might result to the 
reduced half-life in the blood stream (Desai, N 2012).   
In addition, there was a significant improvement of BD profile of SCL-DOX. As a 
widely used and efficient antitumour drug, the risk of severe cardiotoxicity is a well-
known barrier to the use of free DOX in clinical therapy (Tokarska-Schlattner et al. 
2005). Encapsulation of DOX into SCL resulted in an approximate 4-fold lower 
DOX concentration in the heart of rats receiving SCL-DOX (Figure 3-9), which 
represented a significant improvement over those reported by others showing an 
approximately 1.5 times lower DOX accumulation in the heart of other liposomal 
DOX formulation than free DOX (Xiong, Huang, Lu, Zhang, Zhang & Zhang 2005; 
Xiong, Huang, Lu, Zhang, Zhang, Nagai, et al. 2005). As a result, the significant 
reduction in accumulation of DOX in the heart indicated the potential of SCL-DOX 
in reducing the cardiotoxicity of DOX. This was consistent with observations from 
DOX-to-lipid ratio in tissues. The data demonstrated that although there was an early 
accumulation of SCL-DOX in the heart, DOX was eliminate rapidly from the tissue 
(Figure 3-10 (a)), suggesting an improved safety profile of SCL-DOX in vivo. 
3.4 Conclusion 
In conclusion, a series of studies had been designed and carried out to                   
analyse SCL for DOX encapsulation. The simple two-lipid liposomes demonstrated a 
satisfactory loading efficiency of DOX and a high stability in vitro. Moreover, this 
nanodrug had favourable pharmacokinetic attributes in terms of prolonged 
circulation time, decreased clearance rate, reduced volume of distribution and 
enhanced bioavailability in healthy rats. As a result of the improved biodistribution 
and the targeting property of sulfatide to tenascin-C, SCL might have the potential to 
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be an effective and safer nano-carrier for DOX for the treatment of tumours with 
elevated expression of tenascin-C. 
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Chapter 4 - Enhanced antitumour activity and 
reduced systemic toxicity of glioma tumour 
microenvironment targeted sulfatide-containing 
liposomes 
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4. 1 Introduction 
Glioblastoma is very heterogeneous and the most common form of malignant 
primary brain tumours (Ohgaki 2009). It presents with an unfavourable prognosis 
due to its aggressiveness and likelihood of recurrence (Veenman et al. 2010). Thus, 
the development of novel anti-glioblastoma treatments is mandatory. Doxorubicin 
(DOX) is an anthracycline antibiotic widely used in oncology clinics as an anticancer 
chemotherapeutic agents. It was first introduced in the 1970s, and has now become 
one of the most commonly used anticancer drugs in the treatment of haematological 
malignancies and solid tumours (Arola et al. 2000). However, when a cumulative 
dose reaches 450 to 500 mg/m2, it may lead to cardiomyopathy, resulting in 
congestive heart failure (Imondi et al. 1996; Olson et al. 1988), which has become 
one of the well-known barriers of DOX in clinic utility. Moreover, serious toxicity to 
normal tissues, such as myelosuppression, is also leading to a poorer quality of life 
for patients (Charrois & Allen 2003). As a result of ongoing efforts in developing 
nanoparticle drug delivery systems, the liposomal formulations of doxorubicin, such 
as Doxil®, have entered the clinic with improved efficacy and reduced side effects 
(Elbayoumi, T. A. & Torchilin, V. P. 2008). 
One promising strategy to improve anticancer agents binding and penetrating into 
tumours is to develop drug carriers with a component that binds to the tumour cell 
surface or the extracellular matrix of tumours. Sulfatide, a lipid that is found in 
humans, is involved in a variety of biological processes, such as cell adhesion, 
platelet aggregation, cell growth, protein trafficking, signal transduction, neuronal 
plasticity and cell morphogenesis. It is known to bind several extracellular matrix 
glycoproteins including tenascin-C (Townson et al. 2007) which is overexpressed in 
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the microenvironment of most solid cancers, including malignant brain tumours 
(Orend & Chiquet-Ehrismann 2006). Studies had recently shown that sulfatide was 
specifically required for robust uptake of sulfatide-containing nanoliposomes by 
human glioblastoma cells U-87MG (Shao, Ke et al. 2006; Wu, X & Li 1999). The 
unique feature of this nanoliposome is that it is comprised of two natural lipids found 
in human cells, namely sulfatide and DOPE. Thus, this nanoliposome is totally 
human compatible and degradable. The sulfatide-containing liposomal (SCL-DOX) 
had been found to remain intact for hours after uptake by the glioblastoma cells 
(Shao, Ke et al. 2006; Wu, X & Li 1999). Intracellular distribution studies had 
indicated a high accumulation of DOX in the nuclei where it exerted its cytotoxic 
effect after 12 h incubation with SCL-DOX at 37 °C (Shao, Ke et al. 2006; Wu, X & 
Li 1999).  
 Recognising the potential of the use of a tumour environment targeting ligand as 
one of the main structural constituents of the nanocarriers capable of both passive 
and active targeting, a series of studies had been designed and carried out to 
determine the in vitro stability, the pharmacokinetic behaviour and the 
biodistribution pattern of the SCL-DOX (Chapter 3). The data have indicated that the 
sulfatide-containing liposomal carrier system represents a new class of natural lipid-
guided intracellular delivery systems which have the potential to increase treatment 
efficacy and reduce systematic toxicity of the drug encapsulated.  
Therefore, in the current study, cellular uptake and retention of SCL-DOX in U-
118MG glioblastoma cells were examined. The potential clinical utilities of this 
novel class of natural lipid-guided and tumour microenvironment targeting 
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nanoliposome were demonstrated via studies on its biodistribution in both U-118MG 
tumour-bearing mice, as well as its antitumour efficacy and toxicity profiles.   
The work presented here was performed in collaboration with Yan Yu. 
Parts of this work have been submitted to Nanomedicine: Nanotechnology, 
Biology and Medicine for publication. 
4. 2 Results 
4.2.1 In vitro cytotoxicity 
In order to assess the in vitro cytotoxicity of SCL-DOX to glioma cells, U-118MG 
glioblastoma cells were incubated with different formulations of DOX at various 
concentrations (0-100 ȝg/mL) for 48 h and the cytotoxicity of free DOX and SCL-
DOX to cells was compared using the MTT assay which measures the mitochondrial 
conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) to formazan as detected by the change of optical density at 570 nm (Jung et al. 
2009a). The IC50 values for DOX and SCL-DOX are shown in Table 4-1. The IC50 
for free DOX (2.51 ± 0.33 ȝg/mL) in U-118MG cells was lower than that observed 
in U-118MG cells treated with SCL-DOX (19.55 ± 0.68 ȝg/mL). These results 
suggested that U-118MG cells were relatively more sensitive to free DOX than to 
SCL-DOX following exposure to a constant concentration of the agent. There was no 
significant toxicity of blank SCL after 48 h incubation (data not show). The lower 
toxicity resulting from SCL-DOX to U-118MG cells in vitro is in good agreement 
with the literature for other liposomes loaded with free DOX (Chen, Z et al. 2012; 
Shmeeda et al. 2010) and is consistent with the previous stability study (Section in 
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Chapter 3.2.2.2) as the in vitro cytotoxicity is related to the release rate of DOX from 
nanocarriers (Song, H et al. 2006a).  
Table 4-1. Mean IC50 values (ȝg/mL of DOX) for treatment with free DOX and SCL-
DOX. 
Cell line Free Dox (ȝg/ml) SCL-DOX (ȝg/ml) 
U-118MG 2.51 ± 0.33 19.55 ±0.68 
Data are shown as means ± S.E. of three independent experiments performed in triplicate.  
 
4.2.2 Intracellular uptake and retention of SCL-DOX in U-118MG cells 
The accumulation and retention of DOX and SCL-DOX in U-118MG cells were 
studied using laser scanning confocal microscopy utilising the natural fluorescent 
property of DOX. Cellular uptake of free DOX or SCL-DOX by U-118MG was 
examined following 24 h incubation with 2 Pg/mL DOX or equivalent amounts of 
SCL-DOX. As shown in Figure 4-1, both free DOX and SCL-DOX accumulated in 
the glioblastoma cells. The overlay of Hoechst staining (nucleus) and red 
fluorescence (DOX) indicated that SCL-DOX was not adhered to the cell surface but 
actually penetrated into the nucleus. However, there was a slightly stronger DOX 
fluorescence (red) in cells treated with free DOX when compared to those treated 
with SCL-DOX after 24 h incubation. Interestingly, SCL-DOX was better retained 
by the U-118MG glioma cells. As shown in Figure 4-2 (a) and (c), there was a 
significant decrease of DOX fluorescence in cells treated with free DOX only 2 h 
after washing with PBS. In contrast, DOX fluorescence could be found in glioma 
cells treated with SCL-DOX even 24 h after washing (Figure 4-2 (b) and (d)), 
suggesting more sustained retention of DOX in U-118MG cells when delivered via 
SCL-DOX than by free DOX. The improved retention of DOX encapsulated with 
SCL in vitro implies the potential of better treatment efficacy of SCL-DOX in vivo.  
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Figure 4-1. Intracellular uptake of SCL-DOX in U-118MG cells. Intracellular uptake of 
SCL-DOX in U-118MG cells. U-118MG cells were incubated with 2 Pg/mL free DOX or 
equivalent SCL-DOX for 24 h. Cells were washed twice with PBS and imaged with a 
confocal fluorescence microscope. (a) Cells treated with free DOX (low magnification). (b) 
Cells treated with SCL-DOX (low magnification). (c) Cells treated with free DOX (high 
magnification). (d) Cells treated with SCL-DOX (high magnification). Red: fluorescence 
from DOX; blue: nuclei stained with Hoechst 33342. Data are representative of three 
independent experiments. Scale bars: 200 ȝm (for (a) and (b)) or 20 ȝm (for (c) and (d)). 
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Figure 4-2. Intracellular retention of SCL-DOX in U-118MG cells. U-118MG cells were 
first incubated with 2 Pg/mL free DOX or equivalent SCL-DOX for 24 h. Cells were then 
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washed with PBS twice and cultured in fresh full culture medium. The same wells of cells 
were imaged serially at 1 h, 2 h, 4 h and 24 h after washing using fluorescence confocal 
microscopy. (a) Cells treated with free DOX (low magnification). (b) Cells treated with 
SCL-DOX (low magnification). (c) Cells treated with free DOX (high magnification). (d) 
Cells treated with SCL-DOX (high magnification). Data are typical of three independent 
experiments.  Red: fluorescence from DOX; blue: nuclei stained with Hoechst 33342. Scale 
bars: 200 ȝm (for (a) and (b)) or 20 ȝm (for (c) and (d)). 
4.2.3 Establishing standard curves for tissue distribution 
Before the quantitative determination of DOX in tissues, the linearity of the 
calibration curves correlating the fluorescence intensity measured by HPLC and the 
amounts of DOX in different tissues (including heart, liver, spleen, lung, kidney and 
tumour) was verified over the range of 10-500 ng/mL using tissues spiked with a 
serial dilution of DOX solutions. As shown in Figure 4-3, the correlation coefficients 
(R2) for calibration curves were better than 0.996. Thus, under the instrumental 
conditions reported in Chapter 2 (Section 2.3.1.3), a good linearity between peak 
areas and concentrations was obtained over the analytical concentration ranges. 
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Figure 4-3 Standard curves for tissue distribution in mice. Standard curve was 
constructed by measurements of tissues or tumours spiked with a serial dilution of DOX 
solutions. The calibration curve was generated by plotting the peak area of DOX against the 
DOX concentration in solution. Standard formulas were determined by linear regression as y 
 125 
 
= mx + b where y is the peak area of DOX (ȝV × sec) and X is the DOX concentration 
(ng/mL). 
4.2.4 Improved tumour uptake and biodistribution in U-118MG tumour 
xenograft model 
Next, the ability of SCL-DOX to enhance the delivery of therapeutic agents to the 
tumour in vivo was investigated using a mice tumour xenograft model. The uptake of 
DOX in various organs and the tumour was determined 24 h after a single dose of 5 
mg/kg DOX or SCL-DOX by i. v. administration in U-118MG glioblastoma-bearing 
nude mice. Consistent with the results from the study in healthy SD rats in the 
preceding chapter (Chapter 3), the DOX concentration in organs responsible for 
dose-limiting toxicity in clinics, i.e. the heart, in the tumour-bearing mice treated 
with SCL-DOX was significantly lower than those treated with free DOX (33.07 ± 
1.34 Pg/g versus 49.07 ± 2.35 Pg/g) (Figure 4-4 (a)). The DOX concentration in the 
other known major DOX toxicity organ, the skin, was also statistically significantly 
lower in the SCL-DOX group compared to the free DOX animals (0.97 ± 0.06 versus 
1.61 ± 0.11 Pg/g), as well as in the kidneys (403.94 ± 9.99 versus 472.35 ± 20.08 
Pg/g). On the other hand, the measured concentration of DOX in other organs 
indicated that there were significantly higher levels of DOX in the liver, spleen and 
lung in the group treated with SCL-DOX when compared to the free DOX group 
(1.40-fold, 3.78-fold and 1.71-fold, respectively) (Figures 4-4(b) and 4-4(e)). As for 
the xenograft glioma (Figures 4-4(d)), there was a statistically significant elevation 
of DOX level in tumour tissue in the SCL-DOX group compared to that of free DOX 
(1.33-fold), indicating the enhanced intratumoural DOX delivery by SCL-DOX in
vivo. 
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Figure 4-4. BD and tumour uptake of DOX encapsulated in SCL in xenograft-bearing 
mice. Nude mice bearing human glioblastoma U-118MG xenografts were treated with a 
single dose of 5 mg/kg free DOX or SCL-DOX i.v. Mice were euthanised 24 h later.  Organs 
and tissues were harvested, washed, weighed, and the DOX content in tissues, expressed as 
Pg DOX per g tissue, was determined. Data are shown as means r S.E. (n=5-6). *, p<0.05 
compared to free DOX; **, p<0.01 compared to free DOX; ***, p<0.001 compared to free 
DOX. 
4.2.5 Enhanced therapeutic efficacy of SCL-DOX in U-118MG xenograft 
tumour model 
Given that the SCL-DOX is able to deliver more therapeutic agents to the 
xenograft tumour (Figure 4-4d), the antitumour activity of SCL-DOX in vivo was 
proceeded to determine. Mice bearing U-118MG tumours were injected with saline, 
blank SCL, DOX in solution or encapsulated within SCL once a week for 6 weeks 
when subcutaneous tumours reached a volume of 150 mm3. Figure 4-5 shows tumour 
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growth inhibition. There was no significant difference in tumour sizes between mice 
treated with saline control and blank SCL during the study period. Importantly, at a 
dose of 5 mg/kg, all the DOX formulations were effective in preventing tumour 
growth compared to saline and blank liposome control after the 2nd injection. The 
final mean tumour load was 97.29 r 10.71 mm3 in the SCL-DOX treatment group 
while in free DOX group it was 154.76 r 12.53 mm3. Thus, SCL-DOX formulations 
displayed stronger tumour growth suppression than free DOX.  
 
Figure 4-5. Improved therapeutic activity of SCL-DOX against glioma xenograft. Mice 
bearing U-118MG xenografts were injected i.v. with saline, 5 mg/kg of free DOX, SCL-
DOX or empty SCL once a week for 6 weeks when tumour volume reached approximately 
150 mm3. Data shown are means r S.E. (n=5-6). *, p<0.05 compared to saline; **, p<0.01 
compared to saline; #, p<0.05 compared to free DOX; ***, p<0.001 compared to free DOX; 
##, p<0.05 compared to free DOX; &, p<0.01 compared to blank SCL; &&, p<0.01 
compared to blank SCL; &&&, p<0.001 compared to blank SCL. 
 
To further confirm the antitumour efficacy, the survival rates of tumour-bearing 
mice were compared following different treatment regimens. As shown in Figure 4-6, 
the median survival days for saline, free DOX and SCL-DOX group were 45, 61 and 
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93 days, respectively. Therefore, the medium life-span was increased in mice treated 
with SCL-DOX by 2.07-fold and 1.52-fold compared to those treated with saline or 
free DOX, respectively. Taken together, i. v. administration of SCL-DOX 6 times 
over a 6-week period displayed not only a better tumour inhibitory effect but also an 
improved survival of U-118MG xenograft-bearing mice. 
 
Figure 4-6. SCL-DOX enhanced survival of tumour-bearing mice. The Kaplan-Meier 
survival curve shows improvement of life span of U-118MG xenograft-bearing mice treated 
with SCL-DOX (n= 8-10 per group).  Mice were treated as indicated in the legend for Fig. 6 
and were sacrificed when tumour burden reached 800 mm3.  
4.2.6 Reduced toxicity of SCL-DOX in vivo 
Clinically, the efficacy of DOX is limited by dose-limiting toxicities. One 
objective of delivery of chemotherapy agents in a nano-formulation is to reduce 
systemic toxicities. For this aim, the toxicity of SCL-DOX and free DOX was 
evaluated after repeated injection in tumour-bearing nude mice. The tissue 
concentration of DOX was measured 24 h after the 6th administration of either SCL-
DOX or free DOX (Figure 4-7). Consistent with the findings in healthy rats, the 
concentrations of DOX in the heart and skin were significantly lower, 0.56-fold and 
0.08-fold, respectively, in the tumour-bearing mice treated with SCL-DOX than 
 129 
 
those treated with free DOX following repeated administrations. On the contrary, 
compared with the free DOX group, 1.28-fold more DOX accumulation was 
observed in the tumour in SCL-DOX group, clearly confirming the enhanced 
intratumoural DOX delivery by SCL-DOX in vivo. As for plasma biochemistry 
analysis carried out 72 days after the last injection (Figure 4-8), DOX treatment 
alone induced a significant increase in serum creatine kinase (CK) concentration 
(1048.00 ± 100.95 U/L), indicative of heart damage, compared to saline control 
(588.50 ± 167.37 U/L), blank SCL (543.40 ± 86.47) and SCL-DOX groups (430.60 ± 
82.94 U/L). Furthermore, compared with the free DOX group, the plasma 
concentrations of aspartate transaminase (AST), a sensitive indicator of liver damage, 
in the SCL-DOX group (p<0.01) and blank SCL group were significantly lower 
(p<0.05). Moreover, as a marker of DOX-damaged myocytes, troponin was 
measured for the evaluation of DOX-induced cardiomyopathy in vivo (Herman et al. 
1999; Singal & Iliskovic 1998). The method used in the present study has a cut-off 
threshold of <0.01 ȝg/L for normal subjects (Koh, Nakamura & Takahashi 2004). As 
shown in Table 4-2, there was a 1.8-fold higher level of troponin in the mice treated 
with free DOX than those with saline control while in both SCL-DOX and blank 
SCL group, there were no significant elevation compared to the control. Thus, the 
results indicated that the SCL-DOX has the potential to minimise the cardiotoxicity 
of free DOX. 
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Figure 4-7. Encapsulation of DOX in SCL substantially reduced the accumulation of 
DOX in principal sites of DOX toxicity. U-118MG xenograft-bearing mice were treated as 
indicated in the legend for Figure 4-5. Blood was collected immediately after the mice were 
sacrificed upon reaching the end point. Data shown are means r S.E. (n=5-6). *, p<0.05 
compared to saline; **, p<0.01 compared to saline; ***, p<0.001 compared to free DOX. 
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Figure 4-8.  Encapsulation of DOX in SCL significantly reduced cardiac and hepatic 
toxicity. U-118MG xenograft-bearing mice were treated as indicated in the legend for Figure 
4-5. Blood was collected immediately after the mice were sacrificed upon reaching the end 
point.  Serum enzymes indicative of cardiac and hepatic toxicity were analysed. Data shown 
are means r S.E. (n=3-5). *, p<0.05 compared to saline; #, p<0.05 compared to free DOX; 
##, p<0.01 compared to free DOX.  
 
Table 4-2. Plasma levels of troponin. 
Treatment Number of nude mice Troponin (Pg/L) 
Saline 4 <0.01 
Free DOX 5 0.018 ± 0.003 
SCL-DOX 
Blank SCL 
5 
5 
<0.01 
<0.01 
Data are presented as means ± S.E. (n = 4-5).  
 
4.3 Discussion 
As liposomes are composed of naturally biodegradable substances, they are 
metabolised and cleared while in circulation or upon reaching the target sites, making 
them safe novel drug delivery carriers (Domb et al. 2007). The current study 
provided the first report on antitumour efficacy of tenascin-C-targeted SCL-DOX in 
a xenograft model of glioma that expresses high levels of tenascin-C (Reardon, 
Zalutsky & Bigner 2007).  
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As for in vitro cytotoxicity between different liposomes and cancer cell lines, 
published studies have reported contradictory results. For example, in MLLB2 cells 
(rat prostate cancer) (Wang, J et al. 2005) and MCF-7/ADR cells (human breast 
carcinomas) (Li, B et al. 2012), the IC50 of the liposomal formulation was 
significantly lower than that of free DOX, which indicated a higher cytotoxicity of 
liposomal DOX in vitro. On the contrary, in HepG2 cells (human hepatoma) (Li, X et 
al. 2009) and U-87 cells (human glioblastoma) (Shao, Ke et al. 2006), free DOX 
seemed to have higher intracellular uptake with associated higher cytotoxicity than 
that of liposomal DOX. Obviously, the kinetic properties are different between 
liposomal DOX and free DOX. The half-life of liposomal DOX can be up to several 
days while free DOX can be eliminated in a few minutes in vivo (Allen, Theresa M.  
et al. 2006; Cabanes et al. 1999; Unezaki et al. 1994). Moreover, the MTT assay used 
to derive the IC50 is carried out with monolayers in culture dishes, which are very 
different when compared to the 3-dimentional tissue architecture in vivo (Xu & 
Anchordoquy 2011). Thus, comparison of IC50 in vitro, which is relevant to the 
cytotoxicity under the same exposure time and constant concentration, is not a 
reliable predictor of the therapeutic efficacy in vivo (Wu, J et al. 2007). Furthermore, 
SCL-DOX had been found to remain in the nuclei for several hours even after 
washing (Figure 4-2 (b) and (d)). This is in agreement with another study using the 
same DOX delivery system in a different cell line (Shao, Ke et al. 2006). Notably, 
despite the higher IC50 value of SCL-DOX in vitro, it had a much better anti-tumour 
efficacy over the free DOX in U-118MG tumour-bearing nude mice (Figure 4-5). 
As a widely used and efficient antitumour drug, the risk of severe cardiotoxicity is 
a well-known barrier of free DOX in clinical therapy (Tokarska-Schlattner et al. 
2005). Encapsulation of DOX into the SCL resulted in an approximate 4-fold lower 
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DOX concentration in the heart of healthy SD rats (Figure 3-8 in Chapter 3). 
Reduced accumulation of DOX derived from SCL in the heart was also found in U-
118MG tumour-bearing nude mice after single injection and repeated injection 
(Figures 4-4 and 4-7). Therefore, the significant reduction in accumulation of DOX 
in the heart indicated the potential of SCL-DOX in reducing the cardiotoxicity of 
DOX. This had been reinforced by the biochemical studies of the serum creatine 
kinase activity, which is a toxicological indicator of severe cardiotoxicity (Bagchi et 
al. 2003) as well as cardiac troponin, another biomarker for the detection and 
prevention of cardiotoxicity at an earlier phase (Mercuro et al. 2007). Previous 
studies by others revealed an increase in serum troponin levels from week 10 after 
the first administration of DOX in Wistar rats treated with liposomal DOX (Koh, 
Nakamura & Takahashi 2004). This present study revealed no discernable increase in 
serum troponin levels in mice treated with SCL-DOX even 14 weeks after the onset 
of treatment, suggesting a remarkable reduction in cardiotoxicity of DOX delivered 
via SCL. Moreover, the study also found a significant reduction in the amounts of 
serum AST in mice treated with SCL-DOX (Fig. 9). This is important as DOX is 
excreted predominantly through the hepatobiliary route (Cosan et al. 2008) and there 
is a good negative correlation between serum AST activity and hepatic activity 
(Yokogawa et al. 2006).  
Although encapsulation with liposomes has been successful in overcoming 
cardiotoxicity and myelosuppression (for free DOX), the toxicity of liposomal DOX 
has shifted to cutaneous toxicity (Charrois & Allen 2003). Palmar-plantar 
erythrodysesthesia (PPE), also called hand-foot syndrome, is a toxic reaction 
associated with high accumulation of cytotoxic chemotherapeutics, including 
pegylated liposomal doxorubicin formulation in the skin (Farr, Katherina 
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Podlekareva. & Safwat, Akmal. 2011). High liposome localisation in the skin had 
been reported previously in both nude mice and human (Goren, D. et al. 1996). In 
this study, a significantly reduced concentration of DOX in the skin was observed in 
mice treated with SCL-DOX repeatedly when compared to the free DOX group 
(Figure 4-7), suggesting that the SCL formulation of DOX could help to reduce the 
dose-limiting cutaneous toxicity displayed by other liposomal formulations of DOX. 
 In contrast, the uptake of DOX in liver and spleen, which are tissues rich in cells 
of the reticuloendothelial system (RES), was higher for SCL-DOX when compared 
to free DOX (Figure 4-4), in agreement with previous studies (Elbayoumi, TA & 
Torchilin, VP 2009; Xiong, Huang, Lu, Zhang, Zhang & Zhang 2005). The increased 
accumulation of SCL-DOX in the organs of RES might be related to the particle size 
of the SCL (Campbell 2006; Drummond, D. C. et al. 1999b). Therefore, further work 
is needed to reduce the uptake of SCL-DOX by RES. 
As well as a benefit of reduced toxicity by SCL-DOX formulations, better 
treatment efficacy from animals treated with SCL-DOX over free DOX was found in 
the tumour-bearing mice (Figures 4-5 and 4-6). Significantly higher concentrations 
of DOX in tumour from SCL-DOX treated mice were found both after single 
injection (Figure 4-4) and repeated injections (Figure 4-7). Administration of SCL-
DOX had superior tumour inhibitory effects compared to that of free DOX (Figure 4-
5), manifested as both the inhibition of tumour growth and the increased life span 
(Figure 4-6). Importantly, tumours grew much slower in the mice receiving SCL-
DOX when compared with those receiving free DOX. As the repeated injection of 
liposomal formulation could lead to the change of pharmacokinetics of drugs (Cui et 
al. 2008), the difference of tissue concentrations between after single injection and 
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after repeated injections might be resulted from the separated pharmacokinetic 
property of SCL-DOX.  
Nano-carriers can be used to improve the treatment efficacy and reduce the side 
effects of drugs they encapsulate. Due to its high surface-to-volume ratio, 
functionalising the surface of nanoparticles with ligands such as antibodies, aptamers, 
peptides, or small molecules that are tumour-speci¿c or tumour-associated can 
promote the active binding of nanoparticles to tumours (Alexis, F. et al. 2008). The 
composition and structure of the extracellular matrix in tumours are different from 
that in the normal tissues (Liu, F et al. 2008). Certain extracellular matrix 
glycoproteins are highly up-regulated in many different cancers, including gliomas, 
breast cancer and ovarian cancer (Fernando et al. 2008; Quemener et al. 2007). 
Tenascin-C is a protein expressed at low levels in normal adult tissues but high levels 
in many tumours (Mackie & Tucker 1999), including gliomas. Therefore, tenascin-C 
has been implicated as an important target for the treatment of cancer (Adams, M et 
al. 2002). In a previous study, the key component of SCL, sulfatide, was 
demonstrated to mediate the binding and endocytic uptake of SCL in tumour cells via 
the interaction with tenascin-C (Alvarez-Cedron, Sayalero & Lanao 1999). It was 
evident from the current results that SCL conferred sufficient therapeutic activity, as 
well as reduced side effects of its encapsulated drug, in the tenascin-C expressing 
tumour model (U-118MG) used here. Thus, modification with other ligands, which 
could target the cancer stem cells, on the surface of SCLs will likely aid the 
development of novel therapeutic strategies for treating tenascin-C positive tumours. 
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4.4 Conclusion 
In summary, the tenascin-C targeting SCL displayed increased therapeutic effects 
in addition to the reduced toxicity in vivo. These results taken together, therefore, 
demonstrate that SCL has the potential to be an effective and safer nano-carrier for 
the treatment of tumours with elevated expression of tenascin-C. Further 
improvement in therapeutic index can be afforded by the functionalisation of SCL 
with other cancer-targeting ligands, such as antibodies or aptamers. 
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Chapter 5 - Enhanced antitumour efficacy and 
reduced systemic toxicity of sulfatide-
containing nanoliposomal doxorubicin in a 
xenograft model of colorectal cancer 
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5.1 Introduction 
Colorectal cancer is the third most common cause of cancer-related deaths 
worldwide (Sala-Vila & Calder 2011; Szepeshazi et al. 2002), with up to 25% of 
patients presenting with metastatic disease. Despite surgery and chemotherapy, many 
of these patients eventually succumb to metastatic diseases. Adjuvant therapies, 
including radiotherapy and chemotherapy, are designed to target residual tumour 
cells. In stage III patients with colorectal cancer, chemotherapy remains the main 
treatment strategy (Bhattacharya et al. 2009). However, the success of these therapies 
is limited by the emergence of therapy-resistant cancer cells as well as dose-limiting 
toxicities (Segal & Saltz 2009). Liposomes are well-recognised vehicles for drug 
delivery in recent years. They have been indicated to enhance the therapeutic 
efficacy of several traditional antitumour drugs (Lasic, D. D. 1998). Ideal designed 
liposomes for drug delivery have the ability to passively accumulate in tumour 
tissues via the EPR effects in tumours. The passive accumulation can be further 
enhanced by actively targeting liposomes modified by coupling ligands on the 
vesicle surface (Forssen, Coulter & Proffitt 1992).  
The tumour microenvironment has been shown to be one of the key factors 
contributing to the development of cancer (Hanahan & Weinberg 2011). Tenascin-C 
is a glycoprotein found in the extracellular matrix and it is an important target for 
targeted-drug delivery in the treatment of cancer (Hicke, B. J. et al. 2006). The novel 
strategy employed in this study is to use a lipid component of the liposome to target 
the tumour microenvironment. Due to the targeting property of sulfatide, a 
glycosphingolipid known to interact with several extracellular matrix proteins, to 
tenascin-C, sulfatide-containing liposomes (SCL) have the potential to be an 
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effective and safer nano-carrier for the treatment of tumours with elevated expression 
of tenascin-C.  
In view of the limited success of chemotherapy in colorectal cancer and high 
toxicity of DOX, a SCL encapsulation approach was taken to overcome these 
barriers. In Chapter 4, the efficacy of SCL against glioma suggested an enhanced 
treatment efficacy of sulfatide-containing liposomal DOX (SCL-DOX) and a 
reduction in the accumulation of DOX in the drug’s principal toxicity organs 
achieved by SCL-DOX led to a diminished systemic toxicity as evident from the 
plasma biochemical analyses. The SCL-DOX had also demonstrated a good stability 
in vitro, as well as improved pharmacokinetic behaviour and enhanced BD profiles 
(Chapter 3). Now, the study was extended to colorectal cancer. 
In this study, a mouse xenograft model of human colorectal adenocarcinoma (HT-
29) that is known to express tenascin-C (De Santis et al. 2006; Mukaratirwa et al. 
2005) was utilised to study the biodistribution (BD), antitumour efficacy and toxicity 
of sulfatide-containing liposomal carrier system.  
The work presented here was performed in collaboration with Yan Yu. 
Parts of this Chapter have been published (Lin J, Yu Y, Shigdar S, Fang DZ, Du 
JR, Wei MQ, Danks A, Liu K and Duan W. “Enhanced antitumor efficacy and 
reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a 
xenograft model of colorectal cancer”. PLoS ONE, 2012, 7(11): e49277.) 
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5.2 Results 
5.2.1 Intracellular uptake and retention of SCL-DOX in HT-29 cells 
Taking advantage of the natural fluorescent property of DOX, the cellular uptake 
and retention of free DOX or SCL-DOX was studied using laser scanning confocal 
microscopy. HT-29 cells were incubated with 2 Pg/ml DOX or SCL-DOX for 24 h.  
Following washing, the cellular uptake of different formulations of DOX was 
examined.  As shown in Figure 5-1, both free DOX and SCL-DOX were taken up by 
the colorectal adenocarcinoma cells and there was accumulation of DOX in the 
nucleus in both groups (Figure 5-1), albeit cells treated with free DOX showed 
slightly stronger red fluorescence (DOX) than those treated with SCL-DOX after 24 
h incubation. Interestingly, the retention of SCL-DOX in HT-29 cells was better than 
that of free DOX. As shown in Figure 5-2, following washing with PBS and 
incubation in fresh media for 4 h, the DOX fluorescence in the free DOX group 
decreased significantly. Moreover, cells treated with free DOX showed diminished 
red fluorescence 24 h after washing. Conversely, the red fluorescence for SCL-DOX 
was more stable compared to that of the free DOX group. Even 24 h after washing, 
DOX fluorescence could be readily observed in the nuclei of cells treated with SCL-
DOX (Figures 5-2(b) and (c)). The enhanced retention of SCL-DOX in vitro suggests 
that the SCL formulation of DOX might exhibit better treatment efficacy in vivo. 
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Figure 5-1. Intracellular uptake of SCL-DOX in HT-29 cells. HT-29 cells were incubated 
with 2 Pg/mL free DOX or equivalent SCL-DOX for 24 h. Following two washes with PBS, 
cells were imaged with a confocal fluorescence microscope. (a) and (c) Cells treated with 
free DOX. (b) and (d) Cells treated with SCL-DOX. Red: fluorescence from DOX; blue: 
nuclei stained with Hoechst 33342. Scale bars: 200 ȝm (for (a) and (b)) or 10 ȝm (for (c) and 
(d)). 
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Figure 5-2. Intracellular retention of SCL-DOX in HT-29 cells. HT-29 cells were first 
incubated with 2 Pg/mL free DOX or equivalent SCL-DOX for 24 h. After two washes with 
PBS to remove the drugs, cells were cultured in fresh full culture medium followed by 
imaging serially at 1 h, 2 h, 4 h and 24 h using fluorescence confocal microscopy. (a) and (c) 
Cells treated with free DOX. (b) and (d) Cells treated with SCL-DOX. Red: fluorescence 
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from DOX; blue: nuclei stained with Hoechst 33342. Scale bars: 200 ȝm (for (a) and (b)) or 
10 ȝm (for (c) and (d)). 
5.2.2 In vitro cytotoxicity 
To study the in vitro cytotoxicity, HT-29 cells were exposed to various 
concentrations of free DOX or SCL-DOX for 48 h, and the cell viability was 
measured using the MTT assay which measures the mitochondrial conversion of 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) to 
formazan as detected by the change of optical density at 570 nm (Li, G et al. 2012). 
As shown in Table 5-1, the IC50 of DOX for HT-29 cells was 1.74 ± 0.10 ȝg/mL 
while the IC50 of SCL-DOX was 2.77 ± 0.06. Thus, under in vitro conditions where 
cells were exposed to a constant concentration of the agents throughout the entire 
assay period, free DOX was more toxic than SCL-DOX. Empty SCL did not show 
any effects on cell survival (data not shown). 
Table 5-1. Mean IC50 values (ȝg/ml of doxorubicin) for treatment with free DOX and SCL-DOX  
Cell line Free dox (ȝg/ml) SCL-dox (ȝg/ml) 
HT-29 1.74 ± 0.10 2.77 ±0.06
Data are shown as means ± S.E. of triplicate in three independent experiments.  
 
5.2.3 Establishing standard curves for tumour uptake 
Before the quantitative determination of DOX in tissues, HT-29 tumours spiked 
with a serial dilution of DOX concentrations were prepared to obtain the calibration 
curve which was used for determination of the concentration of DOX from the 
measured fluorescence intensity in chromatograms.. As shown in Figure 5-3, the 
correlation coefficient (R2) for the calibration curve was 0.996. Thus, under the 
instrumental conditions described in Chapter 2, a good linearity between peak areas 
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and concentrations was obtained over the analytical concentration ranges within the 
range of 1-100 ng/mL. 
 
Figure 5-3. Standard curve for DOX concentration in HT-28 tumours. A standard curve 
was constructed by measuring fluorescence in tissues or tumours spiked with a serial dilution 
of DOX solutions. The calibration curve was generated by plotting the peak area of 
fluorescence derived from DOX against the DOX concentration in solution. Standard 
formulas were determined by linear regression as y = mx + b where y is the peak area of 
DOX (ȝV × sec) and x is the DOX concentration (ng/mL). 
5.2.4 Tissue distribution and tumour uptake Advantages of SCL-DOX 
Studies comparing the accumulation of free DOX or SCL-DOX in tumours and 
organs were performed in a BALB/c nude mice HT-29 tumour xenograft model. 
Animals were injected i.v. with a single dose of free DOX or SCL-DOX (5 mg/kg) 
and there was no statistically significant difference in DOX concentration in the 
kidneys between the two treatment groups 24 h after administration. The lungs and 
liver showed higher DOX accumulation (4.74-fold and 12.94-fold, respectively) with 
SCL-DOX treatment (Figure 5-4(a)), and the spleen, a major organ of the 
reticuloendothelial system, showed a 17-fold higher DOX accumulation with SCL-
DOX treatment. However, SCL-DOX treatment in the two principal organs that 
display dose-limiting toxicities of DOX clinically, namely the skin and heart, 
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decreased the DOX accumulation to 59.0% (0.039 r 0.001 Pg/g versus 0.066 r 0.003 
Pg/g) and 77.4% (0.956 r 0.073 Pg/g versus 1.235 r 0.083 Pg/g) compared to the 
free DOX, respectively (Figure 5-4(b) and (c)). Moreover, SCL encapsulation 
significantly enhanced DOX accumulation (1.3-fold; 0.060 r 0.005 Pg/g versus 
0.047 r 0.003 Pg/g) in the xenograft tumour compared to free DOX (Figure 5-4(d)), 
clearly confirming the enhanced intratumoural DOX delivery by SCL-DOX in vivo.  
 
Figure 5-4. BD and tumour uptake of DOX encapsulated in SCL in xenograft-bearing 
mice. Nude mice bearing human colorectal cancer HT-29 xenografts were treated with 5 
mg/kg free DOX or SCL-DOX i.v. Mice were euthanised 24 h later.  Organs and tissues 
were harvested, washed, weighed, and the DOX was extracted and quantified. Data are 
shown as means r S.E. (n=5~6). *, p<0.05 compared to free DOX; **, p<0.01 compared to 
free DOX. 
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5.2.5 Enhanced therapeutic efficacy of SCL-DOX 
Having determined the tissue distribution of SCL-DOX, the antitumour activity of 
SCL-DOX was evaluated using the BALB/c nude mice HT-29 tumour xenograft 
model. Once the tumour had grown to approximately 35 mm3, the animals were 
divided randomly into four groups (n=5~10) in order to minimise difference in 
weight and tumour size among the groups. The following regimens were 
administered i.v. twice a week for 3 weeks: (i) saline; (ii) empty SCL; (iii) free DOX 
(5 mg/kg) and (iv) SCL-DOX (5 mg/kg).  The body weight of the animals and the 
tumour size were then monitored until the size of the tumour in the control animals 
reached the end point of the study. As presented in Figure 5-5, for the control groups 
of mice receiving saline or empty SCL, the treatment did not show any efficacy, and 
the mean tumour sizes at the end of the study were 1129.03 r 55.06 mm3, and 
1188.63 r 137.54 mm3, respectively (mean r S.E.; n=5~6). The SCL-DOX treatment 
group demonstrated superior efficacy, with a final mean tumour load of 586.52 r 
29.63 mm3, compared to 809.13 r 43.75 mm3 in the free DOX group.  Thus, 
compared to saline or free DOX treatment, the efficacy of SCL-DOX to suppress 
tumour growth at the dose of 5 mg/kg was significantly improved by ~1.9-fold and 
~1.4-fold, respectively. 
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Figure 5-5.  SCL-DOX produced more reduction in tumour volume. Mice bearing HT-
29 xenografts were injected i.v. with saline,  5 mg/kg of free DOX, SCL-DOX or empty SCL 
twice a week for 3 weeks as indicated, starting on the day when tumour volume reached ~35 
mm3. Data shown are means r S.E. (n=5~6). *, p<0.05 compared to saline; **, p<0.01 
compared to saline; #, p<0.05 compared to free DOX; &&, p<0.01 compared to blank SCL; 
&&&, p<0.001 compared to blank SCL. 
 
  Next, the survival rates of tumour-bearing mice following the four different 
treatment regimens were compared. As shown in Figure 5-6, median survival times 
for the four different groups were 26 days (saline), 33 days (free DOX), 36 days 
(SCL-DOX) and 32 days (blank SCL), respectively. Thus, SCL-DOX treatment 
increased medium life-span by 38.5% compared to the saline control group, by 12.5% 
compared to the blank SCL group and by 9.1% compared to the free DOX group.  
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Figure 5-6. SCL-DOX enhanced survival. The Kaplan-Meier survival curve shows 
improvement of life span of xenograft-bearing mice treated with SCL-DOX (n=9~10 per 
group).  Mice were treated as indicated in Figure 5-3 and were sacrificed throughout the 
study period upon reaching the study end point. 
5.2.6 Reduced systemic toxicity of SCL-DOX 
DOX-induced cardiomyopathy is one of the key dose-limiting toxicities of the 
drug (Rahman et al. 1986b). Cardiac troponin is released from DOX-damaged 
myocytes (Wei, G et al. 2008), therefore, measurement of serum levels of this protein 
provides a sensitive assessment of early cardiotoxicity of DOX. The method used in 
the present study has a cut-off threshold of <0.01 ȝg/L for normal subjects 
(Sugiyama & Sadzuka 2011). As shown in Table 5-2, the free DOX treatment 
resulted in a 75-fold higher troponin serum level compared to the controls, 
confirming the known cardiotoxicity of the free drug. However, no elevation of 
serum troponin was observed for the SCL-DOX treatment group, which remained 
below cut-off levels, as with the control groups, indicating that treating xenograft-
bearing mice with 6 doses of SCL-DOX over the period of 4 weeks had minimal 
cardiotoxicity.  
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Table 5-2. Plasma levels of troponin 
Treatment Number of nude mice Troponin (ug/L) 
Saline 4 <0.01
Free DOX 3 0.750±0.234 
SCL-DOX 
Blank SCL 
5
3
<0.01
<0.01
Data are presented as means ± S.E. (n = 3-5). 
 
To investigate whether encapsulation of DOX into SCL had any impact on the 
severity of bone marrow suppression (myelosuppression), the most common adverse 
effect of DOX chemotherapy (Singal & Iliskovic 1998), the changes in peripheral 
white blood cells count were studied. As shown in Figure 5-7, there was no 
statistically significant difference in the total number of white blood cells between 
the saline treated or SCL-DOX-treated groups. Furthermore, compared with mice 
treated with free DOX, those treated with SCL-DOX had a 2.0-fold and a 3.3-fold 
higher count for lymphocytes and monocytes, respectively.  
 
 
Figure 5-7.  SCL-DOX treatment had significantly reduced myelosuppression.  HT-29 
xenograft-bearing mice were treated as indicated in Figure 5-3. Blood was collected 
immediately after the mice were sacrificed upon reaching the end point.  Data shown are 
means r S.E. (n=3~5). *, p<0.05 compared to saline; ***, p<0.001 compared to saline; #, 
p<0.05 compared to free DOX; ##, p<0.01 compared to free DOX. 
 151 
 
5.3 Discussion 
This study is the first to evaluate the tissue distribution, in vivo anticancer 
activities and toxicity profile of SCL-DOX in a xenograft mouse model of human 
colorectal adenocarcinoma. The current study have shown several important points: 
(a) SCL-DOX was readily taken up by colon cancer cells and displayed prolonged 
retention; (b) encapsulation of DOX in SCL resulted in a decreased distribution of 
the drug to the principal sites of acute and chronic toxicity of free DOX, namely the 
heart and the skin, as well as markedly lowered cardiotoxicity and myelosuppression; 
(c) sulfatide-containing liposomal drug displayed an enhanced therapeutic efficacy in 
a mouse model of human colorectal adenocarcinoma.  
The intracellular uptake of SCL in glioma cells was shown to be a result of 
endocytic uptake of the liposomes in previous work (Shao, K. et al. 2007). In this 
study, the results confirmed the intracellular uptake of SCL-DOX by human 
colorectal adenocarcinoma cells, HT-29, using confocal microscopy. Importantly, it 
has been demonstrated that the encapsulated chemotherapy drug was delivered 
intracellularly to the site of action, the nuclei, of the HT-29 cells (Figures 5-1 and 5-
2).  Furthermore, the delivered liposomal drug was retained by the tumour cells even 
24 h after washing. The in vitro cytotoxicity study compared the viability of 
colorectal cancer cells treated with SCL-DOX and free DOX using the MTT assay 
and showed that both forms possess overt cytotoxicity. Interestingly, the SCL-DOX 
had an IC50 59% higher than that of free DOX (Table 5-1). This is consistent with 
observations from others that the IC50 of the free and liposomal drug, when assayed 
in vitro, varies dependent on the cell lines used and the nature of the liposomes. For 
example, Wang et al. found in the rat prostate cancer cell line MLLB2, the IC50 of 
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the liposomal formulation was significantly lower than free DOX (Wang, J et al. 
2005). In a study of resistant MCF-7/ADR cells (human breast adenocarcinoma), the 
liposomal DOX showed a 30-fold lower IC50 compared to free DOX (Li, B et al. 
2012). However, in other studies free DOX seemed to have higher intracellular 
uptake and displays higher cytotoxicity than that of liposomal DOX. For example, in 
the hepatocellular carcinoma cell line, HepG2, free DOX had been indicated to 
possess a higher cytotoxicity compared to that of DOX-loaded stealth liposomes (Li, 
X et al. 2009). Furthermore, polyethylene glycol (PEG) coated-liposomal DOX had 
been shown to have less toxicity than free DOX in the glioma cell line, U-87 cells 
(Shao, Ke et al. 2006). It is important to appreciate that the in vivo pharmacokinetics 
are very different between liposomal DOX and free DOX. The half-life of liposomal 
DOX can be several days while free DOX can be eliminated in a few minutes in vivo 
(Allen, Theresa M.  et al. 2006; Cabanes et al. 1999; Unezaki et al. 1994). In cell 
culture dishes, cells are exposed to a constant drug concentration throughout the 
entire assay period, and often take up free DOX more rapidly than liposomal 
formulation (Accardo et al. 2012). Furthermore, cells for MTT assays are mostly 
cultured in monolayers, which have a spatial organisation drastically different from 
the in vivo 3-dimensional tissue architecture (Xu & Anchordoquy 2011). Thus, 
comparison of IC50 between a free drug and a nanoparticle-formulation of the drug in
vitro provides a measurement of the cytotoxicity under a constant concentration 
during a chosen assay period, and therefore it may not be able to provide a reliable 
prediction of the therapeutic efficacy in vivo (Wu, J et al. 2007). In the present study, 
although the IC50 of SCL-DOX was higher than that of free DOX in HT-29 cells in
vitro, the SCL formulation was shown to display a much improved tumour inhibitory 
effect over the free DOX in HT-29 tumour-bearing nude mice (Figures 5-4 and 5-5). 
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Gastrointestinal tumours are known to be relatively resistant to chemotherapeutics. 
In 80% of untreated colon tumours, there is an elevated level of the multidrug-
resistant I (MDR I) gene (Oudard et al. 1991). Notably, significantly higher 
concentrations of DOX in tumours from SCL-DOX treated mice were found after 
single administration (p<0.05). Moreover, it is interesting to note that SCL 
encapsulation not only resulted in a significant increase in tumour uptake in vivo, but 
also enhanced anti-tumour efficacy of DOX in HT-29 tumour-bearing nude after 
repeated administration. As the statistically significant difference in tumour growth 
between free DOX and SCL-DOX groups appeared after the 5th administration 
(Figure 5-4), the therapeutic efficacy may be attributed to the preferential 
accumulation of SCL-DOX in the tumour via the enhanced permeability and 
retention effect (EPR effect) over a period of multiple administrations. Moreover, 
after intracellular delivery, the SCL-DOX was retained in the tumour cells much 
better than free DOX (Figure 5-2). Thus, the increased DOX concentration in 
tumours treated with SCL-DOX was consistent with a better treatment efficacy in
vivo. 
In most cases, cancer chemotherapy is limited by the low therapeutic index of the 
anticancer drugs due to serious toxicity to normal tissues. Indeed, the therapy-
limiting toxicity of DOX is cardiomyopathy, which may lead to congestive heart 
failure and death (Singal & Iliskovic 1998). Encapsulation of free DOX using a 
cyanoacrylate nanoparticle shifted toxicity from the heart to the kidney (Manil, 
Couvreur & Mahieu 1995), while the PEGylated liposomal DOX (Doxil) 
accumulates in skin, resulting in a shift in the toxicity profile from cardiotoxicity and 
myelosuppression to cutaneous toxicity, known as palmar-plantar erythrodysesthesia 
(Charrois & Allen 2003). The current study aimed to develop a nanoliposome that 
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improves the biodistribution characteristics and changes the toxicologic properties of 
the encapsulated drug. In current preclinical toxicology experiments, the intended 
clinical administration route, i.e. intravenous (i. v.) injection, was utilised throughout 
the studies with the HT-29 tumour-bearing mice models. The data (Figure 5-4) 
demonstrated that the accumulation of liposomal DOX in the skin and heart were 
significantly lower than that of free DOX. Since tissue levels of DOX were reduced 
by SCL delivery, the decreased concentration of DOX at these sites was likely to 
result in a reduced risk of the development of side effects.  Indeed, the biochemical 
and haematological analyses (Figure 5-7 and Table 5-3) demonstrated that the 
improved therapeutic efficacy of SCL-DOX was obtained without an increase in 
toxicity to the heart or to the bone marrow. It is noteworthy that the troponin level 
was significantly lower in the SCL-DOX group than that of the free DOX group. As 
for indicators of myelosuppression, the higher level of total white cell numbers, 
lymphocytes and monocytes in the SCL-DOX group indicated that formulations of 
SCL decreased the toxic myelosuppression associated with free drug. The increased 
accumulation of SCL-DOX in the liver, spleen and lung compared to free DOX 
might be related to the particle size of SCL, as nanoparticles with sizes of 100-200 
nm preferentially accumulate in organs of the reticuloendothelial system (Alexis, 
Frank , Pridgen, Eric , et al. 2008; Campbell 2006; Drummond, D. C. et al. 1999b) . 
By encapsulating drugs in nanoparticles, nanomedicine reduces drug concentration 
in normal host tissues and increases the concentration of active drug within the 
tumour. To further improve the selectivity and specificity, it is desirable to actively 
target the nanodrugs to the site of the tumour. Targeting nanodrugs using antibodies 
that recognise the tumour-associated antigens is a widely adopted approach. 
However, its application might be limited by altered expression or low percentages 
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of tumour cells that express any given antigen. Therefore, the development of 
alternative targeted drug delivery systems may have important implications for future 
novel anticancer therapeutics. It had been previously demonstrated that sulfatide 
mediates the binding and endocytic uptake of SCL in tumour cells via the interaction 
with tenascin-C (Shao, K. et al. 2007). The extracellular matrix is a major constituent 
of the tumour microenvironment that is very different from that of their normal 
counterparts. Tenascin-C is a large extracellular matrix hexabrachion glycoprotein 
and is absent or greatly reduced in most normal adult tissues. Tenascin-C is highly 
expressed in the majority of malignant solid tumours, including gliomas, and cancer 
of the breast, uterus, ovaries, prostate, colon, stomach, pancreas, lung, liver, skin and 
kidney (Brellier & Chiquet-Ehrismann 2012). Furthermore, high tenascin-C 
expression correlates with a low survival prognosis in cancers such as glioma, breast, 
colon and lung carcinoma. In addition to its roles in promoting tumour cell 
proliferation and angiogenesis, tenascin-C had recently been shown to provide breast 
cancer cells with a key metastatic niche to colonise the lungs by promoting tumour 
cell dissemination and survival during the early steps of metastasis and enhancing the 
fitness of the disseminated cancer cells at the site of colonisation (Oskarsson et al. 
2011). Thus, the production of tenascin-C enhances the ability of micrometastatic 
colonies to survive and expand. Given that up to 20% of new cases of colorectal 
cancer present with metastatic disease, and of the patients who present with localised 
disease, about 20% will subsequently relapse with distant metastases (Segal & Saltz 
2009), targeting tenascin-C would constitute a promising strategy in the effort to 
combat micrometastasis. Sulfatide had been shown to bind to several extracellular 
matrix proteins, including tenascin-C (Miura et al. 1999; Pesheva et al. 1997). In this 
study, the in vivo utilities of the SCL in enhanced efficacy in colorectal cancer 
xenografts known to express tenascin-C as well as reduced concentration and toxicity 
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in tissues that are susceptible to the main side effects of the encapsulated drug, i.e. 
the heart, the bone marrow and the skin were further demonstrated. Future research 
in combining active targeting ligands, such as antibodies and aptamers, which target 
cancer stem cell surface makers with natural lipid-guided intracellular delivery, may 
open a new direction for the development of more effective anticancer 
nanotherapeutics.  
5.4 Conclusion 
In conclusion, the current study had demonstrated that SCL-DOX showed an 
improved toxicity profile and enhanced efficacy in a human colorectal cancer 
xenograft model. It may therefore provide a potent and safe nanomedicine platform 
for treatment of colorectal cancer that has overexpression of sulfatide-binding 
proteins, especially tenascin-C. Functionalising SCL with antibodies or aptamers 
may further enhance the clinical utilities of this natural lipid-guided liposomal 
formulation of anticancer drugs for both primary tumour and micrometastasis via 
effective targeting the tumour microenvironment. 
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Chapter 6 - Exploration of the potential of 
using sulfatide-containing liposomes for drug 
delivery into the brain 
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6.1 Introduction 
Gliomas are the most frequently diagnosed primary brain malignancy in the 
central nervous system (CNS) (Liu, Y, Zhou & Zhu 2012). Although plenty of 
efforts have been done in diagnostic procedures, surgical techniques, radiation 
therapy and chemotherapy, the majority of patients succumb to the disease within 1 
year after diagnosis (Aoki et al. 2004). One of the reasons for high mortality of 
gliomas is that the tumours have the ability to invade diffusely into surrounding 
healthy brain tissue, thereby precluding successful surgical removal (Skog et al. 
2008). Thus, chemotherapeutics play a critical role in the treatment of brain tumours. 
However, the major challenge for chemotherapeutics in the management of CNS 
tumours is the limited penetration of many drugs through the blood–brain barrier 
(BBB) (Ambruosi et al. 2006). The endothelial cells of the blood vessels in the brain 
form cerebralcapillaries which are characterised by tight continuouscircumferential 
junctions, restricting the penetration of most polar solutes across the cerebral 
endothelium (Begley 1996; Marin-Padilla 2012).  
Traditional anticancer agents suffer from various limitations ranging from poor 
treatment efficacy to serious side effects (Allen, T. M. 1994b). Breakdown of the 
BBB is present in several CNS disorders, including brain tumours (Gerstner & Fine 
2007; Nagaraja et al. 2011). However, the BBB could remain intact, especially in the 
early stage of tumour growth and at the tumour invasion edge of the brain tissue 
(Bulnes et al. 2012; Huynh, Deen & Szoka 2006). Thus, most current anticancer 
chemotherapeutics have poor BBB penetration, which prevent them from targeting 
tumours in brain. Therefore, it is critical to develop new approaches which are safe 
and effective against brain tumours. Nowadays, nanomaterials such as liposomes or 
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polymer nanoparticles, offer several therapeutic strategies for treatments of brain 
tumours (Auffinger et al. 2012; Zhou et al. 2012).  
Liposomal drugs are promising candidates for local delivery within the 
CNS. Increasing evidence has indicated the advantages of nanoliposome technology 
in the treatments of gliomas (Gong et al. 2011; Saito et al. 2004). Since they can be 
combined with a variety of drugs that are not able to cross the BBB, as a new form of 
targeted tissue specific delivery, drug encapsulated nanoliposomes can greatly 
improve drug distribution and therefore, its therapeutic effect in brain tumours was 
enhanced (Mamot, C. et al. 2004). For example, in in vivo studies, liposomes showed 
high accumulation in gliomas (Shibata, Ochi & Mori 1990; Siegal, Horowitz & 
Gabizon 1995), indicating the potential of liposomal formulations of anticancer 
agents to overcome the BBB. However, it had been identified that liposomes do not 
undergo significant transport through the BBB in the absence of ligand-mediated 
drug delivery (Misra et al. 2003). In addition, various studies investigating liposome 
penetration into the BBB were carried out in in vitro models (Lohmann, Huwel & 
Galla 2002; Visser et al. 2005) or in healthy animals which is not a reliable predictor 
of the therapeutic efficacy in the tumour-bearing model (Soni, Kohli & Jain 2005; 
Xie et al. 2005).  
 The sulfatide-containing liposomal doxorubicin (SCL-DOX) used in the current 
study had shown reduced toxicity, extended longevity, and enhanced tumour specific 
targeting property in U-118MG and HT-29 subcutaneous xenograft models (Chapter 
4 and Chapter 5). The question arises as to whether the SCL-DOX can penetrate the 
BBB to deliver systemically administered therapeutic agents intracranially. Therefore, 
in the present study, DOX encapsulated in SCL was evaluated for its capacity of 
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delivering chemotherapeutic agents into the brain. The extent of brain delivery was 
first studied in healthy rats to examine the potential of SCL-DOX to cross the BBB. 
Furthermore, tumour uptake, as well as tissue distribution, in intracranial C6 brain 
tumour xenograft rats was studied after a single i.v. administration of SCL-DOX. 
The work presented here was performed in collaboration with Yan Yu, Tao Wang 
and Dongxi Xiang. 
6.2 Results 
6.2.1 Enhanced brain distribution of SCL-DOX in healthy SD rats 
This study initially evaluated the accumulation of SCL-DOX after i. v. injection in 
healthy SD rats with an intact BBB. Therefore, a single dose of 5 mg/kg free DOX or 
SCL-DOX were injected via the tail vein and the brain cortexes of healthy SD rats 
were collected at 4 predetermined time points following injection. As shown in 
Figure 6-1, free DOX showed limited ability to cross the BBB. Conversely, SCL-
DOX led to a significantly elevated DOX accumulation in the brain compared to rats 
treated with free DOX at all time points (p<0.001).  
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Figure 6-1. Improved brain distribution in healthy rats. Healthy rats were injected with a 
single dose of 5 mg/kg free DOX or SCL-DOX i. v. Rats were euthanised at 0.5 h, 2 h, 4 h 
and 24 h after injection. Brain cortex was harvested, washed, weighed, and the DOX was 
extracted and quantified. Data are shown as means r S.E. for Pg DOX per g of tissue (n=5-6). 
***p<0.001 compared to free DOX. 
6.2.2. Enhanced brain distribution of SCL-DOX in perfused healthy SD rats 
As brain tissue collected from unperfused animal might contain up to 2% blood, it 
is desirable to study the drug delivery in perfused animal to minimise the possibility 
of overestimation of the extent of drug delivery due to the contamination of the blood. 
To verify the results obtained in Section 6.2.1, rats were perfused with saline 24 h 
after injection and the brain cortex was collected followed by measurement using 
HPLC. As shown in Figure 6-2, although there was a 3.61-fold decreased (3.57 ȝg/g-
tissue vs. 12.89 ȝg/g-tissue) SCL-DOX accumulation compared to that in the rats 
without perfusion (Figure 6-1), the distribution of DOX in the cortex was 
significantly increased by i. v. administered SCL-DOX when compared to free DOX 
after perfusion.  
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Figure 6-2. Improved brain distribution in perfused healthy rats. Healthy rats were 
injected with a single dose of 5 mg/kg free DOX or SCL-DOX i. v. Rats were perfused with 
saline 24 h later followed by euthanasia. Brain cortex was harvested, washed, weighed, and 
the DOX was extracted and quantified. Data are shown as means r S.E. for Pg DOX per g of 
tissue (n=5-6). ***p<0.001 compared to free DOX. 
6.2.3 Establishment of intracranial brain tumour xenograft models  
Having established that SCL-DOX could penetrate the BBB in healthy rats and 
mice, the study proceeded to investigate whether the SCL system could penetrate the 
BBB to deliver DOX to brain tumours. Taking the volume of the implantation into 
account, 1×106 C6 glioma cells in 10 ȝL volume were implanted into the 
intracerebral region of healthy Wistar rats using a Harvard Apparatus Pump 11 Elite 
Syringe Pumps and stereotaxic device (Figure 6-3 (a)). On day 18 after implantation, 
rats were sacrificed. Tissues and tumours were collected and DOX distribution was 
measured via HPLC. As shown in Figure 6-3 (b) and (c), C6 glioma cells formed a 
tumour in the right hemisphere section, suggesting the successful establishment of 
intracranial brain tumour xenograft models in Wistar rats. 
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Figure 6-3. Establishment of intracranial brain tumour xenograft models. C6 Glioma 
cells were implanted into the intracerebral region of rats using syringe pump and stereotaxic 
device. Rats were euthanised 18 days after implantation. (a) The instrumental set-up used for 
the implantation of C6 glioma cells in the brain of rats. (b) The exterior view of a 
representative brain from a tumour-bearing rat. (c) The vertical view of a dissected right 
hemisphere with the implanted C6 glioma. Arrows: the location of the implanted brain 
tumour.  
6.2.4 Establishing standard curves for tissue distribution in Wistar rats 
Before the quantitative determination of DOX in tissues and tumours, tissues and 
tumours spiked with a serial dilution of DOX solutions were prepared to obtain a 
calibration curve which was used for assessing the DOX concentration 
corresponding to different peaks in the chromatograms. Peak areas were plotted 
against DOX concentrations to obtain the analytical curve followed by linear 
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regression analysis. The linearity of the calibration curves for distribution of DOX in 
different tissues as well as in xenograft C6 gliomas were evaluated over the range of 
50-5,000 ng/mL. As shown in Figure 6-3, the correlation coefficients (R2) for 
calibration curves were better than 0.990, suggesting a good linear regression within 
the analytical concentration ranges. 
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Figure 6-4. Standard curves for tissue distribution in Wistar rats. The standard curve 
was constructed by measurements of tissues spiked with a serial dilution of DOX solutions. 
The calibration curve was generated by plotting the peak area of fluorescence derived from 
DOX against the DOX concentration in solution. Standard formulas were determined by 
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linear regression as y = mx + b where y is the peak area of DOX (ȝV × sec) and x is the 
DOX concentration (ng/mL). 
6.2.5 Tissue distribution and tumour accumulation of SCL-DOX in an 
intracranial brain tumour xenograft model 
  The ability of SCL to improve the delivery of DOX into the intracranial tumour was 
evaluated using a rat glioma xenograft model. The tissue distribution and tumour 
uptake was determined 24 h after a single dose of 5 mg/kg DOX or SCL-DOX i. v. 
administration in C6 glioma-bearing Wistar rats. Consistent with the results from the 
study in healthy SD rats in Chapter 3, there was a significantly reduced accumulation 
in organs responsible for dose-limiting toxicity in patients, i.e. the heart, in the 
tumour-bearing rats treated with SCL-DOX compared to those injected with free 
DOX (0.41 ± 0.05 Pg/g versus 0.64 ± 0.02 Pg/g) (Figure 4-4 (a)). In the kidney, one 
of the other known major DOX toxicity organs (Burke et al. 1977; Giri et al. 2004), 
DOX concentration was also statistically significantly lower in the SCL-DOX group 
compared to that of the free DOX animals (0.96 ± 0.13 versus 3.98 ± 0.36 Pg/g). On 
the other hand, in organs which are at least partly responsible for clearance of 
liposomes from the circulation, such as the liver and spleen, the measured 
concentration of DOX indicated that there were significantly higher levels of DOX in 
the group treated with SCL-DOX when compared to the free DOX group (89.17-fold 
and 3.05-fold, respectively) (Figures 6-5(d)). Notably, there was a statistically 
significant elevation of DOX level in the brain and tumour tissue in the SCL-DOX 
group compared to that of free DOX (p<0.01 and p<0.05, respectively) (Figures 6-
4(b) and 6-4(c)). 
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Figure 6-5. Tissue distribution of DOX encapsulated in SCL in C6 glioma tumour-
bearing rats. Tumour-bearing rats were injected with a single dose of 5 mg/kg free DOX or 
SCL-DOX i. v. Rats were euthanised 24 h later. Tumours and organs were harvested, 
washed, weighed, and the DOX was extracted and quantified. Data are shown as means r 
S.E. for Pg DOX per g of tissue (n=3-4). *p<0.05 compared to free DOX. **p<0.01 
compared to free DOX. ***p<0.001 compared to free DOX. 
6.3 Discussion 
Malignant gliomas are heterogeneous, diffuse and highly infiltrating by nature 
(Linz 2010). Despite wide surgical resection and improvements in radiotherapy and 
chemotherapy, the prognosis of patients with gliomas remains extremely poor, with 
the majority of patients having a survival rate of less than 10% at five years (Stupp et 
al. 2009). As the most vital organ in the body, the brain is isolated and protected 
from the intrusion of potentially toxic substances in the blood stream (Pathan et al. 
2009). The critical brain supporting system restricts and ensures selective access of 
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nutrients and other essential chemicals across the BBB (Kabanov & Batrakova 2004). 
However, the efficacy of anticancer therapeutic agents in targeting brain tumours has 
been limited due to poor penetration of the BBB (Chen, Y, Dalwadi & Benson 2004). 
The BBB is thus considered a major obstacle for chemotherapeutic drugs to 
efficiently reach tumours in the brain (Koukourakis et al. 2000). Various strategies 
had been developed to overcome the BBB, including its temporary disruption by 
hyperosmotic solutions (Hall et al. 2006) or vasoactive agents such as bradykinin 
(Matsukado, Sugita & Black 1998). However, disruption of the BBB has the 
potential to result in non-localised drug delivery, as well as an elevated cellular 
uptake of plasma albumin and other protein components in the blood which were 
toxic to the brain (Vykhodtseva, McDannold & Hynynen 2008). Therefore, new 
alternative approaches, such as nanocarriers which include liposomes, had been 
being developed for drug transportation across the BBB for drug delivery (Huwyler, 
Wu & Pardridge 1996).  
In the new drug delivery strategy, the carried drug selectively accumulated in 
tissues with increased vasculature permeability, such as tumour tissue in the brain, 
(Golub et al. 1994). In vivo studies had shown that liposomes were indeed highly 
accumulated in the brain (Yuan et al. 2010) or in the experimental gliomas (Shibata, 
Ochi & Mori 1990; Siegal, Horowitz & Gabizon 1995), suggesting that liposomal 
drugs might overcome the BBB effectively. Therefore, we used SCL as nanocarriers 
for DOX and evaluated its potential in tumour targeting in intracranial brain tumour 
xenograft rats in the current study. Consistent with the previous studies regarding 
other liposomal formulations of DOX (Saito et al. 2004; Tiwari & Amiji 2006), SCL 
encapsulation has the potential to overcome the limitations of free therapeutic drug 
molecules in crossing the BBB (Figure 6-1 and Figure 6-2). 
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Previous studies had indicated that the C6 rat glioma model simulates the growth 
and invasion of human glioblastoma and could be used as a suitable animal model 
(Grobben, De Deyn & Slegers 2002). For example, Inoue at al. (Inoue et al. 1987) 
studied the therapeutic effects of hyperosmotic BBB disruption using this in situ 
glioma model in SD rats, while Kaye et al. (Kaye, Morstyn & Ashcroft 1985) had 
studied glioma growth in the C6 tumour-bearing Wistar rats. Thus, unlike 
subcutaneous tumour models, the intracranial brain tumour xenograft model 
performed in the present study mimics the natural behaviour of brain tumours. 
Although both Wistar and SD rats were utilised for the study of C6 tumours, the 
C6/Wistar model is more similar to the human Glioblastoma multiforme (GBM) 
characteristics, such as a high mitotic rate, cells forming palisades, and 
neovascularisation (Miura et al. 2008). As a result, Wistar rats were used as the C6 
tumour xenograft model in our study. 
The comparison of brain distribution in healthy SD rats treated with different 
DOX formulations revealed a significantly increased accumulation of SCL-DOX 
compared to the free DOX group (Figure 6-1). As a widely used and efficient 
antitumour drug, DOX delivery to the brain is often restricted because of the poor 
penetration of this therapeutic molecule through the BBB (Rousselle et al. 2001). 
The statistically significant increase of DOX in the brain of perfused healthy SD rats 
injected with SCL-DOX showed that encapsulating DOX by SCL had the potential 
to cross the BBB. Moreover, compared with the free group, SCL encapsulation 
resulted in an elevated DOX accumulation in the cortex of perfused healthy SD rats 
(Figure 6-2), indicating a high accumulation of SCL-DOX in brain cells. As a result, 
the present nanodrug system might be capable of increasing therapeutic efficacy of 
drugs that are unable to penetrate in the BBB in the treatment of brain diseases.  
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In the intracranial C6 glioma model, the BBB would have been, at least partly, 
disrupted by surgery and tumour growth. Nonetheless, there was a significant 
improvement of tumour uptake in tumour-bearing rats (Figure 6-5(c)). DOX 
encapsulation within SCL resulted in 1.67-fold higher uptake by glioma compared to 
free DOX in the current study. Encapsulation of DOX into SCL resulted in a 
significantly higher DOX accumulation in the brain of rats receiving liposomal 
formulation than those in previous studies (Arnold et al. 2005; Yang, FY et al. 2012). 
Moreover, the tumour uptake in the present study was also higher than that in the 
previous study which demonstrated an enhanced therapeutic effect in vivo (1.79 
ȝg/g-tissue in this study vs. 0.16 ȝg/g-tissue reported by others) (Arnold et al. 2005). 
Therefore, the SCL-DOX in the present study indicated its potential to be a better 
nanodrug delivery system for brain tumours or other brain diseases. However, due to 
time constraint, the experiments with C6 glioma model using perfused animals were 
unable to be repeated. Further studies in perfused glioma-bearing rats should be 
performed to confirm the observations presented in this Chapter. 
The increased accumulation of free DOX in the brain of tumour-bearing rats 
compared with the brain uptake in healthy rats was most likely due to the disruption 
of BBB in the brain tumour model (Chekhonin et al. 2007; Wang, P et al. 2010). The 
glioma tumours are characterised by the invasive property, therefore, the capillary 
endothelium could be destroyed by tumour cells when the tumour expand beyond 2.0 
mm3 (Erwin 2009). As a result, the penetration of free DOX into the brain could 
increase, leading to the increased uptake by tumour cells as well as the brain in 
general. Future studies, such as the histopathological analysis (Mohamed, Karam & 
Amer 2011) or studies about apoptosis pathways (Tangpong et al. 2011), need to be 
performed to confirm the toxicity of DOX to normal brain cells. In addition, the use 
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of SCL for the treatment of C6 glioma was also advantageous in view of other tissues. 
The biodistribution (BD) data in this C6 glioma model demonstrated that 
accumulation of liposomal DOX in the heart and kidney were significantly lower 
than those of free DOX (Figure 6-5(a) and (d)). Therefore, the decreased 
concentration of DOX is likely to result in a reduced systemic toxicity in tumour-
baring rats as the reduced tissue levels of DOX afforded by SCL delivery.  
6.4 Conclusion 
  In summary, the present proof-of-principle study had demonstrated that SCL-DOX 
was able to penetrate into the BBB and accumulate in the C6 glioma in vivo. 
Moreover, the improved tissue distribution was confirmed in the glioma-bearing rats. 
Therefore, such nanodrug delivery systems may represent a new strategy for the 
development of effective anticancer chemotherapeutics targeting the brain tumour. 
Further investigations are planned to study the efficacy in inhibition of glioma 
growth, the survival benefit, as well as systemic toxicity. 
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Chapter 7 - Development of EpCAM aptamer 
functionalised PEGylated sulfatide-containing 
liposomal doxorubicin 
 
 
 
 
 
 
 
 
 
 173 
 
7.1 Introduction 
  Many DNA intercalators have been shown to have antitumour and antibiotic 
activity (Lee, CJ et al. 2004). Doxorubicin (DOX), which is well documented to 
function via blocking the progression of topoisomerase II and thus preventing DNA 
replication and cell division, is widely used in the treatment of many malignant 
diseases due to its broad antitumour activity (Kaplan et al. 2010). Cardiotoxicity is a 
major limiting factor in anticancer therapy of DOX (Yeh et al. 2004). Cardiotoxicity 
induced by DOX may present as either acute or chronic cardiomyopathy. While 
chronic cardiotoxicity is dose dependent, due to the limitation of the cumulative dose 
of DOX to <450 mg/m2, acute cardiotoxicity, occurring within 2 to 3 days of its high 
dose administration, is now rare (Zhang, YW et al. 2009). Other preventive strategies 
include modifying DOX with targeting molecular agents (Bagalkot et al. 2006) or 
establishing new drug delivery systems (Nagykalnai 2010), which have the potential 
to improve its distribution in vivo. 
  Aptamers, rapidly generated through the Systematic Evolution of Ligands by 
EXponential enrichment (SELEX), are single-stranded RNA or DNA 
oligonucleotides (Yang, X, Li & Gorenstein 2011). The interactions of aptamers with 
their target molecules mainly rely on hydrogen bonding, electrostatic, and 
hydrophobic interactions rather than Watson–Crick base pairing (Hermann & Patel 
2000). Aptamers possess several advantages when compared to antibodies. These 
include increased stability, smaller size, high target affinity and specificity, 
reproducibility via inexpensive and consistent chemical synthesis, easy modification 
for both labelling and selective changes in sequence, and the possibility against toxic 
or poorly immunogenic targets (Pendergrast et al. 2005; Wang, P, Hatcher, et al. 
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2011; Wang, P, Yang, et al. 2011b). Therefore, nucleic-acid aptamers have become 
increasingly important molecular tools with wide applications in modern medicine, 
including diagnostics and anticancer therapeutics (Rerole et al. 2011).  
Due to their advantages over other ligands used in drug delivery, aptamers had 
been utilised for the targeted delivery of DOX (Zhang, H 2004) or nanocarriers (Herr 
et al. 2006). A study by Zhang successfully conjugated DOX to an aptamer and 
showed that this aptamer-DOX conjugate was capable of specifically targeting 
prostate cancer cells via the prostate-specific membrane antigen (PSMA) and 
delivering DOX inside the cell (Zhang, H 2004). As well, a Sgc8-PEG-liposome for 
targeting CCRF-CEM (T-cell Acute Lymphoblastic Leukemia) was reported by 
Kang et al (Kang et al. 2010b).  
Our lab recently developed a RNA aptamer against a cancer stem cell marker, 
epithelial cell adhesion molecule (EpCAM), and this aptamer efficiently internalises 
upon binding to target cells (Shigdar et al. 2011). EpCAM was firstly described in 
1979 as a 40 KDa cell surface cancer-associated antigen, which is a type I single 
span transmembrane glycoprotein with extracellular epidermal growth factor-like 
(EGF-like) and thyroglobulin (TY) motifs as well as an intracellular domain 
containing an internalization motif and several Į-actinin binding sites (Balzaret, M al. 
1999). Previous studies had shown that the expression of EpCAM in various cancers 
is inversely related to the prognosis of the patients (Baeuerle & Gires 2007). Thus, 
aptamers against EpCAM may have the ability to target cancer cells, especially those 
with high expression of EpCAM. Therefore, preliminary in vitro studies were carried 
out to explore the potential of aptamers in enhancing cellular uptake of sulfatide-
containing nanoliposomal DOX (SCL-DOX) in cells overexpressing EpCAM.  
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7.2 Results 
7.2.1 Establishing a standard curve for DOX concentration in aptamer 
functionalised PEG-sulfatide-containing nanoliposomal DOX (ap-PEG-SCL-
DOX) 
To evaluate DOX concentration in aptamer functionalised PEG-sulfatide-
containing nanoliposome (ap-PEG-SCL) via HPLC, standard curves were 
constructed by plotting peak area of fluorescence derived from DOX vs. DOX 
concentrations. To mimic samples to be determined, ap-PEG-SCL-DOX without 
unconjugated aptamer purification using size-exclusion chromatography were used 
as standards and diluted to series of DOX concentrations from 50 ng/mL to 800 
ng/mL, followed by HPLC measurement. A linear regression analysis was used for 
quantitation. As shown in Figure 7-1, a good linearity between peak areas and 
concentrations was obtained within the tested concentrations with a correlation 
coefficient of R2=0.9984. 
 
Figure 7-1. Standard curve for determination of DOX concentration in ap-PEG-SCL-
DOX. The standard formulas were determined by linear regression as y = mx + b, where y is 
the peak area of DOX and x is the DOX concentration. 
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7.2.3 Cellular uptake of ap-PEG-SCL-DOX 
  To evaluate the binding specificity of the ap-PEG-SCL-DOX, two different 
aptamers were utilised, including the FITC-labelled EpCAM targeting aptamer and 
the FITC-labelled negative control aptamer which is an aptamer of the same 
sequence but with a different side-chain modification which could affect the 3-
dimensional structure of aptamer (Chushak & Stone 2009). Therefore, the negative 
control aptamer does not bind to EpCAM and does not specifically target the cancer 
cells with high expression of EpCAM. The accumulation of free DOX, PEG-SCL-
DOX, ap-PEG-SCL-DOX and negative ap-PEG-SCL-DOX in the EpCAM-negative 
cell line (HEK-293T) and the EpCAM-positive cell line (HT-29) were studied using 
laser scanning confocal microscopy utilising the natural fluorescent property of DOX 
and the FITC label on the aptamer.  
After 24 h incubation with 2 Pg/mL DOX, PEG-SCL-DOX, ap-PEG-SCL-DOX or 
negative ap-PEG-SCL-DOX followed by washing with PBS, cellular uptake of free 
DOX or liposomal formulations by HEK-293T cells and HT-29 cells were examined. 
As shown in Figure 7-3(a), there was no significant difference between HEK-293T 
cells treated with ap-PEG-SCL-DOX and those with negative ap-PEG-SCL-DOX. 
The overlay of Hoechst staining (nucleus) and red fluorescence (DOX) in HT-29 
cells indicated that ap-PEG-SCL-DOX was not adhered to the cell surface but 
actually penetrated into the nucleus (Figure 7-3(b)). Notably, confocal microscopy of 
HT-29 cells exposed to ap-PEG-SCL-DOX demonstrated increased DOX 
fluorescence (red) compared to other groups after 24 h incubation. Moreover, the 
strong green fluorescence (from FITC that was used to label the aptamer) in HT-29 
cells treated with ap-SCL-DOX indicated the accumulation of EpCAM aptamer in 
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the cells. The overlay of nucleus staining and FITC fluorescence in the cells 
suggested that the EpCAM RNA aptamer functionalised PEG-SCL-DOX is 
efficiently internalised after the binding to EpCAM on cell surface. As a control, 
fluorescence of ap-PEG-SCL-DOX was determined in the EpCAM-negative cell line 
HEK-293T. Results indicated that there was cellular uptake of ap-PEG-SCL-DOX in 
EpCAM-negative cell line (Figure 7-3(a)). Moreover, negative ap-PEG-SCL-DOX 
was also taken up by both two cell lines (Figure 7-3), which might have resulted 
from non-specific binding following the long incubation. 
  
 
Figure 
293T ce
or aptam
imaged 
fluoresc
fluoresc
bars: 20
 
7-3. Intrac
lls and HT-
er function
with a confo
ence from 
ence from a
 ȝm.  
ellular upta
29 cells. Ce
alised PEG-
cal fluoresc
DOX; Blu
ptamer. Dat
ke of aptam
lls were incu
SCL-DOX f
ence micros
e: nuclei 
a are represe
179 
er functio
bated with 2
or 24 h. Cel
cope. (a) HE
stained wit
ntative of th
nalised PE
 Pg/mL free
ls were was
K-293T cel
h Hoechst 
ree indepen
G-SCL-DO
 DOX, PEG
hed twice w
ls. (b) HT-2
33342; G
dent experim
 
X in HEK-
-SCL-DOX
ith PBS and
9 cells. Red:
reen: FITC
ents. Scale
 
 
 
 
 
 180 
 
7.2.4 Cellular retention of aptamer functionalised PEG-SCL-DOX 
For the study of cellular retention of ap-PEG-SCL-DOX, cells were first incubated 
with different formulations of DOX for 24 h at the dose of 2 Pg/mL. Cells were then 
washed with PBS twice and cultured in fresh culture medium. The same wells of 
cells were imaged serially at 1 h, 2 h, 4 h and 24 h after washing using fluorescence 
confocal microscopy. The DOX fluorescence in both cell lines treated with liposomal 
formulations decreased slower when compared to cells treated with free DOX, 
suggesting better retention of our liposomal formulation in vitro. In contrast, the 
DOX fluorescence in free DOX and negative ap-PEG-SCL-DOX group decreased 
rapidly after washing with PBS (Figure 7-4). There was a significant reduction of 
DOX fluorescence in free DOX group only 2 h after washing with PBS (Figure 7-5). 
Interestingly, compared to the EpCAM-positive HT-29 cells, the DOX fluorescence 
(red), as well as aptamer fluorescence (green), diminished significantly in the HEK-
293T cells which are EpCAM-negative. HEK-293T cells treated with ap-SCL-DOX 
or negative ap-PEG-SCL-DOX both showed significant decreased red fluorescence 
and green fluorescence 4 h after washing (Figure 7-6(a)). Conversely, the DOX 
fluorescence and aptamer fluorescence for ap-PEG-SCL-DOX was more stable in 
HT-29 cells compared to those treated with other DOX formulations and those in 
HEK-293T cells. Even 24 h after washing, DOX fluorescence and FITC fluorescence 
(aptamer) could be readily observed in the HT-29 cells treated with ap-PEG-SCL-
DOX (Figure 7-7 (b)). 
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7.3 Discussion 
Aptamers are highly selective nucleic acids which have been developed for 
numerous therapeutic applications (Yang, X et al. 2011). In the current study, we 
developed a novel specialised aptamer-liposome bioconjugate for targeted delivery 
of anticancer agents into EpCAM expressing cancer cells. SCL with 5% PEG used in 
our study possesses a negative surface charge (Table 3-1, Chapter 3), which was a 
desirable characteristic as positively charged nanoparticles might lead to nonspecific 
interaction with the negatively charged aptamers and diminish the binding property 
(Farokhzad et al. 2004a). The negative charge on the SCL could repel the similarly 
charged EpCAM aptamers and thus minimise the charge interaction between 
aptamers and SCL surface. As a result, the conjugation in the current study was 
obtained via the chemical reaction between the hydrophilic carboxylic acid 
functional group (-COOH) on the PEG used for SCL and the free amine group (-NH2) 
modified on the aptamers (Figure 7-2). In the presence of sulfo-N-
hydroxysuccinimide (sulfo-NHS) and 1- [3-dimethylaminopropyl]-3-
ethylcarbodiimide hydrochloride (EDC), the carboxylic acid group on the SCL 
surface would easily convert to the NHS ester and link with the NH2-modified 
aptamers (Estevez et al. 2010a; Healy et al. 2004).  
RNA aptamers used in the current study were previously selected against the 
extracellular region of EpCAM (Shigdar et al. 2011). By conjugating the PEG-SCL 
and the EpCAM aptamer, aptamer-liposome bioconjugates were generated for 
assessment in this study. The elevated particle size and increased absolute value of 
zeta potential in ap-PEG-SCL-DOX and negative ap-PEG-SCL-DOX compared to 
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SCL (Table 3-1, Chapter 3) might be attributed to the insertion of the aptamer 
(Wilner et al. 2012). 
Because of previously established EpCAM aptamer binding speci¿city, EpCAM 
targeting aptamers and negative control aptamers which did not target the EpCAM, 
as well as two cell lines, were used to analyse the cellular uptake in vitro. The human 
colorectal adenocarcinoma cell line HT-29 was known to express EpCAM, which is 
a 40-kDa transmembrane glycoprotein frequently expressed in solid tumours 
(Herrmann et al. 2010; Winkler et al. 2009). Conversely, HEK-293T, human 
embryonic kidney cells, was reported to be the EpCAM-negative (Shigdar et al. 
2011). Comparison of cellular uptake between these two cell lines would evaluate the 
specific interaction between EpCAM targeting aptamer functionalised PEG-SCL-
DOX and EpCAM-positive cells. 
The un-functionalised SCL-DOX displayed an enhanced accumulation of DOX in 
HT-29 cells compared to free DOX (Chapter 5). Through current cellular uptake 
studies, confocal microscopy also revealed differences among uptakes of different 
DOX formulations. The data demonstrated that the binding of ap-PEG-SCL-DOX 
bioconjugates to HT-29 cells, which are EpCAM-positive, was significantly 
enhanced when compared with the negative ap-PEG-SCL-DOX complex and the 
SCL-DOX formulation (Figure 7-3 (b)). The overlay of nucleus staining, DOX and 
FITC fluorescence from the aptamer indicated intracellular delivery of our aptamer 
functionalised SCL-DOX to the site of DOX action, the nucleus. In contrast, the 
results in HEK-293T cells, which do not express EpCAM, showed no significant 
difference in cellular uptake between the conjugates and the control groups (Figure 
7-3 (a)). Moreover, the non-specific binding and internalisation of negative ap-PEG-
 187 
 
SCL-DOX in both HEK-293T and HT-29 cells might have resulted from the long 
time incubation (24 h incubation). As shown in previous study, the binding of this 
EpCAM targeting aptamer and cells was observed 0.5 h after incubation (Shigdar et 
al. 2011). To confirm if this was a transient increase observed in the EpCAM 
negative cell line, studies were then proceeded to evaluate the retention of the ap-
PEG-SCL-DOX to both EpCAM-positive and EpCAM-negative cell lines. The 
retention experiment showed that this non-specific binding was transient. The 
fluorescence of aptamer (green), as well as the DOX (red), diminished very fast in 
HEK-293T cells (Figure 7-4 (a), Figure 7-5 (a), Figure 7-6 (a) and Figure 7-7 (a)). 
The rapid clearance of fluorescence in HEK-293T cells suggested the interaction of 
the ap-PEG-SCL-DOX and EpCAM-negative cells might be non-specific. As a result, 
although there was non-specific uptake in the EpCAM negative cell line, both the 
drug and aptamer fluorescence diminished rapidly, indicating the drug solutions had 
also been removed from the cells rapidly. Moreover, in the monolayer model, cells 
cultured in the monolayer are exposed to a constant drug concentration throughout 
the entire assay period (Accardo et al. 2012), which is not a reliable predictor of the 
therapeutic efficacy in vivo where the cells wouldn’t be subjected to a constant 
concentration for so long. Therefore, the fluorescence in the cells in the uptake study 
is not truly representative of what would be seen in in vivo studies. 
On the other hand, there were significantly different retention patterns observed in 
the EpCAM-positive cell line compared to that in the EpCAM-negative cell line 
during the period of observation (24 h). As expected, unlike in the HEK-293T cells 
(EpCAM-negative), in the EpCAM-positive cells, HT-29, the red fluorescence for 
DOX and the green fluorescence for aptamer were more stable compared to cells 
treated with other DOX formulation. Even 24 h after washing, DOX fluorescence 
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and aptamer fluorescence could be readily observed in the nuclei of cells in HT-29 
cells treated with ap-PEG-SCL-DOX compared to those in other groups (Figure 7-7 
(b)). Thus, the prolonged retention of ap-PEG-SCL-DOX in the nuclei for several 
hours even after washing suggested the potential of a better anti-tumour efficacy of 
our bioconjugates.  
7.4 Conclusion 
  In this preliminary study, an EpCAM aptamer functionalised SCL delivery system 
for DOX had been developed. The enhanced cellular uptake and prolonged retention 
of the aptamer-SCL-DOX conjugates studies suggested the potential for efficient 
targeted delivery of anticancer chemotherapeutics to cells overexpressing EpCAM. 
The non-specific binding of the EpCAM aptamer functionalised SCL delivery 
system was transient and was diminished from the EpCAM negative cells within a 
short period of time, indicating that the EpCAM aptamer functionalised SCL 
delivery drug was specifically retained by EpCAM positive cells. More studies, such 
as a semiquantitative cellular uptake study (flow cytometry assay), quantitative 
cellular uptake study (HPLC assay) and in vitro toxicity study (MTT assay) should 
be utilised to confirm the improved drug delivery property of the EpCAM aptamer 
functionalised SCL delivery system in the EpCAM positive cell lines. Moreover, as 
EpCAM is a cell surface marker of cancer stem cells (CSCs), our EpCAM aptamer 
functionalised SCL delivery system has the potential to be an effective nano-carrier 
for the specific targeting of CSCs. Further studies, including the tissue distribution 
and treatment efficacy of these vehicles in vivo, are needed to evaluate the specificity 
to target the CSCs. 
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8.1 Summary 
  Cancer is still the leading cause of death in worldwide despite advances having 
been made in reducing morality and improving survival (Klein, C. A. 2009). Current 
cancer treatments mainly include surgical intervention, radiation and 
chemotherapeutic drugs (Miller et al. 2012). However, most deaths from cancer 
result from distant metastatic disease, and surgery is not generally able to 
treat metastatic cancer (Ruiterkamp & Ernst 2011). Thus, effective management of 
metastases has moved to the centre of clinical attention and chemotherapy has been 
widely used for the treatment of metastases (Wolf et al. 2012). Nevertheless, in the 
anticancer area, one of the biggest challenges that still remain is the low therapeutic 
index of the majority of anticancer agents (Wang, Y, Newell & Irudayaraj 2012). As 
traditional anticancer chemotherapeutics often kill healthy cells as well as tumour 
cells and cause toxicity to the patient, it would therefore be desirable to develop 
chemotherapeutics that could either passively or actively target cancerous cells 
effectively (Urbinati, Marsaud & Renoir 2012). Present applications of 
nanotechnologies for the treatment of cancers represent a new direction for future 
cancer therapeutics and liposomes play a critical role in the formulation of potent 
drugs to improve the therapeutic index (Samad, A., Sultana, Y. & Aqil, M. 2007). 
The utility of liposomes as a nanodrug delivery system has been demonstrated by its 
ability to efficiently deliver cytotoxic agents to tumour tissue while minimizing the 
undesired negative side effects associated with these drugs (Cukierman & Khan 
2010). Moreover, new formulations of liposomes are targeted to the reduced toxicity 
and increase accumulation at the target site via passive or active targeting 
modification (Elbayoumi, T. A. & Torchilin, V. P. 2008; Gabizon, AA 2001a). 
However, significant challenges remain.  
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As a glycosphingolipid which can bind to several extracellular matrix proteins, 
sulfatide has the potential to become an effective targeting agent for tumours 
overexpressing tenascin-C in their microenvironment. To overcome the dose-limiting 
toxicity of the anticancer agent DOX, a SCL encapsulation approach was employed 
to improve treatment efficacy and reduce side effects of free DOX. This study 
analysed in vitro characteristics of SCL-DOX and assessed its cytotoxicity in vitro, 
as well as pharmacokinetics (PK), biodistribution (BD), therapeutic efficacy and 
systemic toxicity in vivo. Due to the overexpression of tenascin-C on cell surface, a 
human glioblastoma U-118MG xenograft model and a human colon carcinoma HT-
29 cell line were chosen as models in the study for the targeting property of SCL. 
Firstly, the characteristics of SCL-DOX in vitro and in healthy rats were analysed 
(Chapter 3). The SCL-DOX was shown to achieve the highest drug to lipid ratio of 
0.5:1 among all such systems reported so far, a high encapsulation of DOX with an 
ideal average size less than 100 nm and a remarkable in vitro stability. The in vitro 
uptake and retention studies suggested that DOX encapsulated in SCL was delivered 
into the nuclei and displayed prolonged retention over free DOX in both U-118MG 
cells and HT-29 cells in vitro. Although there were no advantages of cytotoxicity in 
culture dishes in vitro compared to free DOX, this simple two-lipid SCL-DOX 
nanodrug has favourable pharmacokinetic attributes in terms of prolonged circulation 
time, reduced volume of distribution, slow clearance rate and enhanced 
bioavailability in healthy rats. The improved tissue distribution in SD rats revealed in 
the present study, indicated that SCL-DOX significantly reduced the DOX 
accumulation in the heart and kidney compared to free DOX, suggesting the potential 
of decreased toxicity to these organs of the SCL-DOX in vivo. 
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The prolonged cellular retention in vitro, as well as the improved pharmacokinetic 
and tissue distribution profiles in vivo, suggested the potential of enhanced treatment 
efficacy and reduced systemic toxicity of SCL-DOX. Therefore, the in vivo BD and 
antitumour treatments efficacy of SCL-DOX was evaluated in the nude mice bearing 
U-118MG glioblastoma or HT-29 colorectal cancer (Chapter 4 and Chapter 5). As 
expected, in addition to the improved PK and BD profiles in healthy SD rats, an 
enhanced treatment efficacy of SCL-DOX was found in tumour-bearing mice 
compared to the free drug. The use of this nanodrug delivery system to deliver DOX 
for treatment of tumour-bearing mice produced a much improved therapeutic 
efficacy in terms of suppression of tumour growth and extended survival in contrast 
to the free drug. Furthermore, a reduction in the accumulation of DOX in the drug’s 
principal toxicity organs, the heart and the skin, in U-118MG and HT-29 xenograft 
mice models was observed. Also, SCL-DOX led to the diminished systemic toxicity 
as evident from the plasma biochemical analyses. Moreover, reduced 
myelosuppression was observed in HT-29 tumour-bearing mice treated with SCL-
DOX. Thus, SCL has the potential to be an effective and safer nano-carrier for 
targeted delivery of therapeutic agents to tumours with elevated expression of 
tenascin-C in their microenvironment. Such natural lipid-guided nanodrug delivery 
systems may represent a new strategy for the development of effective anticancer 
chemotherapeutics targeting the tumour microenvironment for both primary tumours 
and micrometastases. 
The ability of a drug to penetrate the blood-brain barrier (BBB) is crucial for its 
utility in the pharmaceutical treatment of the central nervous system (CNS) diseases, 
including gliomas (Lohmann, Huwel & Galla 2002). In the BD study of healthy SD 
rats, a significantly improved DOX accumulation induced by SCL encapsulation was 
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observed in normal brain and in the perfused brain, indicating the SCL-DOX was 
able to penetrate the BBB and remain in the brain cells (Chapter 6). To evaluate the 
ability of SCL-DOX to cross the BBB and the treatment efficacy of DOX 
encapsulated by the SCL in gliomas, an intracranial brain tumour xenograft model in 
Wistar rats was established. SCL-DOX was administrated via i. v. injection and 
DOX concentration in tumour and brain were analysed. As shown in Chapter 6, the 
significantly improved tumour uptake and brain accumulation, as well as improved 
tissue distribution, indicated that SCL-DOX could effectively increase the 
penetration of DOX across the BBB and reduce its systemic toxicity. Therefore, SCL 
has the potential to be utilised as an anticancer agent nanocarrier for the delivery of 
drugs across to the BBB.  
The SCL-DOX has been identified as a liposome formulation which could target 
the tumour with high expression of tenascin-C effectively (Chapter 3 and Chapter 4). 
However, previous studies have indicated that conjugating targeting molecules, such 
as antibodies, ligands, peptides, or aptamers, to the surface of liposomes could lead 
to an improved targeting liposome formulation (Herrmann et al. 2010). As a result, 
the aptamer functionalised PEG-SCL-DOX (ap-PEG-SCL-DOX) was developed to 
further improve the targeting property of SCL-DOX (Chapter 7). The treatment of 
HT-29 tumour, which has been reported to have a high expression of epithelial cell 
adhesion molecule (EpCAM), was showed to be effectively improved by SCL-DOX 
in the tumour xenograft mice. However, DOX has been reported to not be able to 
eradicate cancer stem cells (CSCs) which are related to the recurrence of tumours 
(Zheng, X et al. 2010). Thus, PEG-SCL-DOX modified with aptamer targeting 
EpCAM, one of the cell surface markers for CSCs, has the potential to target CSCs. 
In the Chapter 7, the aptamer-facilitated cellular uptake and retention of DOX 
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encapsulated PEG-SCL showed the accumulation, as well as retention time, of DOX 
had been enhanced via the highly specific RNA aptamer modified PEG-SCL in HT-
29 cells. Therefore, the strategy of delivering DOX via the EpCAM targeted aptamer 
functionalised PEG-SCL might be suitable for systemic targeted therapy of EpCAM-
positive cancers, or even CSCs. 
8.2 Perspectives 
As shown in Chapter 6, it is likely that SCL could improve the delivery efficiency 
of DOX into the brain. However, due to time constraints, the assays for evaluation of 
SCL for brain delivery mainly focused on preliminary studies of tissue distribution 
and tumour uptake in vivo. More studies need to be designed and carried out to study 
the therapy efficacy and safety of SCL-DOX in the treatment of gliomas. Thus, the 
next step following current studies would investigate the outcome of tumour 
inhibition, survival and systemic toxicity of SCL-DOX in intracranial brain tumour 
xenograft rats with treatment of free DOX as a control. Moreover, histopathological 
analysis of tissue and tumour sections would be useful to investigate DOX toxicity to 
the normal brain cells as well as DOX accumulation in the xenograft glioblastoma in
vivo. Furthermore, the study about tissue distributions in perfused glioma-bearing 
rats would be utilised to confirm the enhanced tumour uptake of SCL-DOX in vivo. 
Another essential future research direction is to study the targeting property of 
aptamer functionalised PEG-SCL to CSCs. The concept of CSCs is that only a 
minority of cells within a tumour is able to generate a new tumour (Lin et al. 2011). 
Most of current antitumour therapies can only treat rapidly dividing tumour cells 
effectively (Bitarte et al. 2011). However, tumour proliferation may be driven by 
CSCs which divide slowly and are relatively resistant to cytotoxic drugs (Koch, 
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Krause & Baumann 2010). Thus, many tumours may progress because CSCs are not 
sensitive to the treatment. Therefore, targeting CSCs for the prevention of tumour 
progression and treatment could become a novel strategy for better treatment. 
EpCAM, a glycosylated, 30- to 40-kDa type I membrane protein, which is expressed 
in a variety of human epithelial tissues, cancers, and progenitor and stem cells, is a 
cell surface marker for CSCs in numerous types of cancers, including hepatocellular 
carcinoma and colon carcinomas (Munz, Baeuerle & Gires 2009). Recently, our lab 
developed a RNA aptamer targeting EpCAM overexpressed on the cancer cells 
(Shigdar et al. 2011). Current results of the study indicated the effective binding and 
internalisation of EpCAM targeting aptamer functionalised PEG-SCL-DOX in the 
EpCAM-positive cell line. However, confocal microscopy is more a qualitative study. 
To further confirm the specific targeting properties of CSCs of our ap-PEG-SCL-
DOX, more specific studies need to be designed. For example, a semiquantitative 
cellular uptake study (flow cytometry assay), quantitative cellular uptake study 
(HPLC assay) and in vitro toxicity study (MTT assay) should be utilised to confirm 
the improved drug delivery property of the EpCAM aptamer functionalised SCL 
delivery system in the EpCAM-positive cell lines and compared with that in the 
EpCAM-negative cell lines. Furthermore, the newly developed CD133 aptamers in 
our laboratory could be utilised as another targeting agent against glioblastoma stem 
cells. 
As the in vitro monolayers in culture dishes are very different when compared to 
the 3-dimentional tissue architecture in vivo (Chen, SF et al. 2012; Xu & 
Anchordoquy 2011), the 3-dimentional tumoursphere (gliosphere and colonosphere) 
should be utilised for the evaluation of cellular uptake, penetration and retention of 
ap-PEG-SCL-DOX in vitro, which would be a more reliable predictor of the 
 196 
 
therapeutic efficacy in vivo. Moreover, the side-population or the aldehyde 
dehydrogenase activity assay of cell fraction can be assessed by flow cytometry, 
which are assays utilised to identify CSCs after treatment in vitro (Peeters et al. 
2006). The ap-PEG-SCL-DOX is expected to reduce the percentage of CSCs when 
compared to other DOX formulation as it targets CSCs as well as the normal bulk 
cancer cells. In vitro tumoursphere formation assays can be utilised to evaluate the 
ability of cells treated with ap-PEG-SCL-DOX to grow as flowing spheres in 
nonadherent conditions in serum-free environment, which reflects the capacity of 
CSC to self-renew in vitro (Azzi et al. 2011). In order to verify the reduction of 
CSCs resulted from the ap-PEG-SCL-DOX treatment, in vivo limiting dilution assays 
(LDA) and xenotransplantation shall be employed in the future, which is the gold 
standard to demonstrate the reduction of CSC after treatment (O'Brien, CA, Kreso, A 
& Jamieson, CH 2010; Zhang, M, Atkinson & Rosen 2010).  
In conclusion, an effective and safe nanocarrier, SCL, using two human 
compatible and degradable lipids for the anticancer agent DOX was characterised in 
this project. Due to the SCL encapsulation, DOX is better delivered into the target 
cells with a prolonged retention. Furthermore, the favourable pharmacokinetic 
properties and improved tissue distributions induced by SCL encapsulation translated 
into enhanced antitumour activity, which result in significant growth inhibition, 
prolonged life-span and reduced systemic toxicity compared to free DOX. Moreover, 
results from preliminary data suggest that SCL have a great potential to overcome the 
BBB. Aptamer-directed PEG-SCL was then developed by conjugating the EpCAM 
targeting aptamer to the surface of PEG-SCL loaded with DOX. The aptamer 
functionalised DOX-encapsulated PEG-SCL showed improved uptake and retention 
in EpCAM-positive tumour cells in vitro. With the successful development and 
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characterisation of a novel and safe nanocarrier for DOX, future studies will 
investigate the potential of SCL in improving the therapeutic index of the traditional 
anticancer drugs, in overcoming the BBB and in targeting CSCs.  
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